Mechanistic differences in interactions of HIV-1 and HIV-2 with dendritic cells by Kijewski, Suzanne Delight Geer
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Mechanistic differences in
interactions of HIV-1 and HIV-2 with
dendritic cells
https://hdl.handle.net/2144/13991
Boston University
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Dissertation 
 
 
 
 
 
MECHANISTIC DIFFERENCES IN INTERACTIONS OF 
  
HIV-1 AND HIV-2 WITH DENDRITIC CELLS  
 
 
 
 
by 
 
 
 
 
SUZANNE DELIGHT GEER KIJEWSKI 
 
B.A., Williams College, 2007 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Doctor of Philosophy 
 
2015  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 
 SUZANNE DELIGHT GEER KIJEWSKI 
 All rights reserved except Introduction ©
 2015 Future Virology and parts of  
 Chapter 3 © 2015 ACS Nano 
   
Approved by 
 
 
 
 
 
First Reader ___________________________________________________ 
 Suryaram Gummuluru, Ph.D. 
 Associate Professor of Microbiology 
 
 
Second Reader ___________________________________________________ 
 Andrew Henderson, Ph.D. 
 Associate Professor Medicine and Microbiology 
 
 
 
  
  
 
 
 
 
“Discovery consists of seeing what everybody has seen and thinking what 
nobody has thought.” - Albert Szent-Gyorgyi 
 
 
 
 
 
 
	  v 
DEDICATION 
 
 
 
To my amazing husband, Michael, for believing in me and always making me 
smile throughout this adventure. 
 
  
	  vi 
ACKNOWLEDGMENTS 
First I would like to thank my mentor, Rahm Gummuluru for his guidance and for 
sharing his scientific knowledge throughout my graduate career.  I would also like 
to thank my whole committee for the wonderful feedback and support. Thank you 
to Greg Viglianti for listening to me worry for the past five years. I would really 
like to thank the members of the Gummuluru Lab past and present. It has been a 
wonderful experience working in such a collaborative environment. Wendy 
Puryear, Hisashi Akiyama, Caitlin Miller, and Nora Ramirez, I have learned from 
you all. Thanks to everyone in the Microbiology Department and the Immunology 
Training Program. Special thanks to Krishna Moody for the guidance through 
classes and Linda Parlee and Kathy Furness for providing M&Ms and making the 
department run. 
 
Lunches with my colleagues were always helpful to troubleshoot experiments or 
just to take a breather to reboot. Thanks to Claire Marie Filone, Dan Rozelle, 
Judy Yen, Caitlin Miller, Liz Stanford, and Chadene Tremaglio. Thanks to my 
friends outside of science for understanding how stressed graduate school made 
me. To name a few: Louisa Pitt Connaughton, Elisabeth Hosmer, Courtney 
Asher, Ally Holmes, Addie Buck, Elizabeth Dy Parulan and Kristy Callahan. Also, 
many thanks to Carrie Keogh, who was always there to listen and understood the 
rollercoaster that is grad school. 
 
	  vii 
I would like to thank my parents for always supporting me and pushing me to do 
my best and to thank my brothers for never accepting that it’s my best. Thanks to 
my brother Chris, sister in law Kelly and their gorgeous two kids Maverick and 
Mckinley for being a wonderful nearby distraction. My wonderful in-laws, Lisa and 
Larry, have been amazing additional supports along with Kim, Marcel and Sarah 
Macauley, all the Dervins especially Grandma Joan Dervin and all of the 
Kijewskis especially Grandmom Jane Kijewski.  
 
Finally, I would like to thank my husband who has been by my side supporting 
me throughout this whole journey.  You believed in me when I didn't (often) and 
was the best cheerleader I could have asked for.  
  
	  viii 
MECHANISTIC DIFFERENCES IN INTERACTIONS OF  
HIV-1 AND HIV-2 WITH DENDRITIC CELLS 
SUZANNE DELIGHT GEER KIJEWSKI 
Boston University School of Medicine, 2015 
Major Professor: Suryaram Gummuluru, Ph.D., Associate Professor of 
Microbiology 
 
ABSTRACT 
Pathogenic mechanisms that account for the dramatic differences between the 
HIV-1 and HIV-2 epidemics remain unknown. Myeloid dendritic cells (DCs) are 
sentinels of the immune system, which sense invading pathogens and initiate 
immune responses. I hypothesize that failure of HIV-2 to overcome DC-intrinsic 
defense mechanisms results in diminished virus replication and reduced 
pathogenesis in vivo. Recent studies from our laboratory have identified capture 
of HIV-1 by CD169 (Siglec1), which results in preservation of virus infectivity in 
peripheral non-lysosomal compartments and transfer to CD4+ T cells, a 
mechanism of DC-mediated trans infection. HIV-1 interaction with CD169 was 
dependent on incorporation of a ganglioside, GM3, in the virus particle 
membrane. We hypothesized that reduced interaction of HIV-2 with CD169 is 
crucial for its attenuated pathogenic phenotype in vivo. Interestingly, HIV-2 virion 
assembly sites were divergent from HIV-1, which correlated with reduced 
incorporation of GM3 in HIV-2 virions, and a significant decrease in capture of 
HIV-2 compared to HIV-1 by mature DCs. Furthermore, reduced CD169-
dependent HIV-2 capture by DCs attenuated access of HIV-2 to DC-mediated 
	  ix 
trans infection. In contrast to the trans infection pathway, HIV-2 could establish 
productive infection in DCs, though productive infection of DCs by HIV-2 resulted 
in innate immune activation, induction of IFN-α production and attenuated spread 
of virus in DC – CD4+ T cell co-cultures. As opposed to HIV-2, productive 
infection of DCs by HIV-1 was attenuated and failed to trigger type I IFN 
responses, thus allowing for efficient spread of HIV-1 in DC – CD4+ T cell co-
cultures. These results suggest that immune sensing of HIV-2 in productively 
infected DCs limits viral spread. Finally, we investigated GM3-expressing 
nanoparticles (GM3-NPs) for delivery of therapeutics that trigger innate immune 
responses in CD169+ myeloid cells as a novel strategy to mimic myeloid cell-
intrinsic virus control observed in HIV-2 infection. We tested the ability of GM3-
coated nanoparticles that incorporated a TLR2 ligand, Pam3CSK4, to activate 
CD169+ cells. Interestingly, Pam3CSK4 containing GM3-NPs robustly activated 
CD169+ cells. These results suggest that induction of dendritic cell-intrinsic type I 
IFN responses might be a fruitful therapeutic strategy to restrict HIV-1 replication 
in vivo. 
  
	  x 
TABLE OF CONTENTS 
 
TITLE PAGE……………………………………………………………………………...i 
COPYRIGHT……….....…………………………………………………………………ii 
APPROVAL PAGE……………………………………………………………………...iii 
EPIGRAPH……………………………………………………………………………...iv 
DEDICATION ......................................................................................................... v 
ACKNOWLEDGMENTS ....................................................................................... vi 
ABSTRACT .......................................................................................................... viii 
TABLE OF CONTENTS ......................................................................................... x 
LIST OF TABLES ............................................................................................... xiv 
LIST OF FIGURES .............................................................................................. xv 
LIST OF ABBREVIATIONS ................................................................................ xvii 
INTRODUCTION ................................................................................................... 1 
HIV: Global Health Threat/Dissemination .......................................................... 1 
Current Treatment and Lack of Vaccine ............................................................ 2 
HIV-1 Versus HIV-2 ............................................................................................ 5 
History and Epidemiology .................................................................................. 5 
Infection Course ................................................................................................. 6 
Genome Similarities & Differences .................................................................... 8 
Life Cycle ......................................................................................................... 12 
	  xi 
Fusion & Entry.................................................................................................. 12 
Reverse Transcription and Integration ............................................................. 14 
Assembly and Release .................................................................................... 16 
Immune Sensing of HIV-1 and HIV-2 ............................................................... 18 
Adaptive Immune Responses against HIV-1 and HIV-2 .................................. 19 
HIV Interaction with Target Cells ..................................................................... 20 
Dendritic Cells and their role ............................................................................ 20 
Dendritic Cell Subsets ...................................................................................... 22 
DCs and HIV: Cis Infection .............................................................................. 24 
Restriction Factors ........................................................................................... 24 
HIV Capture/Trans Infection ............................................................................ 26 
First Evidence of Trans Infection ..................................................................... 26 
Receptors ......................................................................................................... 27 
GM3/Gangliosides ........................................................................................... 32 
CD169 .............................................................................................................. 34 
HIV-1 Trafficking in DCs and Trans Infection ................................................... 37 
Clinical and Therapeutic uses for Capture Mechanism ................................... 42 
GM3 CD169 Interaction Used for Targeting .................................................... 45 
Scientific Proposal and Hypothesis .................................................................. 46 
Materials and Methods ........................................................................................ 49 
CHAPTER ONE: Access of HIV-2 to CD169-dependent Trans Infection Pathway 
is Attenuated Compared to HIV-1 ........................................................................ 72 
	  xii 
1.1 Attenuated Capture of HIV-2 VLPs by CD169 ........................................... 75 
1.2 Decreased Incorporation of GM3 in HIV-2 Gag-eGFP VLPs ..................... 77 
1.3 Interactions of HIV-2iGFP Virions with Mature DCs and THP1/CD169 Cells 
are Attenuated ................................................................................................. 80 
1.4 HIV-1 and HIV-2 Traffic to a CD169+CD81+ Compartment in Mature DCs 85 
1.5 Reduced Access of HIV-2 to the Mature-DC Mediated Trans Infection 
Pathway. .......................................................................................................... 87 
Discussion ........................................................................................................ 89 
CHAPTER TWO: Consequences of Establishment of Productive Infection of 
Immature Dendritic Cells by HIV-2 ...................................................................... 94 
2.1 HIV-2 is More Efficient at Infecting Immature Dendritic Cells .................... 96 
2.2 HIV-2 Induces a Spreading Infection of Immature Dendritic Cells ............. 97 
2.3 Differential Immune Sensing of HIV-1 and HIV-2 in Dendritic Cells ........ 102 
Conclusions and Future Directions ................................................................ 111 
CHAPTER THREE: Design and Validation of GM3-incorporating Membrane 
Encapsulated Nanoparticles to Target CD169+ Myeloid Cells In Vivo .............. 118 
3.1 CD169 Specifically Binds α-2,3 sialylated GSLs and is Highly Conserved 
Across Species .............................................................................................. 129 
3.2 Nanoparticle Designed to Imitate Virus Composition and Trafficking ...... 135 
3.3 Nanoparticles Carrying Adjuvant Specifically Stimulate Dendritic Cells .. 141 
3.4 NPs with PAM3csk4 Specifically Trigger Cytokine Stimulation in CD169+ 
Cells ............................................................................................................... 142 
	  xiii 
Conclusion ..................................................................................................... 146 
Future Directions ............................................................................................ 147 
Concluding Remarks ......................................................................................... 149 
Summary of Results ....................................................................................... 149 
APPENDIX: Different Assays to Compare HIV-1 and HIV-2 ............................. 160 
List of Abbreviated Journal Titles ...................................................................... 164 
BIBLIOGRAPHY ................................................................................................ 170 
CURRICULUM VITAE ....................................................................................... 206 
 
  
	  xiv 
LIST OF TABLES 
Table 1. Receptors that Capture HIV-1. .............................................................. 31	  
Table 2. Primer Sequences ................................................................................. 57	  
Table 3. Classes of Clinically Used and Tested Adjuvants……………………...127 
  
	  xv 
LIST OF FIGURES 
Figure 1. Genome Organization of HIV-1 and HIV-2. ............................................ 9	  
Figure 2. Phylogenetic Tree Comparing SIV, HIV-1 and HIV-2. .......................... 11	  
Figure 3 Differences in HIV-1 Capture and Trans Infection by Immature and 
Mature DCs. ................................................................................................. 41	  
Figure 4. Attenuated Capture of HIV-2 VLPs by CD169. .................................... 76	  
Figure 5. Decreased Incorporation of GM3 in HIV-2 Gag-eGFP VLPs. .............. 78	  
Figure 6. Characterization of HIV-2iGFP.. ........................................................... 81	  
Figure 7. Capture of HIV-2iGFP Virions by Mature DCs is Attenuated. .............. 84	  
Figure 9. Access of HIV-2 to Mature DC-Mediated Trans Infection Pathway is 
Diminished. ................................................................................................... 88	  
Figure 11. HIV-2 Causes a Spreading Infection in DC Cultures.. ...................... 100	  
Figure 12. DC-T Co-Cultures Infected with HIV-2 Produce Less Virus Than DCs 
or T Cells Alone. ......................................................................................... 104	  
Figure 13. HIV-2 Infection of Myeloid DCs Trigger and Interferon Signature. ... 108	  
Figure 14. Induction of IP-10 (CXCL10) Production in HIV-2 Infected DCs.. .... 110	  
Figure 15. Type I Interferon Production by HIV-2 infected DC-T Co-Cultures.. 115	  
Figure 16. Interferon Restriction of HIV-2 Infection of T cells and DCs. ............ 117	  
Figure 17. Design of AVNs. ............................................................................... 123	  
Figure 18. Schematic Diagram Showing Lymph Node Sinus-Resident 
Macrophage Populations Along with the Surface Markers they Express.. . 124	  
Figure 19. Diagram of Possible Advantages to New Adjuvants. ....................... 128	  
	  xvi 
Figure 20. Retroviral Capture and Transfer Function is Conserved Between 
Human and Murine CD169. ........................................................................ 130	  
Figure 21. Murine DCs Transfer HIV-1 More Efficiently than HIV-2 to Human 
CD4+ T Cells.. ............................................................................................. 133	  
Figure 22. GM3-AVNs Recapitulate GM3-CD169 Mediated HIV-1 Sequestration 
into Peripheral Non-Lysosomal Compartments in mDCs. .......................... 139	  
Figure 23. Characterization of Oriented mDC-T cell Conjugates Through 
Correlated Darkfield /Fluorescence Imaging. ............................................. 140	  
Figure 24. Formulation of Nanoparticles with Pam3CSK4. ............................... 144	  
Figure 25. Immature Human DCs are Activated by Nanoparticles Containing 
Pam3CSK4.. ................................................................................................ 145	  
Figure 27. Model of How HIV-1 and HIV-2 Interact with Dendritic Cells ........... 158	  
  
	  xvii 
LIST OF ABBREVIATIONS 
3TC     lamivudine 
Ab     antibody 
AF     Alexafluor 
AIDS     acquired immune deficiency syndrome 
AML     acute myeloid leukemia 
APC     antigen presenting cell 
APOBEC    apolipoprotein B mRNA editing enzyme,  
      catalytic polypeptide-like 
APS      ammonium persulfate 
BLAM     β-lactamase 
BDDC     bone marrow derived dendritic cell 
BDM     bone marrow derived macrophage 
BME     β-2-Mercaptoethanol 
BSA     bovine serum albumin 
°C     degree(s) Celsius 
CaCl2     calcium chloride 
CA     capsid protein  
cART     combination anti-retroviral therapy 
CCR     C-C chemokine receptor 
CD     cluster of differentiation 
CDC     Centers of Disease Control and Prevention 
	  xviii 
cDNA      complementary deoxyribonucleic acid 
cGas     cyclic-GMP-AMP synthase 
CMV      cytomegalovirus 
CO2      carbon dioxide 
CXCR     C-X-C chemokine receptor 
DAPI      4’,6’-diamidino-2-phenylindole 
DC     dendritic cell 
DCIR     dendritic cell immunoreceptor 
DC-SIGN    dendritic cell-specific ICAM-3 grabbing 
 nonintegrin 
dH2O      distilled H2O 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DMSO     dimethyl sulphoxide 
DNA      deoxyribonucleic acid 
dNTP      deoxynucleotide triphosphate 
dNTPase    deoxynucleotide triphosphatase 
dsRNA     double stranded RNA 
DTT      dithiothreitol 
E. coli     Escherichia coli 
EDTA     ethylenediaminetetraacetic acid 
EGFP     enhanced green fluorescent protein 
EFV     efavirenz 
	  xix 
ELISA     enzyme-linked immunosorbent assay 
EM      electron microscopy 
Env     envelope 
FACS     fluorescence-activated cell scanning 
FBS      fetal bovine serum 
FI     fusion inhibitor 
FITC     fluorescein isothiocyanate 
g      gram 
gag     group-specific antigen 
GALT     gut-associated lymphoid tissue 
GFP     green fluorescent protein 
GM-CSF    granulocyte/monocyte colony stimulating factor 
GSL     glycosphingolipid 
HAART     highly active anti-retroviral therapy 
HEK     human embryonic kidney 
HIV     human immunodeficiency virus 
HIV-1     human immunodeficiency virus type 1 
HIV-2      human immunodeficiency virus type 2 
hpi      hours post infection 
HRP      horseradish peroxidase 
HSPG     heparin sulfate proteoglycan 
ICAM     intercellular adhesion molecule 
	  xx 
IFN      interferon 
IL     interleukin 
IN     integrase 
IRF     interferon regulatory factor 
ISG     interferon sensitive gene 
ISRE     interferon-sensitive response element 
J      Joule 
kDa      kiloDalton 
LAMP-1    lysosomal-associated membrane protein 1 
LB      Luria Broth 
LC     Langerhans cell  
LPS     lipopolysaccharide 
LTNP     long term non-progressors 
LTR      long terminal repeat 
M      Molar 
mA      milliampere 
MA     matrix protein 
mAb     monoclonal antibody 
mDC     myeloid dendritic cell 
MDDC    monocyte-derived dendritic cell 
MHC     major histocompatibility complex 
MgCl2     magnesium chloride 
	  xxi 
ml      milliliter 
mM      milliMolar 
MOI      multiplicity of infection 
mRNA     messenger RNA 
nAbs     neutralizing antibodies 
NaCl      sodium chloride 
NC     nucleocapsid 
NaOAc     sodium acetate 
NaOH     sodium hydroxide 
NCS     newborn calf serum 
Nef     negative infectivity factor 
NFκB      nuclear factor κ of B cells 
ng     nanogram 
nm      nanometer 
nM      nanoMolar 
NNRTI    non-nucleoside RT inhibitors 
NRTI     nucleoside/nucleotide RT inhibitors 
nt      nucleotide 
NTP      nucleotide triphosphate 
ORF      open reading frame 
PAGE     polyacrylamide gel electrophoresis 
PAMP     pathogen-associated molecular pattern 
	  xxii 
PBMC     peripheral blood mononuclear cell 
PEB     PBS + EDTA + BSA 
PBS      phosphate-buffered saline 
PBS-T     PBS-Tween 
PCR      polymerase chain reaction 
pDC     plasmacytoid dendritic cell 
PE      phycoerythrin 
PFA     paraformaldehyde 
PHA     phytohemagglutinin 
PI     protease inhibitor 
PMA     phorbol-12-myristate-13-acetate 
pmol      picomole 
Pol     polymerase 
Poly I:C    polyinosinic:polycytidylic acid 
PPT     poly proline tract 
PR     protease 
PrEP     pre-exposure prophylaxis 
PRR     pattern recognition receptor 
P/S     penicillin, streptomycin 
PVDF     polyvinylidene difluoride 
Rev     regulator of viral expression 
RNase     ribonuclease 
	  xxiii 
RNA      ribonucleic acid 
RRE     rev response element 
RT      reverse transcriptase 
rt     room temperature 
RT-PCR    reverse transcriptase-polymerase chain  
      reaction  
s     second 
SAMHD1    SAM domain and HD domain containing  
      protein 1 
SAP     shrimp alkaline phosphatase    
SDS      sodium dodecyl sulfate 
SDS-PAGE                                   sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SIV                                                simian immunodeficiency virus 
SSC      saline-sodium citrate 
ssRNA     single stranded RNA 
STI     sexually transmitted infection 
SU     surface 
TAR      trans-activation response element 
Tat     trans-activator of transcription 
Ta      annealing temperature 
TBE      Tris borate EDTA 
	  xxiv 
TBS     Tris-buffered saline 
TCR     T cell receptor 
TDF     tenofovir 
TE      Tris-EDTA 
TEMED     tetramethylethlenediamine 
Th1      T helper cell type 1 
Th2      T helper cell type 2 
TLR      toll-like receptor 
TM     trans membrane 
TNF-α     tumor necrosis factor α 
tRNA     transfer RNA 
V      volts 
V3     gp120 variable loop 3 
Vif     viral infectivity factor 
VLP     virus-like particle 
Vpr     viral protein R 
Vpu     viral protein U  
Vpx     viral protein X 
VSV      vesicular stomatitis virus 
VSV-G    vesicular stomatitis virus glycoprotein 
W      watts 
WHO     World Health Organization 
	  xxv 
WT      wild type 
X-gal     5-bromo-4-chloro-3-indolyl-P-D- 
      galactopyranoside 
µ      micron 
µg      microgram 
µl      microliter 
µm      micrometer 
µM     microMolar 
 
	  1 
INTRODUCTION 
Note that some figures and text in this introduction have appeared in print 
previously; 10.2217/FVL.15.2 © 2015 Future Medicine Lt Future Virol. (2015) 
10(3), 257–269 ISSN 1746-0794 All Rights Reserved. 
 
HIV: Global Health Threat/Dissemination 
It has been over 30 years since the causative agent of AIDS was discovered. In 
that time approximately 78 million people have been infected with HIV and 39 
million people have died of AIDS-related illnesses (1). There are 35 million 
people infected worldwide, ranking HIV a serious global health issue (1). While 
the infection rates worldwide have decreased 38% since 2001, primarily because 
of significant improvements in anti-retroviral therapy, there is no viable vaccine or 
cure for HIV infection.   
 
On the front lines of HIV infection there is an arms race between establishment of 
virus infection and the immune system’s ability to react and block virus infection 
and dissemination. It is now understood that once HIV infects an individual, a 
reservoir of latently infected, long-lived memory CD4+ T cells is quickly 
established, creating a virus stronghold, that is maintained through-out the 
course of disease. Considerable research effort has been expended on finding 
methods to inhibit the initial establishment of virus infection and the subsequent 
depletion of the immune system. My dissertation will focus on the role of dendritic 
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cells in the systemic dissemination and establishment of HIV infection. I 
hypothesize that HIV-2, which displays an altered natural course of disease in 
infected individuals and has been reported to be a significantly less transmissible 
virus in the human populations, displays divergent interactions with dendritic cells 
than HIV-1. This dissertation, in particular, will discuss the mechanistic 
differences in how HIV-1 and HIV-2 interact with dendritic cells, and the 
consequences of these altered interactions on HIV-2 pathogenesis.  
 
Current Treatment and Lack of Vaccine 
The current standard treatment is called combination anti-retroviral treatment 
(cART) and was introduced in 1996. In their last update, UNAIDS reported that 
9.7 million HIV+ people were on antiretroviral therapy in 2012 compared to 8.1 
million in 2011 (1). This is a significant increase, however with the current 
guidelines of when to start cART, approximately 26 million more individuals 
should be on therapy (1). The WHO recommends that the first line of treatment 
should consist of two nucleoside reverse transcriptase inhibitors (NRTIs) and one 
non-nucleoside reverse transcriptase inhibitor (NNRTI). For example, the 
combination pill consisting tenofovir, lamivudine, and efavirenz (TDF + 3TC + 
EFV) is the preferred fixed dose option (197). The recommendations differ 
depending on CD4 count, age, whether the patient is pregnant or displays 
resistance to existing drug regimens. Other anti-viral options include protease 
inhibitors (PI) and fusion inhibitors (FI). Recent cohort studies have shown that 
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the life expectancy of an HIV-1+ twenty year old with access to cART is two thirds 
that of the general population (115). However, due to chronic immune activation, 
there is a substantial increase in non-AIDS related illnesses in this population. 
These include cardiovascular disease, cancer, kidney disease, liver disease, 
neurologic disease, and bone diseases (141). Nevertheless, cART does increase 
the quality of life for HIV-1+ patients, but access and affordability are still very 
large problems.  
 
Recently, PrEP, which stands for pre-exposure prophylaxis, has been promoted 
in high-risk communities. The combination pill called Truvada that contains 
tenofovir and emtricitabine was approved for HIV treatment in 2004 and for use 
as PrEP in 2012. The iPrex study found that among men who have sex with men, 
PrEP reduces the overall risk of infection by 44% (96). Additionally, among the 
men who had detectable drug in their system, PrEP reduced risk of infection up 
to 92% (96).  Additionally, innovative studies are investigating optimal schedules 
for dosing anti-retrovirals for effective treatment/prevention without inducing 
resistance and reducing side effects.  Such studies have yielded possible 
treatment schedules based on intercourse occurrence or taking weekends off 
from treatment.  The latter has shown to be popular in teen populations for 
reducing side effects and increasing adherence to medication (40). Thus, 
developments in treatment and prevention are progressing. However, not much 
is known about the best treatment protocol for HIV-2 and in West Africa there are 
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individuals who are HIV-2+ and HIV-1+HIV-2+ that confound the treatment 
protocols.  
 
Over thirty years after the emergence of HIV, there is only one example of a 
“cure” and no vaccine. The “Berlin Patient”, Timothy Ray Brown, is the one 
example of an HIV+ individual being cured (39). He was both HIV+ and diagnosed 
with acute myeloid leukemia (AML), resulting in the need for a stem cell 
transplant.  His doctor found a stem cell donor match that also contained the 
CCR5Δ32 mutation, which leads to resistance to HIV infection (230). He stopped 
taking antiretrovirals on the day of his transplant and has been declared HIV- 
ever since. Many speculate that there are some remnants of virus in the patient’s 
body, but his result may equate to a “functional cure” since it appears the 
residual proviruses cannot infect new cells. Many investigators have attempted to 
use stem cell transplants to “functionally cure” additional HIV-1+ patients (15, 55, 
111, 112, 116, 122, 272), however without the CCR5Δ32 mutation (111, 112). 
Interestingly, doctors found a sustained reduction in viral load post 
transplantation not on cART treatment. However, viral rebound did occur in these 
cases implying that viral reservoirs persisted (111). Researchers concluded that 
it would be necessary to define the latent reservoirs and determine their half-life 
(111). Subsequently, in the search to emulate the Berlin Patient functional cure 
many researchers are seeking to use gene therapy to alter a patient’s own cells 
to be CCR5Δ32 (255). 
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HIV-1 Versus HIV-2 
History and Epidemiology 
There are two viruses that cause Acquired Immune Deficiency Syndrome (AIDS) 
in humans: HIV-2, is believed to have made a zoonotic jump from SIVsmm-
infected sooty mangabeys (Cercocebus atys) in 1940 ± sixteen years while the 
major pandemic strain of HIV-1 (Group M), has been hypothesized to have made 
the jump from SIVcpz-infected chimpanzee (Pan troglodytes) in 1930 ± fifteen 
years (154). Both viruses have resulted from multiple jumps due to human 
exposure to infected non-human primates (238). Interestingly, SIV infection rate 
of sooty mangabeys’ that are native to coastal West Africa, and are frequently 
hunted or kept as pets, is approximately 22% (100). Meanwhile, HIV-1 shares the 
exact genome organization, viral protein vpu, and has geographical linkage with 
SIVcpz (100). HIV-2 was identified in 1986 in AIDS patients who tested negative 
for HIV-1 antibodies (54). It was hypothesized that exposure to primate blood 
during hunting and handling bush meat allowed for transmission combined with 
socioeconomic conditions such as prostitution and social disruption contributed 
to the AIDS epidemic (100). 
 
The HIV-2 epidemic has predominantly been confined to West Africa while HIV-1 
has spread worldwide. While the HIV-1 epidemic is still a major public health 
concern, especially in sub-Saharan Africa, HIV-2 epidemic appears to be 
diminishing (60, 101). Most of the HIV-2+ cases in other countries can be linked 
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to a connection with West Africa. For example, there has been documentation of 
HIV-2 cases in Portugal, which has historically traded with West African 
countries.  From 1988 to June 2010, the CDC was notified of 242 cases of HIV-2 
in the United States (with 166 meeting their criteria of HIV-2 detection), which is 
0.01% of the 1.4 million cases of HIV-1 reported in the same time period in the 
U.S. (259). Of those 166 cases, 132 (81%) were individuals who were born in 
West Africa (259). Interestingly, 19 of the 166 cases were also positive for HIV-1, 
indicating co-infection (259). Co-infection has been a controversial topic of study. 
Some cohort studies have found that co-infection of HIV-1 and HIV-2 can lead to 
a slower disease progression (75). Additionally, this study also found that if 
seroconversion of HIV-2 occurred first, HIV-1 disease progression was blocked 
(75). This may point to HIV-2 priming the immune system to better control HIV-1 
viral load and could have implications for therapeutics.  
 
Infection Course 
The typical course of infection for HIV-1 involves flu-like symptoms 2-3 weeks 
post exposure, including fatigue and swollen lymph nodes (76). Within eight 
weeks of infection viral load spikes and CD4+ T cell count drastically declines 
(84). The intensity and persistence of the symptoms vary by individual, but they 
typically resolve within weeks, coinciding with viral loads plateauing and CD4+ 
counts rebounding some, but not back to baseline levels (76). Ideally, 
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antiretroviral treatment is started at this acute stage of infection to lower the 
baseline viral load. 
 
This next stage is known as the clinically latent stage of infection, which is where 
HIV-1 and HIV-2 diverge the most. In the absence of anti-retroviral therapy, HIV-
1 will typically progress to AIDS within eight to ten years (76). However, less than 
1% of HIV-1+ individuals are known as elite controllers or long term non-
progressors (LTNP) and are able to control their viral load to below detectable 
levels without anti-retrovirals (195). In contrast to the rapid disease course of 
HIV-1, HIV-2 pathogenesis has been characterized as heterogeneous, with some 
infected individuals progressing to AIDS similar to HIV-1, but with the majority 
displaying relative viral control and maintaining high CD4+ T cell counts (63). In 
contrast, only 20-30% of untreated HIV-2+ individuals progress to AIDS (75). 
Thus a much larger proportion of HIV-2+ patients are considered LTNP (70-80% 
controlling viral load), an observation that is intriguing and is important to 
research. A prospective cohort study of treatment naïve women found that five 
years post-seroconversion 100% of HIV-2+ women were AIDS free compared to 
67% of HIV-1+ women (172). Thus, investigating the critical differences in these 
two virus strains and the immune system’s response to them will inform 
therapeutic design. 
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Genome Similarities & Differences 
HIV-1 and HIV-2 are enveloped RNA viruses with similar genome organization 
and are part of the subgenus of primate lentiviruses. The HIV genome is 
comprised of nine genes or open reading frames (ORFs), which encode fifteen 
viral proteins that provide structural, enzymatic, and regulatory functions (Figure 
1) (155).  The gag  (group specific antigen) gene encodes a precursor p55 kDa 
myristoylated polyprotein which the viral protease processes into four structural 
proteins Matrix (MA), Capsid (CA), Nucleocapsid (NC) and p6, that comprise the 
inner core of the virus (268). Viral gene pol encodes the critical viral enzymes: 
Protease (PR), Reverse Transcriptase (RT) and Integrase (IN), produced as gag-
pol polyprotein, and are also subsequently processed by viral protease (268). 
Viral gene env encodes the viral envelope glycoproteins gp120 (or surface, SU) 
and gp41 (or transmembrane, TM), that are incorporated in the viral membrane 
and confer specificity of receptor binding and fusion into target cells (81). The 
remaining genes code for regulatory proteins: Tat and Rev and accessory 
proteins: Vif, Vpr, Vpu or Vpx and Nef. 
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Figure 1. Genome Organization of HIV-1 and HIV-2. LTR= long terminal 
repeat, gag= group specific antigen gene, ma= matrix, ca= capsid, p7= 
nucleocapsid, pol= polymerase, PR= protease, RT= reverse transcriptase, IN= 
integrase, env= envelope. 
 
 
 
 
 
 
 
 
 
	  10 
Importantly, HIV-2 is genetically more similar to SIVsmm than HIV-1; while HIV-1 is 
closer to SIVcpz than HIV-2 based on maximum-likelihood phylogenetic analysis 
of full-length Pol protein sequence (Figure 2) (100). As previously mentioned, 
both SIVcpz and HIV-1 encode vpu; meanwhile SIVsmm and HIV-2 encode Vpx. 
Beyond these two viral protein differences, there is approximately 60% sequence 
similarity between HIV-1 and HIV-2 in the regions of Gag and Pol and 30-40% 
sequence homology for the other genes and LTRs (99). The HIV-2 LTR 
components (U5, R and U3) are all longer than those of HIV-1 due to insertions 
that suggest distant homology (99). The majority of the differences between HIV-
1 and HIV-2 lie in env, which correspond to differences in co-receptor usage for 
fusion (184).  
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Figure 2. Phylogenetic Tree Comparing SIV, HIV-1 and HIV-2. Phylogenetic 
tree displaying the evolutionary relationships of primate lentiviruses based on 
maximum-likelihood phylogenetic analysis of full-length Pol protein sequences. 
The scale bar indicates 0.1 amino acid replacement per site after correction for 
multiple hits (100).Figure from Hahn et al. Science 2000 
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Life Cycle 
Fusion & Entry 
As an obligate intracellular parasite, HIV needs cellular machinery to replicate. 
Therefore, the first step of the HIV life cycle is fusion with host cell receptors to 
allow entry into the host cell. Fusion occurs between viral glycoproteins 
incorporated in the viral membrane and receptors and co-receptors on the target 
cell surface. Cryoelectron microscopy demonstrated that there are ~14 and ~73 
glycoprotein spikes on HIV-1 and SIV viral particle surfaces respectively (282). 
Early studies suspected that SIV and HIV-2 particles contain more glycoprotein 
spikes than HIV-1, but more studies are needed (105, 282). Many studies 
determined that the primary receptor necessary for HIV-1 entry is CD4 (163, 
178). Nevertheless, expression of CD4 alone on non-human cells do not render 
them susceptible to HIV indicating that co-receptors are necessary for fusion and 
entry (14, 53). Subsequent studies identified the G-protein-coupled chemokine 
receptors, CXCR4 and CCR5, as co-receptors necessary for virus entry (66).  
Binding of envelope glycoprotein, gp120, to CD4 causes a rearrangement of the 
V1, V2, and V3 loops resulting in a bridging sheet and co-receptor engagement 
(50, 145). This conformation is the target for neutralizing antibodies (nABs) and it 
has been found that HIV-2 gp125 is more frequently found in this conformation, 
rendering it more sensitive to nABs (166). HIV-1 virus strains can be classified as 
CCR5 tropic, CXCR4 tropic or dual tropic, depending on if the virus utilizes CCR5 
alone, CXCR4 alone or either co-receptors for entry. However, HIV-2 has been 
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shown to be much more promiscuous than HIV-1 with the ability to use co-
receptors other than CCR5 and CXCR4 including chemokine receptors CCR1, 
CCR2b, CCR3, and BOB receptors (184). There are also differences in fusion 
kinetics between HIV-1 and HIV-2. Studies with HIV-2 Env have demonstrated 
an enhanced kinetics of conformation change of Env variable loops and 
subsequently faster CD4-dependent fusion compared to HIV-1 (85).  More 
studies are needed to understand the effects of these differences in co-receptor 
usage and fusion kinetics between HIV-1 and HIV-2.  
 
After fusion and entry into the target cell, the virus must uncoat and release the 
particle contents, which then travel toward the nucleus via the microtubule 
network (176). The kinetics and logistics of this process has been a difficult area 
of study especially since the capsid core is fragile in vitro. What is known is that 
during uncoating the viral RNA is reverse transcribed in association with the RTC 
(reverse transcription complex) (11). Uncoating kinetics of the viral capsid may 
play a critical role in sensing of viral determinants by the host cell.  A genetic 
screen in a rhesus cDNA library found a conserved restriction factor termed, 
TRIM5α, which restricts HIV-1 infection but not SIV in monkey cells, by 
recognizing the hexameric Gag lattice structure of the incoming viral capsid and 
targeting them to proteasomal degradation (247). The family of TRIM proteins 
share a tripartite motif (TRIM), RING domain, a B-box 2 domain, a coiled-coil 
domain and the alpha isoforms contain the important C-terminal PRYSPRY 
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(B30.2) domain (186, 193, 247). The sequence of the PRYSPRY domain dictates 
species specific restriction (186). For example, the TRIM5α of old world monkeys 
(OWM) such as Rhesus monkeys, cynomolgus monkeys and baboons restricts 
HIV-1, while there is variable restriction of HIV-2 depending on strain (43, 44, 83, 
157, 158). Recent studies found that HIV-2 may uncoat faster than HIV-1 though 
the mechanism explanation is unknown (252).   
 
Reverse Transcription and Integration 
As retroviruses, converting their RNA genome to DNA is their defining 
characteristic. Thus reverse transcription and integration are critical steps in HIV-
1 and HIV-2 life cycles. Another factor indicating its importance is the fact that the 
first anti-retroviral drug, AZT, was directed at the viral enzyme reverse 
transcriptase (RT) and many of the current drugs still target RT. Interestingly, 
there is only 60% amino acid sequence homology between HIV-1 and HIV-2 RT 
(99). Importantly, most RT inhibitors, called NNRTIs, are not effective against 
HIV-2 RT due to significant structural differences in the binding area (219). 
Recently it has been discovered that a large difference in the RT activity between 
HIV-1 and HIV-2 can be attributed to a glutamine at position 294 in HIV-2 RNAse 
H domain (proline in HIV-1), which leads to 10-fold less RT activity (113) Both 
HIV-1 and HIV-2 RT have RNA dependent and DNA dependent polymerase 
activity along with RNAse H activity, but in limiting dNTP conditions, such as 
those found in quiescent or non-dividing cells, HIV-1 RT has been shown to be 
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significantly more efficient (210). Many studies have shown that additional steps: 
RNAse cleavage, tRNA removal, and reduced affinity to the RNA polypurine tract 
(PPT) on top of increased salt sensitivity reduces the efficiency of HIV-2 RT 
(210). How these findings relate to in vivo replication is unclear since 
comparative cohort studies show no differences in proviral DNA content in HIV-1 
and HIV-2 infected individuals in the absence of therapy (209).  
 
Beyond differences in the reverse transcriptase enzymes and processes, there 
are multiple cellular restriction factors, which limit lentivirus infections at the RT 
step. One restriction factor is APOBEC3G, which is incorporated into virions and 
inhibits HIV via its cytidine deaminase activity that results in introduction of G to A 
mutations in HIV DNA during the RT process (207), leading to introduction of 
stop codons or non-sense mutations in the viral ORFs. HIV-1 and HIV-2 both 
encode accessory protein called Viral infectivity factor, Vif, which counteracts 
APOBEC3G restriction by recruiting cullin5-elonginB/C ubuiquitin ligase complex 
and inducing polyubiquitylation and degradation of Apobec3G (171, 239, 246). 
Although HIV-1 and HIV-2 vif only share 25% amino acid sequence, both 
proteins are able to facilitate the degradation of APOBEC3G (221). Another 
restriction factor that limits the reverse transcription is SAMHD1, which through 
both its dNTPase and RNase activity depletes the intracellular pool of dNTPs and 
HIV-1 genomic RNA available for RT (118, 147, 226). Importantly, HIV-2 and 
some primate lentiviruses, but not HIV-1, encode Vpx, which directs SAMHD1 for 
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degradation via the CUL4/DCAF1 E3 ubiquitin ligase complex (118, 147). 
Therefore, HIV-2 is able to counteract SAMHD1 restriction in monocytes, resting 
T cells, dendritic cells and macrophages (20, 118, 147, 244). We will investigate 
the consequence of SAMHD1 degradation on productive infection by HIV-2 and 
subsequent immune sensing of HIV-2 in dendritic cells in Chapter 2. 
 
 After reverse transcription, viral DNA integrates into the host genome. It has 
been shown that HIV-1 and HIV-2 have similar integration site selection within 
transcriptional units (161). Interestingly, HIV-2 has been found to preferentially 
integrate in the antisense direction to the transcriptional start site, which may 
negatively impact the transcriptional activity of the HIV-2 LTR (similar to HERV 
(human endogenous retroviruses), which are less transcriptionally active) (234). 
Once integrated, many cis acting elements are involved in HIV-1 and HIV-2 gene 
expression including NF-kB, SP1, TATA and TAR (an RNA element in the LTR 
essential for Tat activation) (89). The TAR element of HIV-2 consists of two stem 
loops compared to the one in the TAR of HIV-1 (89). Interestingly, HIV-1 tat 
transactivates HIV-1 and HIV-2 LTRs to the same extent, while HIV-2 tat 
transactivates HIV-1 LTR to a lower level than HIV-2 LTR (73, 74). 
 
Assembly and Release 
As viral proteins are translated they aggregate and begin to assemble new 
virions at the plasma membrane (249). The Gag polyprotein plays a critical role 
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in organization of the other viral proteins and successful assembly and budding 
from the host cell. In fact, expression of HIV Gag alone is sufficient to drive 
immature virus particle assembly and budding at the plasma membrane, 
although production of infectious virus particles requires other viral proteins 
(249). Targeting of HIV-1 Gag to the plasma membrane is dependent on N-
terminal myristate group added co-translationally to Gag and interactions 
between basic residues at the N-terminus of MA and acidic headgroups of 
phospholipids enriched at the plasma membrane, including phosphatidylinositol-
(4,5)-bisphosphate [PI(4,5)P2] (227). At the plasma membrane, the Gag protein 
begins to multimerize by mechanisms that are poorly understood. While Gag 
multimerization and assembly are still in progress, the immature particles begin 
to bud, which activates Protease (PR) to cleave the Gag polyprotein into MA, CA, 
NC and p6 (249). HIV hijacks the intracellular endosomal sorting complexes 
required for transport  (ESCRT) system in order to bud from the cell (179).  Gag 
cleavage activates the condensing and stabilization of the dimeric genome- NC-
enzyme complex (249). Studies have found that while HIV-1 can replicate 
despite mutations in the dimer initiation site (DIS), HIV-2 requires dimerization via 
a palindrome in the packaging signal for both replication and packaging (146). 
Interestingly, in a study using Saccharomyces cerevisiae as a model system to 
investigate necessary host factors for immature virus particle budding, HIV-2 was 
found to be deficient in budding from transfected yeast spheroplasts, while HIV-1 
was able to produce virus like particles from yeast spheroplasts (181). The 
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relative inability of HIV-2 to bud from yeast spheroplasts is thought to be due to 
the inability of HIV-2 Gag to maintain a stable association with the plasma 
membrane (181). Additionally, multiple studies have shown that HIV-2 envelope 
glycoprotein potentiates virus budding similar to HIV-1 vpu (38, 223). Thus there 
are significant differences in viral assembly and budding between HIV-1 and HIV-
2.   
 
Immune Sensing of HIV-1 and HIV-2 
In addition to the restriction factors mentioned above that can block HIV 
replication, HIV-2 RT intermediates can be detected by cytosolic DNA sensors in 
DCs. Recent studies have identified a cytosolic DNA sensor, cGAS, cyclic-GMP-
AMP synthase, which binds adaptor protein STING and triggers type-I interferon 
through TBK1 and IRF3 (87, 253). Multiple interactions play a role in lentiviral 
DNA sensing via cGAS including the stability of the virus capsid (CA) and its 
interaction with cellular proteins, cyclophilin A (CypA) and CPSF6 (164). There 
appears to be significant differences in how HIV-1 and HIV-2 capsids interact 
with these cellular proteins. The increased affinity of HIV-1 CA for CypA may 
protect viral DNA from immune sensing; while HIV-2 CA has a lower affinity for 
CypA. Additionally, HIV-2 capsid uncoats at a faster rate (252)  and incorporation 
of Vpx in HIV-2 capsids results in degradation of SAMHD1, thus resulting in the 
presence of enhanced levels of HIV-2 RT intermediates that might be sensed via 
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cGAS (148, 215). More studies are needed to determine why HIV-2 viral DNA is 
exposed in the cytosol and not delivered efficiently to the nucleus for integration.  
 
Adaptive Immune Responses against HIV-1 and HIV-2 
There are various cohort studies looking at the immune responses elicited in 
HIV-1 and HIV-2 infected patients and how immune responses correspond to 
viral load. One study found that generation of autologous neutralizing antibodies 
is very rare in HIV-1 infected individuals (10-31%) but in a study of HIV-2 infected 
individuals, the majority of infected patients (68%) developed antibodies that 
effectively neutralized their virus (31). Interestingly, cytotoxic T cells (CTLs) 
generated during HIV-2 infection have been shown to cross react with different 
HIV-1 clades (27, 206). In contrast to the chronic inflammation in HIV-1 infected 
individuals, another study concluded that HIV-2 Env can have an 
immunosuppressive effect that might be beneficial to the infected host (45). 
Another study found that HIV-2 Nef, but not HIV-1 Nef functions to reduce 
CD3/TCR expression of T cells, reducing immune activation during infection 
(232). These results correspond to a cohort study finding that hypothesizes that 
immune activation plays a more important role in CD4+ T cell depletion than viral 
load (242). More research into the diverse immune response, the resulting 
immune activation and the necessary elements for viral control is needed. We 
compared immune activation resulting from HIV-1 and HIV-2 infection in Chapter 
2. 
	  20 
 
Despite all of these differences, HIV-1 and HIV-2 can both cause AIDS in 
humans though the course of disease progression is significantly different. 
Studies from our laboratory as well as others have previously shown the 
importance of dendritic cells in mediating efficient systemic dissemination of HIV-
1 (125, 211). Therefore, I will investigate if the differential replication outcome of 
HIV-1 and HIV-2 in dendritic cells provides a mechanistic understanding for the 
pathogenic differences in HIV-1 and HIV-2 infections in vivo.  
 
HIV Interaction with Target Cells 
Dendritic Cells and their role 
In 1974, Ralph Steinman identified a new cell type in lymphoid organs of mice. 
Steinman and colleagues named this new cell type “dendritic” cell due to the 
cell’s stellate or tree-like morphology (245). Since their discovery, dendritic cells 
(DCs) have been found to populate all of the peripheral mucosal tissues and are 
at the front line of defense for the immune system. They are not only able to 
launch innate immune responses upon pathogen detection but also contribute to 
modulating subsequent adaptive immune responses. Located in mucosal tissues, 
these sentinel cells sample and patrol their environment for foreign pathogens 
and have the ability to traffic to secondary lymph organs where they present 
antigens to naïve CD4+ T cells to initiate adaptive immune responses (21).  
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DCs express a number of pattern recognition receptors (PRRs), which they use 
to detect viral and bacterial invaders. PRRs recognize common pathogen 
associated molecular patterns (PAMPs) and this recognition is essential for 
triggering pro-inflammatory genes, maturation of DCs and subsequent migration 
to the secondary lymph nodes. DCs form immunological synapses with T cells 
presenting antigens through MHC complexes and signaling through co-
stimulatory molecules (121). Due to these features, DCs are known as 
professional antigen-presenting cells (APCs) that link the innate and adaptive 
immune responses (21). Therefore, DCs have a central role in pathogen 
recognition and directing the immune response. Not surprisingly, viruses such as 
HIV-1 have evolved to subvert DC functions to facilitate dissemination. An 
example of HIV-1 subversion of DC function is the use of synaptic junctions to 
facilitate efficient cell-associated virus spread to target CD4+ T cells and evade 
detection by PRRs within DCs. DCs have been shown to be integral in the 
dissemination of  HIV by either transferring de novo replicated virus to CD4+ T 
cells or by capturing HIV-1 particles and retaining them in an infectious state that 
are then subsequently transmitted to CD4+ T cells, a mechanism of DC-mediated 
trans infection (204, 273). Transfer of captured HIV-1 particles across DC – T cell 
synaptic junctions, also called “virological” synapses”, primarily because of the 
presence of virus particles at the DC – T cell contact site, is a robust mechanism 
for establishment of productive infection in CD4+ T cell (133, 134, 203). In this 
way HIV-1 appears to exploit DCs for dissemination.  
	  22 
 
Dendritic Cell Subsets 
DCs are found throughout the body, in the bloodstream and are known to traffic 
to secondary lymph nodes. Three main DC subsets have been described in 
human blood: plasmacytoid DCs (pDCs) (CD11c-CD123+) and two types of 
CD11c+ myeloid DCs (mDCs) divided into the major BDCA1+ and a minor 
BDCA3+ DC subsets (72, 224). In addition to peripheral blood, DCs have also 
been described in mucosal tissues, such as the tissue resident Langerhans cells 
(LCs) (CD1a+ E-cadherin+ langerin+) (91, 156, 199). Myeloid DCs are a relatively 
short-lived DC subset, which constantly circulate between blood and tissues, 
monitoring viral and bacterial pathogens. Immature myeloid DCs are highly 
phagocytic and express toll like receptors (TLRs) 2, 3, 4, and 7 that sense both 
extracellular and phagocytosed PAMPs, and upon binding their ligands trigger 
cytokine release that shape T cells responses to a Th1 or Th2 phenotype (91, 
156).  
 
In contrast to mDCs, pDCs are mainly tissue resident, have a longer life span 
and are known for their rapid response to viral pathogens by producing type I 
interferon (156). Expression profile of TLRs in pDCs is divergent from that 
observed in mDCs. Specifically, pDCs express TLR7 and 9, which are triggered 
by sensing viral RNA and DNA respectively in endosomal compartments (156). 
Plasmacytoid DCs may play a key role in the immune system’s control of HIV-1 
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infection with early IFNα expression upon detection of viral RNA and subsequent 
inhibition of virus production. However these cells may also contribute to the 
chronic inflammation that leads to HIV persistence (79). The chronic 
inflammation seen in HIV infection may be due to continued unchecked 
production of IFNα and apoptotic ligand TRAIL by activated pDCs, which has 
been shown to trigger apoptosis in CD4+ T cells during the course of infection 
(23, 79). While type I IFN production can result in the induction of ISGs 
(interferon-stimulated genes) that restrict HIV-1 infection, it might also result in 
chronic production of chemokines, such as CXCL9 and CXCL10, that result in 
persistent recruitment of activated cells to tissue sites of virus infection (240). 
Interestingly, pDC dysfunction has been associated with rapid disease 
progression in HIV-1 infected individuals (79).  
 
Langerhans cells (LCs) are DCs found in the epidermis. They are characterized 
by the expression of unique organelles called birbeck granules, endosomal 
compartments that are exclusively expressed in LCs and are thought to be 
involved in antigen presentation (29, 136, 256). Langerhans cells sample the 
microenvironment in the genital mucosa and in the luminal space by extending 
dendrites across the epithelial barrier (114). Epidermal LCs in the genital mucosa 
have been shown to harbor lentiviral genomes early after transmission (114) and 
transfer virus to T cells (86, 187). Furthermore productive infection of LCs in vitro 
has also been observed (16, 42, 48, 254, 279, 280).   
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Although the above three DC subsets can be isolated from either blood or tissue 
samples, the cell yield is limiting for in vitro experiments. Due to ease of isolation 
and cell yield, most of the research on DCs is performed with monocyte derived 
dendritic cells (moDCs) by differentiating blood-derived monocytes (CD14+) in 
the presence of the cytokines, granulocyte/macrophage colony stimulating factor 
(GM-CSF) and interleukin 4 (IL-4), as an in vitro model of conventional mDCs 
(229).  
 
DCs and HIV: Cis Infection 
Restriction Factors 
DCs have long been implicated in facilitating HIV transmission and dissemination 
at mucosal surfaces (4, 222, 273), via mechanisms that have yet to be clearly 
defined.  Although moDCs are susceptible to infection by HIV-1, productive 
infection of moDCs in vitro and in vivo is 10-100 fold lower than CD4+ T cells 
(273).  There are many pre and post entry restrictions that lead to this deficiency. 
The first of these restrictions is the low levels of entry receptors CD4 and CCR5 
on DCs (152). As a result, virions are less able to attach, fuse and enter moDCs. 
The virions that are able to fuse and enter are confronted with many interferon-
dependent and independent viral restrictions that block virus replication at early 
steps in the viral life cycle (95, 189, 190, 207, 264). For instance, IFNα-inducible 
restriction factors, APOBEC3G and SAMHD1 (118, 147, 207) can block virus 
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replication at the reverse transcription step via diverse mechanisms. Apobec3G 
deaminates cytidine residues in the viral DNA to uracils (239) while SAMHD1 
restricts HIV-1 replication by hydrolyzing deoxyribonucleotides in cells, thus 
reducing the pool of nucleotides available for reverse transcription (20, 118, 147, 
244). In addition to its dNTPase activity, SAMHD1 has also been recently 
described to encode RNase activity, which may contribute to its ability to restrict 
HIV-1 infection in moDCs by degrading the incoming viral genomic RNA (226). 
Interestingly, HIV-2 and primate lentiviruses encode Vpx, which through the 
CUL4/DCAF1 E3 ubiquitin ligase complex targets SAMHD1 for proteasomal 
degradation, allowing for productive infection of DCs (118, 147). However, other 
studies have reported that infections with primary or lab-adapted HIV-2 isolates 
do not result in robust replication in DCs (49, 70). In contrast to the reported 
disparities on relative infection of DCs with HIV-1 and HIV-2, most studies are in 
agreement that HIV-2 is capable of infecting CD4+ T cells at an equivalent level 
as HIV-1 (49, 70). 
 
Despite the pre and post entry restrictions to virus replication in DCs, low levels 
of productive HIV-1 infection of moDCs and mDCs have been reported in vitro 
(94, 159, 262). Furthermore, de novo synthesized HIV-1 particles can be 
transferred to CD4+ T cells with high efficiency across virological synapses (262). 
Interestingly, it has been hypothesized that establishment of productive infection 
of moDCs and de novo expression of Gag in moDCs triggers activation of a yet-
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to-be identified cytoplasmic sensing mechanism that results in type I interferon 
response and maturation of moDCs (169). Whether these late anti-viral 
responses also inhibit virus replication and dissemination is of active research 
interest (148, 169, 250) and remains unclear. Therefore, due to the listed 
restrictions to virus replication, cis infection of moDCs by HIV-1 presumably 
occurs at a low efficiency and possibly leads to immune detection. However, the 
moDC-mediated trans infection pathway might play a key role in HIV-1 
dissemination.  We investigated if the trans infection pathway plays a role in HIV-
2 dissemination in Chapter 1. 
 
HIV Capture/Trans Infection 
First Evidence of Trans Infection 
In 1992, Cameron and colleagues made the first observation of moDC-mediated 
HIV-1 trans infection and the role of DCs as a catalyst of virus dissemination 
(41). Interestingly, the authors were able to demonstrate that while moDCs 
themselves were not infected, they however played a key role in transferring 
infectious virus particles to CD4+ T cells. To prove virus-exposed but uninfected 
DCs were able to transfer virus to T cells, the authors used xenogeneic co-
cultures of either murine bone marrow derived DCs or human moDCs pulsed 
with HIV-1 and combined with either murine or human CD4+ T cells. Interestingly, 
both human and murine DCs transferred HIV-1 to human CD4+ T cells (41). 
These data suggested that HIV-1, an obligate intracellular parasite, might exploit 
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DCs to spread efficiently and evade immune sensing by not infecting DCs 
themselves.  
 
Receptors 
After the discovery of this new role of moDCs, identification of the receptor/ligand 
interaction responsible for moDC-mediated transfer of virus to CD4+ T cells was 
of major research interest. HIV-1 primarily interacts with its environment via the 
viral envelope, the outermost structure of the virion, which consists of projecting 
glycoprotein (gp120) spikes on a membrane derived from an infected host cell. 
Using cryo-electron microscopy, Zhu and colleagues discovered that on average, 
wild-type HIV-1 particles express 7-14 glycoprotein spikes on its surface (282). 
Much smaller in number than previously hypothesized, these limited number of 
spikes leave a large portion of the virion membrane devoid of virus-encoded 
determinants. Rather, numerous host-derived factors are incorporated in the lipid 
bilayer of the virion and have been hypothesized to play important roles in HIV-1 
interactions with host cells (52, 80). Thus, receptors that recognize both viral and 
host-derived determinants have been hypothesized to mediate virus interactions 
with moDCs. First we will focus on receptors that interact with HIV-1 gp120.  
 
Beyond the primary receptor CD4 and co-receptors CCR5 and CXCR4 that 
mediate virus fusion and entry, there are a multitude of receptors that can act as 
attachment factors for HIV-1 gp120 (Table 1), and enhance virus capture without 
	  28 
triggering virus particle fusion. Many of these attachment factors are C-type 
lectins, or calcium-dependent glycan binding proteins. These receptors are trans-
membrane proteins that are commonly involved in cell-to-cell adhesion and 
immune signaling (58). Additionally, this family of receptors all contain 
carbohydrate recognition domains (CRDs), which facilitate the high affinity 
binding of high mannose oligosaccharides found on glycoproteins of enveloped 
viruses (58). 
 
In 1992, Curtis et al. used an expression cloning strategy to screen a placental 
cDNA library for gp120 binding proteins independent of CD4 and identified a new 
C-type lectin (59).  Following this initial finding, Geijtenbeek and colleagues 
described a C-type lectin expressed in DCs that bound HIV-1 and assigned it the 
name DC-SIGN (Dendritic Cell-Specific Intercellular adhesion molecule 3 
Grabbing Non-integrin) (90).  Interestingly the sequence of DC-SIGN was 
identical to the C-type lectin Curtis et al. had previously identified (90). Using 
both a Raji B cell line expressing DC-SIGN and antibodies to block DC-SIGN 
function in DCs, the authors went on to demonstrate the ability of DC-SIGN to 
specifically capture HIV-1 particles by binding mannosylated gp120 and transfer 
virions to CD4+ T cells (90). While DC-SIGN was originally believed to be the 
essential DC-specific receptor necessary for capture and trans infection of HIV-1 
to CD4+ T cells, subsequent findings suggest that other C-type lectin receptors 
such as mannose receptor, langerin, and DC immune-receptor (DCIR) (also 
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called Lectin-like immunoreceptor, LLIR) expressed on dermal DCs, LCs, and 
blood mDCs could mediate HIV-1 trans infection (114, 150, 261). From all of 
these findings (summarized in Table 1), it is clear that many C-type lectins 
expressed on varied DC subsets have the capability to bind mannosylated 
gp120, though the relative contribution of these lectins to HIV-1 capture and trans 
infection in vivo remains to be determined.  
 
Beyond C-type lectins there are additional HIV-1 attachment factors on DCs that 
can capture and transfer HIV-1 to CD4+T cells. Syndecan-3 is a heparin sulfate 
proteoglycan that binds gp120, presumably via charge based interactions (36). In 
addition, galactosyl ceramide (GalCer), expressed on both mDCs circulating in 
blood and mucosal tissue resident DCs has also been shown to play a role in 
mediating virus transfer from DCs to autologous CD4+ T cells (165). Thus, 
despite the relatively low expression of gp120 on the virus surface, it is evident 
that sentinel DCs have many receptors that have the ability to specifically bind 
HIV-1 gp120. Notwithstanding the above list of HIV-1 attachment factors, there 
must be a hierarchy of physiologically relevant interactions, which determine the 
ultimate fate of the virus particles upon capture by DCs.  
 
While it has been hypothesized that the virus captured by gp120 binding 
receptors might play a role in evasion of HIV-1 from innate immune sensing 
mechanisms and trafficking of captured virus particles to T cells (90), capture of 
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HIV-1 by DC-SIGN can result in virus particle trafficking to a degradative 
endosomal compartment and enhanced MHC I presentation of viral antigens 
(182, 183). Furthermore, capture of virus by langerin on LCs can result in virion 
targeting to Birbeck granules for degradation (65). Alternatively, it has been 
shown that binding of gp120 by CLRs, including DC-SIGN can trigger an IL-10 
response, which may play a role in immune evasion by down-regulating MHC-II 
and co-stimulatory molecules (22, 97, 236). Thus, as the sole virus determinant 
exposed on the surface, gp120 is subject to detection by a number of receptors 
that might impact innate responses. Whether these receptors that capture HIV-1 
particles in a gp120-dependent manner enable virus dissemination or play an 
integral role in DC-intrinsic innate responses remains to be determined.  In 
contrast to virus-encoded determinants, incorporation of host determinants might 
facilitate virus capture by DCs and result in evasion from immune sensing or 
degradation of virus particles. 
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Table 1. Receptors that Capture HIV-1. 
Receptor Ligand Subset References 
DC-SIGN 
 
 
HIV Env gp120 Sub-epithelial rectal 
and lamina propria 
DCs 
(90), (129) 
Mannose HIV Env gp120 Dermal DCs (261) 
Langerin HIV Env gp120 Langerhans cells in 
the skin in genital 
epithelia 
(114), (261) 
DCIR HIV Env gp120 Immature moDCs (150) 
HSPG HIV Env gp120 Immature moDCs (180) 
Syndecans HIV Env gp120 Immature moDCs (36); (64) 
GSL 
(galactosylceramide) 
HIV Env gp41 & 
gp120 
moDCs, myeloid 
DCs, mucosal tissue 
resident DCs 
(165) 
CD169/Siglec1 GM3 Mature moDCs, (211); (125)  
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GM3/Gangliosides 
The majority of known receptors that capture virus do so through an interaction 
with HIV-1 gp120 or gp41 (Table 1). However, capture of HIV-1 particles by DCs 
can occur even in the presence of inhibitors that block all of the gp120-
dependent interactions (123). Furthermore, it has long been appreciated that 
while maturation of DCs down-regulates cell surface expression of DC-SIGN and 
phagocytosis, capture of HIV-1 particles is dramatically enhanced upon 
maturation of moDCs (108, 123, 269). Interestingly, gp120-deficient HIV-1 
particles can also be captured by moDCs at an efficiency similar to that observed 
with gp120-containing virus particles and, capture of gp120-deficient HIV-1 
particles was enhanced upon maturation of both monocyte-derived and blood 
myeloid DCs (108, 123, 127, 269). These findings suggested that in addition to 
gp120, host determinant(s) incorporated into the lipid bilayer of HIV-1 particles 
can also mediate efficient virus interactions with DCs. The host determinant 
necessary for HIV-1 capture by DCs is a glycosphingolipid (GSL) (108, 127). 
GSLs comprise one of three families of complex sphingolipids derived from a 
common ceramide backbone (233). While these molecules make up 
approximately five percent of the overall plasma membrane lipid composition, 
they are highly enriched in lipid rafts and are selectively incorporated in HIV-1 
particles as they bud from the host cell (212, 233).  
 
In 2012, using independent experimental approaches, the Gummuluru and 
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Martinez-Picado laboratories identified GSLs containing terminal α-2,3 sialic acid 
residues, such as GM3 (trisialotetrahexosylganglioside), as the host 
determinant(s) incorporated within virus particle membrane, necessary for 
gp120-independent HIV-1 capture by mature moDCs (124, 213). Specific 
requirement for GM3 was demonstrated by competitive inhibition of HIV-1 
capture by mature moDCs only by virus-sized liposomes or giant unilamellar 
vesicles bearing α-2,3 sialylated GSLs but not by α-2,6 or α-2,8 sialylated or 
asialo-GSLs (124, 213). Additionally, specific depletion of GM3, from virus 
particle membrane by deriving HIV-1 particles from virus producer cells with 
targeted deficiency in GM3 synthase, significantly reduced virus capture and 
mature moDC-mediated trans infection (213). Therefore, mature DC capture and 
trans infection of HIV-1 is independent of gp120 and dependent on GM3 
expression on the viral membrane. GM3 is expressed in the plasma membranes 
of macrophages and CD4+ T cells (33, 93), the primary virus reservoirs in vivo.  
Interestingly, GM3 expression in plasma membrane lipid rafts is up-regulated 
upon T cell or macrophage activation (212), resulting in increased levels of GM3 
incorporated into budding virions derived from these cells (213). Enhancement of 
GM3 levels in HIV-1 virions can result in significant increases in virus capture by 
mature DCs (212, 213) with subsequent enhancements to mature DC-mediated 
trans infection of T cells.  
 
Importantly, incorporation of host cell-derived gangliosides, such as GM3, within 
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the virus particle membrane is dependent on HIV-1 Gag-directed budding from 
GSL-enriched lipid raft plasma membrane microdomains (192, 196). Choice of 
plasma membrane microdomains preferentially accessed for virus assembly is 
governed by sequences in the matrix (MA) domain of HIV-1 Gag. Hence, 
mutations in the N-terminal basic region or deletion of the membrane-targeting 
domain of HIV-1 matrix (MA) that alter virus assembly site to intracellular 
membranes, results in reduced GM3 incorporation in MA-deficient viruses and 
diminished virus capture by mature moDCs (6). Interestingly, diverse enveloped 
viruses including Nipah and Hendra hemorrhagic fever viruses 
(paramyxoviruses), and MLV (murine leukemia virus, a retrovirus), incorporate 
sialylated GSLs in the virus particle membranes and are captured by mature 
moDCs (6, 47, 211), suggesting that GSL-dependent interactions with mature 
moDCs might be a conserved mechanism of DC-mediated enveloped virus 
dissemination (6). 
 
CD169 
Identification of GM3 as the virus particle-associated ligand necessary for virus 
capture by moDC and mDCs was critical to the discovery of CD169 or Siglec1 as 
the receptor responsible for DC-mediated HIV-1 trans infection (125, 211). 
CD169 satisfied all the requirements of DC-associated HIV-1 attachment factor: 
1) CD169 is expressed exclusively on myeloid cells, such as macrophages and 
DCs (107, 160). While peripheral blood monocytes do not express CD169, 
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expression is induced upon differentiation of monocytes into macrophages or 
moDCs (211); 2) CD169 preferentially binds to glyco-conjugates with terminal α-
2,3 sialic acid residues (160); 3) Expression of CD169, a type I IFN-inducible 
protein, is enhanced on mature moDCs, thus accounting for the dramatic 
increase in HIV-1 capture by moDCs matured by TLR ligands that initiate TRIF-
dependent signaling cascades resulting in type I IFN production over that 
observed with immature moDCs (211). 
 
CD169, also called sialoadhesin or Siglec 1 (sialic acid binding Ig-like lectin 1), a 
member of the immunologlobin-like lectin superfamily [30], was first 
characterized as a sialic-acid dependent receptor of sheep erythrocytes (9, 107) 
expressed on mouse bone marrow derived and tissue-resident macrophages. 
CD169 is a myeloid cell-specific activation marker, whose expression is 
enhanced on inflammatory monocytes and tissue-resident macrophages in 
chronic inflammatory diseases (28, 107, 168, 218, 265). All Siglecs, including 
CD169, have been implicated to play roles in cell-to-cell adhesion and initiate cell 
signaling to dampen or activate immune responses (56). Furthermore, Siglecs 
have a homologous amino-terminal immunoglobulin (Ig)-like V-set domain that 
contains the sialic acid binding site, and a variable number (2 – 17) of Ig-like C2 
set domains. CD169 is the largest member of the Siglec family with seventeen 
Ig-like domains in the amino terminus, but unlike other members of the Siglec 
family, lacks signaling domains in the cytoplasmic tail (188, 267). It has been 
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speculated that the function of the seventeen Ig-like domains is to extend the 
sialic acid binding site of the molecule away from the plasma membrane, favoring 
cell-cell interactions (107). The extended extracellular domain of CD169 is also 
hypothesized to favor cell – pathogen interactions in trans (160). 
 
As seen in Table 1, CD169 is the one attachment factor that has been reported 
to bind both sialylated HIV-1 envelope gp120 as well as sialylated GSLs (213, 
218, 283). While gp120-dependent capture of HIV-1 particles by CD169 was 
primarily observed on macrophages (283) knockdown of CD169 strongly 
abrogated capture of virus like particles (VLPs), gp120-deficient HIV-1, and 
infectious HIV-1 by mature moDCs, pointing to the importance of CD169 in 
gp120-independent capture of HIV-1 particles by mature DCs (211). Importantly, 
mature moDC-mediated trans infection to CD4+ T cells was attenuated only when 
capture of HIV-1 by CD169 was blocked by usage of either shRNAs to knock-
down CD169 expression or when CD169 function was blocked by antibodies 
(211). Furthermore, reduction in GM3 content of HIV-1 particles by targeting virus 
assembly to GM3-deficient intracellular membranes (6) or by pharmacologic 
manipulation of GSL biosynthesis in virus producer cells (125, 211) resulted in 
reduced virus capture by CD169 and reduced access to CD169-mediated trans 
infection pathway. These findings suggest that GM3 (GSL)-dependent 
recognition of HIV-1 particles by CD169 is the critical interaction that drives 
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mature DC-mediated dissemination of HIV-1 infection to CD4+ T cells (seen in 
Figure 3). 
 
HIV-1 Trafficking in DCs and Trans Infection 
In 2003, McDonald et al., used live cell microscopy to demonstrate recruitment of 
both captured virus and receptors to the junction between mature DCs and T 
cells (177), called a virological synapse due to the structural similarity to an 
immunological synapse (203). There is ongoing debate and investigation into 
whether HIV-1 virions are maintained on the cell surface or internalized post 
capture within endosomal compartments prior to trafficking to virological 
synapses and transfer to CD4+ T cells. A number of previous studies have tried 
to address this question by treating virus-exposed moDCs to proteases to 
determine whether captured virions are at the surface and remain sensitive to 
cleavage or were internalized and protected from protease treatment (46, 127, 
144, 177, 270). Though these experiments demonstrated that moDC-associated 
virus is partially protected from protease treatment, the nature of the 
compartment harboring captured virus has proven elusive. Additionally, 
immunofluorescence microscopy suggests that virus particles are routed to a 
tetraspanin (CD81+ CD82+ CD9+)-rich compartment with a pH of 6.2 following 
virus capture (88), prior to retrograde transfer to the mature DC – T cell 
virological synapse. Interestingly, virus capture by CD169, results in localization 
of HIV-1 particles within minutes in a CD169+ CD81+ pocket-like structure at the 
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cell periphery in mature moDCs, and upon initiation of mature DC – T cell 
contacts, are trafficked to the DC – T cell junctions (125, 211). Additionally, this 
CD81+ pocket-like structure, harboring virus in mature moDCs appears to be 
induced by interaction between HIV-1 and CD169 rather than be constitutively 
present. The current hypothesis is that HIV-1 traffics to an invaginated pocket, 
which appears internal but is actually accessible to the surface of the mature 
moDC (7, 276). This pocket appears to be accessible to small HIV-1 neutralizing 
agents such as soluble CD4 (sCD4) (7) or Fab fragments of anti-gp120 bNAbs 
(7, 228) but restricts entry to larger sized-antibodies.  Therefore, we hypothesize 
that virus is kept protected from degradation within non-acidic compartments in 
an invagination contiguous with the mature DC surface but protected from 
detection and neutralization by anti-gp120 bNAbs (modeled in Figure 1). These 
findings suggest that CD169 might also be responsible for routing captured virus 
particles to locate within the CD81+ compartment and to mature DC – T cell 
virological synapse. Interestingly, CD169 has no known cytoplasmic tyrosine-
based signaling or endocytic motifs. Future studies will need to address the 
molecular details of CD169-mediated HIV-1 trafficking in mature DCs. 
 
Use of sophisticated microscopy techniques such as ion abrasion SEM (IA-
SEM), electron tomography and super-resolution light microscopy have provided 
fine structural details of the mature moDC – T cell virological synapse (78). 
These approaches have provided visual evidence of sheet-like dendrites 
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emanating from mature moDC surface enveloping CD4+ T cells during the 
establishment of the virological synapse (78). With the IA-SEM technology, Felts 
et al. were also able to image filopodial extensions from T cells which were 
shown to extend into the mature moDC folds containing virus, and virions 
“surfing” on these filopodial extensions to reach T cell surface (78). This 
conformation of folds and filopodia provides a pocket or microenvironment, which 
previously was thought to be internal.  
 
The importance of the virus path centers on the search for effective neutralizing 
antibodies in disrupting cell-to-cell transmission. The search for effective broadly 
neutralizing antibodies (bNAbs) has been at the crux of designing a successful 
HIV vaccine. Large strides have been made in designing effective bNAbs by 
mapping the origin of antibodies produced in HIV+ patients (174). Antibodies 
targeting particular areas of HIV-1 envelope, specifically the variable regions 1 
and 2 (V1V2), have recently shown great promise in both preventive and 
therapeutic approaches (68). While most studies have demonstrated potent 
efficacy of bNAbs against cell-free virus infections, neutralization potency of 
bNAbs is attenuated in cell-associated virus challenges (3, 167, 228) presumably 
because bNAbs are restricted from accessing HIV-1 particles transmitted across 
virological synapses (228). Since cell-to-cell transmission of HIV-1 likely 
accounts for significant viral spread in vivo, higher concentration of neutralizing 
antibodies might be required to achieve significant suppression of ongoing virus 
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replication. To this end, the Baltimore lab has described an adeno-associated 
virus vector strategy for achieving high concentrations of bNAbs in vivo, with 
demonstrated efficacy against HIV-1 mucosal transmission in a humanized 
mouse model of infection (18, 19). Further understanding of the virus trafficking 
and localization within DCs will allow for rational design of inhibitors to target DC-
mediated HIV-1 trans infection that will complement bNAb therapeutic. In 
particular, these inhibitors will need to be directed at the virus capture receptor, 
CD169, or be rationally designed to access the mature DC – T cell virological 
synapses and block trans infection.  
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Figure 3 Differences in HIV-1 Capture and Trans Infection by Immature and 
Mature DCs. Immature DCs express high levels of DC-SIGN and other C-type 
lectin receptors relative to mature DCs. Most of the virus particles captured by 
immature DCs are targeted to lysosomal compartments for degradation. In 
contrast, mature DCs express high levels of CD169 and GM3-dependent HIV-1 
capture by CD169 results in virus particle trafficking to non-lysosomal 
compartments at the cell periphery that remain contiguous with the extracellular 
milieu.  HIV-1 particles captured by CD169 on mature DCs are transferred to 
CD4+ T cells across virological synapses. 
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Clinical and Therapeutic uses for Capture Mechanism 
There are ongoing challenges in determining the in vivo relevance of DC-
mediated trans infection and how much this pathway contributes to virus 
dissemination.  Determining the level of trans infection in vivo is critical for 
developing new therapies to potentially inhibit capture and trans infection of virus 
by DCs. The studies cited throughout this review have used in vitro studies to 
model what may occur in vivo. Current options to investigate in vivo relevance 
are animal models including experimental infections of humanized mice and non-
human primates (Asian macaques) as well as human tissue explants. Each of 
these model systems has their limitations in recapitulating the HIV-1 
pathogenesis observed in humans. Most humanized mouse models fail to 
incorporate human myeloid cells in significant numbers and are thus not suitable 
for systematically testing the role of DCs in HIV-1 pathogenesis (109). 
Experimental infection of Asian macaques (which are not natural hosts for 
primate lentiviruses) by SIV strains have shown that DCs in vaginal epithelium 
and lamnia propria are infected early in infection and could possibly migrate to T 
cell rich areas (119). Other macaque studies have found lack of infection of DCs 
in the genital mucosa, but point to the likelihood that DCs will capture virus 
without being infected and subsequently migrate to lymph notes (243). 
Notwithstanding the ability to induce an AIDS-like illness in Asian macaques with 
select SIVmac strains, there is significant sequence diversity between SIVmac and 
HIV-1 and presence of additional orfs within the viral genome (SIVmac encodes an 
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additional protein, Vpx, that is not present in HIV-1 genome) that might 
differentially impact virus interactions with host cells. A limiting factor with tissue 
explants is that DCs tend to migrate out of explant tissues making it difficult to 
investigate later time-points post virus inoculation.  
 
Interestingly, in a recently published clinical study, DCs from HIV-1 infected non-
progressors were unable to mediate HIV-1 trans infection of CD4+ T cells (214). 
This deficiency was mapped to increased expression of the reverse cholesterol 
transporter, ABCA1 (ATP-binding cassette transporter A1) in DCs resulting in 
reduced cellular levels of cholesterol (214). These in vivo findings nicely 
corroborate previous in vitro observations that demonstrated robust decreases in 
HIV-1 capture and trans infection by DCs upon cholesterol depletion (98, 103). It 
is entirely possible that lowering cholesterol levels in DCs either reduces cell 
surface CD169 expression, prevents clustering of CD169 in plasma membrane 
microdomains for optimal virus interactions or reduces the probability of 
formation of DC – T cell virological synapses. Future in vitro studies will need to 
address the molecular basis for the observed clinical benefit of lowering 
cholesterol levels in DCs.  
 
The relevance of CD169 capture and trans infection has been supported by 
multiple studies that investigated the level of CD169 on circulating monocytes in 
HIV-1 infected patients (218, 265). Individuals with high viral loads and those that 
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had progressed to AIDS had increased expression of CD169 on their circulating 
monocytes compared to patients with undetectable viral loads (218, 265). The 
authors point to up-regulation of CD169 on monocytes due to early induction of 
type I IFN responses and suggest the possibility that CD169+ monocytes are 
enhancing systemic dissemination of virus (218). In a recent study TGFβ, the 
most abundant cytokine found in semen, was shown to increase expression of 
CD169 on moDCs resulting in increased virus capture suggesting an in vivo role 
in sexual transmission (62). Additionally, CD169 expression in lymphatic tissues 
is conserved across species, and has been shown to be prevalent in secondary 
lymphoid organs, tissue sites that are integral to HIV-1 dissemination (107). 
Future studies using better animal models for infection will have to examine 
whether blocking CD169 is able to diminish spread of HIV-1 to CD4+ target cells 
and decrease establishment of infection in vivo. 
 
HIV-1 exploits DC biology to evade the immune system and disseminate virus to 
target CD4+ T cells. This CD169-dependent DC-mediated trans infection pathway 
might be an efficient method of HIV-1 dissemination and contribute significantly 
to viral pathogenesis. We will investigate in Chapter 1 whether HIV-2 is able to 
access the CD169-dependent virus dissemination pathway. 
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GM3 CD169 Interaction Used for Targeting  
The future of therapeutics will be based on targeted nanoparticles that are able to 
deliver a lower dose of drug to a precise area and limit off target effects. We 
propose CD169 as a target receptor to direct therapeutics to stimulate a specific 
immune response against HIV-1. CD169 is not only expressed on myeloid cells 
found in secondary lymph nodes, but also upregulated on peripheral blood 
monocytes upon stimulation with type I IFN (211). Additionally, CD169+ 
macrophages present in the secondary lymphoid tissues are concentrated in the 
sub-capsular sinus and play an important role in orchestrating an adaptive 
immune response in the lymph nodes. Therefore, these locations in vivo suggest 
that CD169 is an important pathogen recognition receptor in close proximity to 
stimulate surrounding T cells and B cells.  For example, in a VSV infection model 
in mice, CD169+ sub-capsular macrophages were primarily infected, and this 
enforced viral replication resulted in enhanced antigen presentation and priming 
of T cells (117). Another study found that glycan coated liposomes targeted to 
CD169+ macrophages were able to prime invariant killer T cells (iNKT) in a 
CD169 specific manner (137). Our studies with HIV-2 infection of DCs and T 
cells in vitro demonstrate enhanced immune sensing relative to HIV-1 that might 
play a role in the reduced pathogenesis of HIV-1 in vivo. Therefore, we propose 
to construct nanoparticles (NPs) that can target CD169+ myeloid cells as a novel 
strategy to prime the innate immune system and restrict HIV-1 replication in vivo. 
Typically smaller than 100nm, NPs can be modulated to emulate virus like 
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particles. Our collaborators have shown that they can mimic virus/cell 
interactions by reverse engineering artificial NPs to mimic the HIV-1 virion but 
with a metal NP core (277). By incorporating GM3 into the engineered 
nanoparticles CD169-targeting specificity was achieved. Future studies are 
needed to validate nanoparticle therapeutics exploiting the GM3/CD169 
interaction mimicking the immune sensing seen in HIV-2 infection for various 
indications in humans. We will explore the possibilities of targeted nanoparticles 
in Chapter 3.  
 
With approximately 35 million people living with HIV and an additional two million 
new infections per year, it is essential to find strategies to inhibit virus 
dissemination. In order to combat viral infection and slow its attack on the 
immune system, it is critical to understand the techniques HIV-1 uses to 
parasitize DC functions and disrupt HIV-1 immune evasion strategies. 
 
Scientific Proposal and Hypothesis 
HIV-1 and HIV-2 are two different strains of the same virus with similar modes of 
transmission, but different courses of disease. Thus, investigating the differences 
in how the two virus strains interact with target cells will elucidate the 
mechanisms responsible for the differences in pathogenesis. Dendritic cells are 
important to investigate in this context since they are critical in bridging the innate 
and adaptive immune responses are thought to be one of the first cell types to 
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encounter HIV at mucosal surfaces (21). By defining the differences in 
interactions with dendritic cells there will be significant implications for 
therapeutic and vaccine development for both HIV-1 and HIV-2. Moreover, 
identifying specific mechanisms by which HIV-2 is deficient for replication in DCs 
and T cells will allow for rational design of therapeutics to target that pathway for 
HIV-1. Thus, the goal of the following studies was to determine the mechanistic 
differences in how HIV-1 and HIV-2 interact with dendritic cells. 
 
In our study, we have investigated whether HIV-2 is capable of utilizing the 
CD169/GM3 DC-T trans infection pathway for efficient dissemination. We 
observe significantly less capture of HIV-2 by CD169+ mature DCs and 
subsequently less transfer to autologous CD4+ T cells. Deficiencies in HIV-2 
capture by CD169 were primarily due to reduced incorporation of GM3 in HIV-2 
virus particle membranes. We hypothesize that diminished GM3 incorporation in 
HIV-2 virions is due to reduced interaction of HIV-2 Gag with the producer cell 
GM3-enriched plasma membrane microdomains thus attenuating HIV-2 access 
to the CD169-dependent trans dissemination pathway. In contrast to trans 
infection, HIV-2 was able to productively infect DCs. Expression of viral protein X 
(Vpx) by HIV-2 results in degradation of SAMHD1 in DCs and allows HIV-2 to 
efficiently infect DCs. Surprisingly, efficient productive infection of DCs by HIV-2 
resulted in robust innate immune activation and attenuated spread of virus to 
target CD4+ T cells. Finally, we explored the use of GM3-expressing 
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nanoparticles for delivery of therapeutics that trigger innate immune activation in 
CD169+ myeloid cells as a novel strategy to restrict HIV-1 replication in the 
secondary lymph nodes. 
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Materials and Methods 
Common Media, Buffers, & Reagents 
Penicillin-Streptomycin- (P/S), 100x (Fisher catalog #SV30010), 5 ml added 
per 500 ml of media for a final concentration of 100U/ml penicillin, 100 mg/ml 
streptomycin, and 5 ml aliquots P/S stored at -20°C. 
Fetal bovine serum (FBS) (Invitrogen catalog #26140079), thawed at 37°C, 
heat inactivated for 30 min at 56°C; 45 ml aliquots stored at -20°C. 45 ml added 
per 500ml of media (10%). 
Media for adherent cells: Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Invitrogen catalog #11965-118), 10% heat inactivated fetal bovine serum (FBS), 
penicillin/streptomycin  
Media for non-adherent cells: RPMI-1640 (Invitrogen catalog #11875-119), 
10% heat inactivated fetal bovine serum (FBS), penicillin/streptomycin  
Fixing solution for flow cytometry and microscopy: 4% paraformaldehyde 
(PFA) (Boston Bioproducts catalog #BM-155) 
Solution for lifting adherent cells: Trypsin 0.25% (Invitrogen catalog #15050-
065), 0.5M EDTA pH8.0 (Boston Bioproducts catalog #BM-150) 
Phosphate buffered Saline (PBS) (Invitrogen catalog #14190-250) 
Ficoll-Paque Plus (GE Healthcare Life Sciences catalog #17-1440-02) 
Gentamycin (Thermo Fisher Scientific catalog# 10131027) 
Puromycin ((Thermo Fisher Scientific catalog# A1113802) 
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Polybrene (Fisher catalog#TR-1003-G)- used in infections of T cells and in 
TZMbl experiments. 
 
Kits 
Miniprep kit (Fisher catalog #PR-A1460) 
Midiprep Kit Purelink hipure plasmid filter (Invitrogen catalog #K210014) 
Maxiprep Kit Purelink hipure plasmid filter (Invitrogen catalog #K210017) 
 
Cell lines 
Human cell lines, HEK293T (a human kidney epithelial cell line) and TZM-bl, 
have been described before (211). THP1 and CD169 expressing THP1 
(THP1/CD169) cells have been described previously (7). 
 
Isolation of PBMCs 
PBMCs were isolated from source leuokocytes (New York Biologics Inc., 
Southhampton, NY) using density gradient centrifugation with Ficoll-Paque Plus 
(Amersham Biosciences).  Peripheral blood was diluted with equal volume RPMI-
1640 and 35 ml was overlayed onto 10 ml of Ficoll-Paque Plus in 50 ml conical 
tubes. The gradients were centrifuged with the break off at 1400 rpm for 30 min 
at room temperature. PBMCs, forming a dense white interphase above the red 
blood cell and granulocyte layer were collected with a 10ml pipette and washed 
three times with RPMI-1640 with centrifugation at 1400 rpm for 10 min at room 
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temperature to remove residual Ficoll-Paque Plus and contaminating cell 
populations. PBMCs were either frozen down for future use (freezing media: 50% 
FBS, 40% RPMI, 10% DMSO) or used immediately for CD14+ monocyte 
isolation. 
  
CD14+ Monocyte Isolation/Generation of DCs 
Primary CD14+ monocytes were isolated from fresh or freeze thawed PBMCs. 
Mouse anti-human CD14 magnetic beads (Miltenyi catalog#130-050-201) were 
added to PBMCs at a ratio of 8-10 µl/107 PBMCs in 80 µl PEB (1xPBS ph7.2, 2 
mM EDTA, 0.5% BSA (Sigma catalog #A9576)  /107 PBMCs and incubated for 
15-30 min at 4°C. After pre-wetting the columns, approximately 2x108 stained 
cells were added to LS MACS cell separation columns (Miltenyi Biotech catalog 
#130-042-401) according to the manufacturer’s protocol. Flow through CD14- 
cells were collected if autologous CD4+ cells were being isolated in parallel. 
Columns were washed three times with 3 ml PEB and the labeled CD14+ 
monocytes were plunged from columns, counted and cultured (1.5 x 106 cells/ml) 
were cultured in RPMI supplemented with 100 U/ml penicillin, 100 mg/ml 
streptomycin, 1400 U/ml Human GM-CSF (Miltenyi Biotech catalog #130-093-
866) and recombinant Human IL-4 (Fisher BD catalog #BDB554605) for a period 
of six days with half the media changed every two days. For mature DCs, cells 
were matured with 100 ng/ml LPS for 48 hrs at day 6.  
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Isolation of CD4+ T cells 
Starting with either flow through CD14- cells or frozen PBMCs, cells were 
incubated with mouse anti-human CD4 magnetic beads (10 µl/107 cells) (Miltenyi 
Biotech catalog #130-045-101) for 15-30 min at 4°C in PEB (80 µl/107 cells). LS 
columns (Miltenyi Biotech catalog #130-042-401) were pre-wet with 3 ml PEB 
before stained cells were added. Columns were washed three times with 3 ml 
PEB. Flow through was discarded and the columns were plunged using 5 ml 
PEB into a 50ml conical to collect CD4+ T cells. Cells were washed and cultured 
in RPMI 10% FBS, P/S with IL-2 and stimulated with PHA (Invitrogen 
catalog#10576-015) for 48 hrs.  
 
Murine Bone Marrow Derived DCs 
Murine GM-CSF (Peprotech catalog #315-03) 
Bones (received from Dr. Lee Wetzler) were placed in a 10 cm TC dish on ice. 
Muscles were removed from the bones with sterile forceps and scissors and the 
ends of bones were cut. The bones were flushed with a 22G needle, 5 ml 
syringe, with RPMI 10% FBS P/S (R10). The cells flushed from the femurs and 
tibias were spun down at 1100 rpm, 5 min at 4°C, lysed using 2 ml Gey’s 
Solution (mix in order 1 ml Solution A, 0.25ml Solution B, 0.25 ml Solution C and 
3.5 ml H20) and incubated for 1 min at room temperature. R10 was added and 
the cells were spun again, counted and cultured in R10 with Murine GMCSF (100 
ng/ml) and BME in 10 ml non-TC dishes.  
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Calcium Phosphate Transfections 
10cm Tissue Culture Dish (Fisher catalog #08-7772E)- HEK293T cells were 
seeded at 2-3x106/dish and 13-15 µg/dish DNA were transfected in 1:1 0.25M 
CaCl and 2x BBS in a volume of 2ml/dish 24 hours after seeding. One day post 
transfection, plates were washed with 1xPBS and fresh media was added back. 
Two days post transfection supernatants were collected and filtered using a 0.45 
µm sterile syringe filter (Corning catalog #431220).  
 
6-well plate (Fisher catalog #08-722-1B):  HEK293T cells were seeded at 
2.5x105/ml (5x105/well) and transfected with 3 µg/well DNA in 1:1 0.25M CaCl 
and 2x BBS in a volume of 375 µl/well 24 hrs after seeding. One day post 
transfection, plates were washed with 1xPBS and fresh media was added back. 
Two days post transfection supernatants were collected and filtered using 0.45 
µm sterile syringe filter (Corning catalog #431220). 
 
2.5 M CaCI2 (50 ml):  g CaCI2 (anhydrous) was added to 50 ml dH2O, filtered 
through a 0.45 µm filter and stored at -20°C. A working 0.25M stock was 
prepared in dH2O (50 ml) and stored at -20°C.  
 
2 x BBS (100 ml): 50 mM BES/280 mM NaCI/1.5 mM Na2HPO4. The BES was 
made up in 85 ml of dH2O and the pH is adjusted to 6.95 with 4M NaOH. The 
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NaCI and Na2HPO4 were then added. The volume is brought up to 100 ml with 
dH2O. The solution is filtered through a 0.45 µm filter, aliquoted, and stored at -
20°C. Stocks were tested for efficiency using eGFP transfection. 
 
Primary Isolate Viruses 
HIV-2 CDC77618  and HIV-2310319 were originally isolated from diagnostic cultures of 
Ivorian AIDS patients (NIH AIDS Reagent Program, contributed by Dr. Stefan 
Wiktor and Dr. Mark Rayfield) (198) 
 
Virus Production from PBMCs 
PBMCs were either isolated as previously described or thawed and stimulated 
with 2% PHA (Invitrogen catalog #10576-015) and cultured in IL-2 (50 U/ml) (NIH 
AIDS Reagent Program, contributed by Dr. Maurice Gately) (149)  for 48 hrs. 
PHA was washed out and cells were infected with primary isolate viral stocks at 
100 µl/106 cells with polybrene (Fisher catalog # TR-1003-G). Cultures were kept 
for twelve days, replacing half the media every three days.  All supernatants were 
filtered, combined and concentrated via ultracentrifugation.  
 
Concentration of Virus by Ultracentrifugation 
Supernatants were harvested from transfected HEK293T cells two days post 
transfection and filtered through a 0.45 µm sterile syringe filter (Corning catalog 
#431220). Filtered transfection supernatants were layered over 3-5 ml 20% 
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sucrose (Fisher catalog #s5500) in an ultracentrifuge tube (Beckman catalog 
#326823).  Tubes were centrifuged in an ultracentrifuge at 24,000rpm for 2 hrs at 
4°C.  
 
Virus Quantification 
Infectious titers of virus preparations was determined using the reporter cell line, 
TZM-bl cells (NIH AIDS Reagent Program, contributed by Dr. John C. Kappes 
and Dr. Xiaoyun Wu). Virus stocks were serially diluted and added to TZM-bl 
cells in the presence of 10 µg/ml polybrene. Virus-cell mixtures were cultured for 
two days and then fixed using 1% formaldehyde (Calbiochema catalog # 
344198), 0.2% Glutaraldehyde (Fisher Scientific catalog #BP 2548-1) in PBS.  
Cells are then stained using a solution made up for every 1 ml of solution: 950 µl 
PBS, 20 µl 0.2M potassium ferrocyanide, 20 µl 0.2M potassium ferricyanide, 1µl 
2.0 M MG2Cl, and 10µl X-gal stock (Fisher catalog #7240-90-6) (40mg/ml in 
DMSO stored in the dark at -20°C). Blue cells indicate productively infected cells 
or syncytia. 
 
p24 capid ELISA 
Tween (Fisher catalog #BP-337-500) 
A Nunc 96 well flat bottom maxisorp plate (Fisher catalog #12-565-136) was 
coated with 100 µl HIV-Ig (NIH AIDS Reagent Program, contributed by NABI and 
NHLBI, Dr. Luiz Barbosa) (4 µl HIV-Ig in 10.5ml PBS) per well, covered with 
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microplate adhesive film (USA Scientific catalog #2920-0000), and placed at 
37°C overnight. The next day the plate was blocked with 5% normal calf serum 
(NCS) 200 µl per well for two hours at 37°C. Standards were set up in a 96 well 
round bottom dilution plate (USA Scientific catalog #5665-0101) with p24 stock 
starting at 4 ng/ml with 1:2 dilutions across the plate in duplicate. For tittering 
virus, viral stock samples were added 1:50 for the first dilution and 1:3 across the 
plate. After blocking the wells were emptied and 100 µl samples were added for 2 
hrs at 37°C. The plate was then washed six times using a plate washer, then 
primary p24 hybridoma was added 1:10 100 µl/well and stored at 4°C overnight. 
When comparing HIV-1 and HIV-2 AG3.0 p24 was used as the primary antibody.  
The plate was washed six times using a plate washer, and goat anti mouse HRP 
was added at 1:70,000 as secondary antibody 100 µl/well for 1 hr at 37°C.  
To read out the reaction KPL TMB peroxidase substrate A and substrate B 
(Fisher catalog #50-76-00) were added 1:1 100 µl/well for 30 min at room 
temperature. The reaction was stopped using 4N Sulfuric acid (Fisher catalog 
#SA818-1) 50 µl/well. Plates were read using a micro plate reader.  
 
Plasmids & Cloning 
The proviral plasmid, HIV-1/Lai-YU2env (CCR5-tropic) and the CCR5-tropic Lai-
Bal envelope expression plasmid have has been described previously (7, 211). 
pROD9 was a generous gift from Dr. Geoffrey Gottlieb, (241). HIV-2 ST envelope 
expression plasmid was a gracious gift of Dr. Paula Cannon (110). HIV-1Δenv 
	  57 
and HIV-2Δenv provirus plasmids encoding gfp in place of nef, have been 
described previously (200, 275). HIV-2iGFP, an infectious molecular clone 
encoding GFP between MA and CA flanked by protease cleavage sites, was 
constructed using a cloning strategy similar to the one previously described for 
construction of HIV-1iGFP proviral plasmid (120). The plasmids, HIV-1 Gag-
eGFP and HIV-1 Gag-mCherry express a Gag-eGFP (NIH AIDS Reagent 
Program; contributed by Marilyn D. Resh and George Pavlakis) or Gag-mCherry 
fusion proteins (127). To limit GSL incorporation in virions budding from 
transfected HEK293Ts, transfections were performed with media containing 
phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP; 10 µM; Calbiochem) 
as described previously (108) 
 
Table 2. Primer Sequences 
NAME PRIMER SEQUENCE 
CD169 R96A F-GGAACCCCGAGCACGCGGTGTGCAACCTGC 
R-GCAGGTGCAGGTTGCACACCGCGTGCTCGGGGTTC 
CD169 4132G F-CCACCTGCTGAGCTGGCCCTATCTCATGATG 
R-CATCATGAGATAGGGCCAGCTCAGCAGGTGG 
CD169 R116A F-CTGGTTCCTACAACTTCGCTTCGAGATCAGTGAGG 
R-CCTCACTGATCTCGAAGGCGAAGTTGTAGGAACCAG 
Mouse CD169 5’ NotI F- ATAAGAAT GCGGCCGC ATGCACCTGGGCAC 
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Asp718 R- AGCTCCGTTCAGGTACCAGGAGAAG 
Mouse CD169 3’ F- AGCTCCTGACACTCGCTTCTCC 
XbaI R- CGTCTAGACAGAGAGCAGCAACCACTTCC 
HIV-2 MA NcoI F-AGGCTAGAAGGAGAGCCATGGGTGCGAGAGCG 
BSSH2 R-TTTGCGCGCATTGTGGGAGATGGG 
HIV-2 MA ATG 
mutagenesis 
F- GCTAGAAGGAGAGAGAAGGGTGCGAGAGCGT 
 
 
Carbacillin (Fisher catalog #BP2648-1) 
Kanamycin (Sigma catalog # 25389-94-0) 
LB broth (Fisher catalog #240230) 
QIAXII Agarose Gel Extraction Protocol (Qiagen catalog #20021) 
Agilent Strategene Blunt PCR (catalog #240207-5) 
T4 DNA Ligase (NEB catalog #M02025) 
Quikchange II Site Directed Mutagenesis Kit (Agilent/Fisher catalog # 200521) 
 
CD169 Mutagenesis 
Point mutations in human CD169 orf, R116A (Arg!Ala) and R96A (Arg!Ala) 
were introduced by site-directed mutagenesis (Quikchange; Agilent 
Technologies) using the primers listed in Table 2. 
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Cloning of Murine CD169 into the pHIV-dTomato lentiviral expression vector 
Murine CD169 was amplified from total RNA derived from RAW264.7 mouse 
macrophage cell line by overlap RT-PCR using the primer sets described above 
in Table 2. cDNA was generated using Superscript III Reverse Transcriptase kit 
(Invitrogen catalog # 18080051). Mouse CD169 was PCR amplified in two parts 
using the above four primers for the 5’ and 3’ segments respectively. 98°C 1min 
(98°C 15sec, 52°C 30sec, 72°C 1.25 min) 5 cycles (98°C 15s, 58°C 30s, 72°C 
1.25min) 35 cycles 72°C 10 min. Both the 5’ half and 3’ half of murine CD169 
were inserted into pSC-blunt vector and transformed with DH5-α bacteria. Using 
restriction enzymes NotI and Asp718 (KpnI) the 5’ fragment was isolated from 
the backbone vector. Similarly using Asp718 and XbaI the 3’ fragment was gel 
isolated. HIV-dTomato vector was digested with NotI and XbaI and the two 
mouse fragments were ligated into the lentivector. 
 
Cloning of HIV-2igfp construct 
HIV-2iGFP was constructed similarly to the previously described HIV-1iGFP 
proviral clone (120). Briefly, sequences encoding HIV-2/ROD-9 matrix (MA) and 
capsid (CA) were cloned into a cloning vector, pSL1180, using KasI and ApaI 
restriction enzymes, and was used for subsequent cloning steps. HIV-2 ROD-9 
MA sequence containing the protease cleavage site was amplified using the 
following primers: ROD9 matrix-Kas-F (5’- 
CGGTGTGAAATACCGCACAGATGCGTAA-3’), ROD9 matrix-R 
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(TTTTTTACGCGTGTGCTGTACAGGATAGTTACCACCCTTCTCGCTAGATGGT
GCTGTTGG). HIV-2 ROD-9 CA sequence including the protease cleavage site 
was amplified with the following primers: ROD9 CAC_F 
(TTTTTTTCTAGAGGAGGAAA TTACCCAGTG CAACATGTAG G) and M13-R-
long (5’- GGATAACAATTTCACACAGGAAACAGCTATGAC-3’). The PCR-
amplified MA and CA fragments and an AflIII-XbaI fragment from HIV-iGFP 
proviral clone containing the GFP sequence was ligated into the pSL1180 vector. 
Additionally a non-coding segment of ROD-9 was cloned into psL1180-MA-GFP-
CA after CA using restriction enzymes ApaI and AvrII.  Finally, ROD-9 was cut 
with EcoRI and AvrII restriction enzymes and ligated with the PCR-generated 
fragments cut out of psL1180. 
 
Cloning of HIV-2 Gag-eGFP 
HIV-2 Gag-eGFP was constructed by PCR amplifying HIV-2 ROD Gag orf with 
the following primers: ROD_GAG_BSSH2_F (TTT GCG CGC ATT GTG GGA 
GAT GGG) and ROD_GAG_BGLII_R (TTT AGA TCT CCG TTT CTG TTC TGG 
TCT TTT CCA AAG AGA G), and cloning the PCR product into the HIV Gag-
eGFP plasmid using the restriction enzymes BsshII and BamHI. Additionally, 
HIV-1 RRE (rev responsive element) was inserted after Gag-eGFP orf using XbaI 
and HpaI restriction sites. All plasmids were verified by sequencing.. 
 
Virus infections 
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All virus infections of immature and mature DCs or CD4+ T cells were performed 
by incubating cels with viruses for 2 hrs at 37°C 5% CO2, washed four times with 
1xPBS and cultured in cell media.  
 
Virus Capture 
Sialoadhesin Antibody CD169 (7D2) (Novus Biologicals Catalog #NB600-534) 
96-well u-bottom non-TC coated plate (Fisher Catalog #07-200-95) 
2x105 cells were added to each well in 25-50 µl media and challenged with virus 
or VLPs for 2 hrs at 37°C. Wells were washed thoroughly with 1x PBS four times 
and fixed with 4% PFA.  
 
Virus Transfer 
Mature monocyte derived DCs were pulsed with either Brugfpnef-env- 
pseudotyped with Bal envelope or RODgfpnef-env- pseudotyped with ST 
envelope at an MOI=5. Cells were cultured for two hours at 37°C, washed 
thoroughly and either cultured alone for six days or autologous CD4+ T cells were 
co-cultured for six days at a ratio of 1:2. Autologous CD4+ T cells were infected in 
parallel at an MOI=5 with spinoculation (centrifuge for 1hr at 2300rpm at room 
temperature). The number of GFP+ CD4+ T cells was determined by FACS using 
CD3PE antibody, run on the LSRII (BD) and analyzed with Flowjo software 
(Flowjo).  
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Readouts: 
Flow Cytometry 
OneComp eBeads (eBioscience catalog #01-1111-42) 
Mouse Anti Human CD169 AlexaFluor-647 Abd Serotec- MCA2517A647 
Anti-HIV-1 core antigen, clone KC57 FITC Beckman Coulter- 6604665 
Mouse Anti Human CD3 PE Fisher- BD 555-333 
Mouse IgG1 Isotype Control PE Fisher- BDB559320 
 
IP-10 ELISA 
Human IP-10 ELISA Set (Fisher BD catalog #BDB550926) 
An ELISA plate is coated with 100ul per well of Capture Antibody (provided in kit; 
diluted 1:250) diluted in Coating Buffer (10% NCS in PBS) overnight at 4°C. Cells 
were aspirated and washed three times using Wash Buffer (0.05% Tween in 
PBS; ELISA wash buffer diluted 1:10 in 1xPBS). Plates were blocked with 200ul 
per well of Assay Diluent (10% NCS) and incubated 1 hr at room temperature. 
Again wells were aspirated and washed three times. The highest concentration of 
standard is 500pg/ml and used 3 µl in 648 µl (in 10% NCS 1:1 with ELISA 
diluent) for one plate; 1:2 dilutions were made in microcentrifuge tubes and 100ul 
was added per well in duplicate. Samples were lysed in p24 ELISA diluent and 
added to the plate and incubated for 2 hrs at room temperature. The plate was 
aspirated and washed five times followed by addition of 100 µl of Working 
Detector (Detection Antibody + Streptavidin HRP reagent) to each well for 1 hr at 
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room temperature. Next the plate was washed seven times and 100 µl of 
Substrate solution was added (TMB Peroxidase (Fisher catalog #50-76-00)) for 
30 min and stopped and readout is similar to p24 ELISA.  
 
HEK293 ISRE-luc IFN ASSAY 
Promega Bright-glo Luciferase Assay System (Fisher catalog #PR-E2610) 
96-well flat bottom non-treated white polystyrene plate (Corning Costar #3693) 
HEK293 ISRE-luc cells were cultured in DMEM/10%FBS the presence of 2 µg/ml 
Puromycin. Cells are detached with enzyme free cell dissociation buffer (Millipore 
catalog #S-014B), washed once in PBS and seeded at 4x104 cells/well in a 96-
well flat bottom plate (Corning Costar catalog #3596). Samples were added in 50 
µl as well as IFN-α2 standards (the linear range will be between 1-62.5 U/ml). 
Samples were incubated for 21 hrs at 37˚C, supernatants were removed and 50 
µl Glo Lysis Buffer was added for 5 min for complete Lysis.  Using a white plate 
25ul lysates and 25 µl Bright-Glo were added to each well and luminescence was 
read out via a luminometer.  	  
TZM-bl Luciferase Assay 
TZM-bl cells were seeded in a 96-well flat bottom (Corning Costar catalog #3596) 
at 1x104 cells/well. One day later infection supernatants were added to wells in 
the presence of 10 µg/ml Polybrene. Two days post infection media was 
removed and wells were lysed with 50 µl Glo Lysis Buffer for 5 min for complete 
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lysis. Using a (Corning Costar #3693) 25 µl lysates and 25 µl Bright-Glo were 
added to each well and luminescence was read out via a luminometer.  
 
Vpr-BLAM-based HIV-1 fusion assay  
DCs were infected with BlaM-virus for 2 hrs in incubator in a total volume of 100 
µl in a 96 well round bottom plate (Corning Costar catalog #3799). Cells were 
washed thoroughly and then stained with CCF2. The following control samples 
were included for compensation: no stain (no CCF2) and mock infected stained 
with CCF2. Cells were washed once with CO2-independent medium (w/o serum) 
before adding the ß-lactamase substrate prepared as following: 1 µl CCF2 
(Solution A), 4 µl Solution B, 1 ml CO2-independent medium with 10% FBS, 10 µl 
probenecid. Substrates A and B were incubated for ten minutes at room 
temperature and then the rest were added. 70 µl of the substrate was added to 
each well and incubated at 18˚C in a dark wet chamber over night (in a 
centrifuge). The next day the cells were washed once with 2% NCS in PBS, fixed 
with 100 µl 4% PFA and ran on the LSRII. 
 
Exogenous RT Assay 
RT Cocktail Recipe:  
1M Tris-HCl (pH 8.0)= 1.2ml 
1M MgCl2=129ul 
1M KCl= 3.6ml 
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1M DTT= 120ul 
0.5M EGTA= 24ul (Omnipur catalog #4100) 
10% Triton C-100=0.24ml 
dH20 (ultrapure)=14.69ml 
To 17ml of the RT buffer, add 5U of poly (A)-oligodT (Midland Certified Company 
catalog #P-4012) and freeze 1ml aliquots at -80˚C.  
The exogenous RT assay was performed similar to previously described (2). 15ul 
of cell-free virus containing supernatant was added to each well of a 96 well 
plate. 50ul of 32P was added to the RT Cocktail mix, then to each well, mixed, 
and incubated for 2 hours at 37˚C. 10ul of the mix in each well was dotted on 
DEA filter paper and allowed to dry protected in a fume hood. The filter paper 
was washed five times with 1x SSC buffer (5 minutes each wash) and then twice 
with ethanol. The filter paper was allowed to dry protected in the fume hood and 
the quantity of radioactivity incorporation was quantified using a PhosphoImager 
(Molecular Dynamics, Sunnyvale, CA) 
 
Real-Time quantitative RT-PCR for Viral RNA  
QuantiTect Probe PCR kit (Qiagen catalog #204343) 
Qiamp Viral RNA mini kit (Qiagen catalog #52904) 
 
Microscopy 
Microscope slides (Fisher catalog #12-550-15) 
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Microscope cover slips No.1 12mm (Fisher catalog #12-545-80) 
Polystyrene lids non-sterile (USA Scientific catalog #5665-6101) 
Normal goat serum (Southern Biotech Fisher catalog #OB0060-01) 
 
Immunofluorescence Microscopy 
To determine the cellular location of virus post capture, 4x105 mature DCs were 
pulsed with 50ng HIV-1iGFP or HIV-2iGFP for 2 hours at 37°C, washed 
thoroughly with PBS, and fixed with 4% PFA. Cells were then permeabilized with 
0.1 % Triton-X100 for 15min at room temperature followed by blocking with 20% 
NCS for 30min at room temperature. Cells were stained with primary antibodies 
against CD169 (Novus), CD81 (BD), CD63 (BD), or LAMP1 (BD), washed and 
stained with secondary conjugated with AlexaFluor 594 and Dapi (4=,6-
diamidino-2-phenylindole; Sigma).Cells were also stained with the corresponding 
isotype controls (AbdSerotec) or secondary only to subtract background.  Cells 
were mounted on slides with Fluoromount-G (Southern Biotech) and imaged 
using a Zeiss microscope and AxioVision software. Transfected cells (green) 
were stained with Dapi and with cellular markers Lysotracker, Wheat Germ 
Agluttinin (WGA) and CTXB (Sigma).  Using a Leica SP5 confocal microscope 
images were acquired and analyzed with Image J. Co-localization was analyzed 
using the Pearson’s coefficient.  
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To visualize virus assembly sites in HEK293T cells, cells were co-transfected 
with Gag-eGFP (HIV-1 or HIV-2) and HIV-1 Gag-mCherry expression plasmids. 
Cells were fixed with 4% paraformaldehyde (PFA; Boston Bioproducts) at 24 h 
post transfection, stained with DAPI (4=,6-diamidino-2-phenylindole; Sigma) to 
visualize nuclei and processed for confocal microscopy.  Images were acquired 
on a Leica SP5 confocal microscope and analyzed with Image J and pseudo-
colored for data presentation. Extent of co-localization between eGFP and 
mCherry fusion proteins was analyzed using Pearson’s correlation of coefficient 
analysis in Image J from at least 7 fields of view and 95-155 cells per 
transfection. HEK293T cells were transfected with either HIV-1iGFP or HIV-
2iGFP proviral plasmids and stained with AlexaFluor 594-conjugated Wheat 
Germ Aggluttinin (WGA-AF594) and counterstained with DAPI at 24 hr post-
transfection. Co-localization between green (GFP) and red (WGA) signals is 
reported as mean (±SEM) Pearson’s coefficient analyzed using Image J of at 
least 3 fields of view and 30-45 cells per condition. 
 
RNA Isolation 
RNAeasy kit (Qiagen catalog #74104) 
Superscript III First Strand Synthesis System (Invitrogen catalog #18080-051) 
SuperScipt III Reverse Transcriptase (Invitrogen catalog #18080-051) 
  
qRTPCR for host mRNAs 
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SYBR Green  (Fisher catalog# AB-1219) 
 
Microarray 
The experiment was run using 12 Affymetrix Human Gene 1.0 ST arrays to 
profile monocyte-derived dendritic cells from three independent donors and 
infected with either HIV-1 or HIV-2 compared to mock infection. The arrays were 
normalized together using the Robust Multiarray Average (RMA) algorithm and a 
CDF (Chip Definition File) that maps the probes on the array to unique Entrez 
Gene identifiers. The result is a matrix in which each row corresponds to an 
Entrez Gene ID and each column corresponds to a sample. The expression 
values are log2-transformed by default. 
 
Western Blotting  
PageRulerTM Prestained NIR Protein Ladder (Fisher catalog #PI26635) 
Sample loading buffer: 6x SDS 
Running buffer: 1x SDS 
PVDF 
Filter Paper (Fisher catalog #PI 88600) 
Whatman Nitrocellulose Membrane, 0.45µm (Fisher catalog #09-301-108) 
Licor Blocking Buffer (Fisher catalog #NC9877369) 
Recombinant GFP  
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Gel-Saver round gel loading tip, 0.6mm OD orifice (USA Scientific catalog #1022-
0600) 
 
10% Separating Gels : Gels were prepared by mixing 3.8ml dH2O, 2.5ml 40% 
Polyacrylamide (Fisher catalog #161-0148), 3.8ml Tris HCL pH8.6, 10µl Temed 
(), 120µl 10% APS (), and loaded leaving ~1inch from top of glass for stacking 
gel. 
 
4.5% Stacking Gel: Gels were prepared by mixing 3.8ml dH2O, 562.5µl 40% 
Polyacrylamide (Fisher catalog #161-0148), 625µl Tris HCl pH 6.8, 20µl TEMED, 
80µl 10% APS and loaded to the top of the casting glass. 
 
Western blots 
GFP content of Gag-eGFP VLPs and iGFP infectious viruses were titered using 
quantitative western blot analysis, as described previously (211). Briefly, virus 
particle lysates were run on 10% SDS-PAGE gel, transferred to nitrocellulose 
membrane and blocked with Odyssey Blocking Buffer (Licor). Membranes were 
probed for GFP (goat anti-GFP polyclonal antibody, Novus #NB600-313) 
followed by a donkey anti-goat-IgG-IRDye 800CW (Licor). Membranes were 
scanned with an Odyssey Scanner (Licor) and the GFP content in VLPs or 
infectious viruses was determined by comparison to recombinant GFP standard 
(Roche). To determine if HIV-2iGFP viruses incorporated Env, virus particle 
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lysates were probed for Gag and Env expression using anti-Gag mouse mAb 
(AG3.0) (231) and anti-HIV-2 Env antisera (obtained through the NIH AIDS 
Reagent Program, Division of AIDS, NIAID, NIH: Antiserum to HIV-2ST gp120 
from Dr. Raymond Sweet, SmithKline Beecham Pharmaceuticals). 
 
Lipid Quantification 
The GM3 ELISA was adapted from previous lipid extraction (34) and GM3 
detection protocols (61, 251). Briefly, lipids from equal amounts (ng GFP) of Gag-
eGFP VLPs (total volume 40 µl) were extracted with a 1:2 Chloroform: Methanol 
mixture (150 µl). Subsequently, chloroform (50 µl) and water (50 µl) were 
sequentially added with vortexing in a glass tube (Pyrex), and were centrifuged 
for five minutes at 1500rpm. The non-aqueous (bottom) phase containing 
chloroform was discarded. The aqueous phase containing lipids was mixed with 
additional100 µl methanol and added to an ELISA plate (Thermo-Scientific 
#442404) and allowed to dry overnight. Soluble GM3 (Avanti) standards were 
added in parallel. The wells were blocked with PBS/5% nonfat milk for 2 hrs at 
room temperature followed by addition of α-GM3 monoclonal antibody (DH2 
hybridoma supernatant) for one hour at 37°C (67).The plates were washed four 
times with PBS followed by addition of HRP-conjugated secondary goat anti 
mouse antibody (Sigma). Finally, the plates were readout using TMB peroxidase 
as a substrate (KPL) and a micro plate reader.  
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GM1 and PS Quantification by Plasmon Coupling 
GM1 and PS quantification by plasmon coupling followed a recently described 
procedure (77). Briefly, biotinylated gold NPs were targeted to the lipid of interest 
on HIV-1 and HIV-2 VLPs functionalized with either biotinylated Annexin V (in 
case of PS) or Cholera toxin B (in case of GM1) using Neutravidin as a linker. 
The spectral response of the VLP-bound gold NPs depends on the label density. 
After calibrating the spectral response with liposomes of known target lipid 
concentration, the measured spectral response provides a quantification of target 
lipids in individual VLPs. 50-300 VLPs were evaluated per condition. 
 
Quantification and statistical analysis 
Experimental samples were compared using a two-tailed paired t-test using 
Prism. Unless otherwise stated in the figure legends, experiments were 
performed with at least three independent donors. Data are presented as the 
mean ± standard error of pooled data from at least three donors unless otherwise 
indicated.
	  72 
CHAPTER ONE: Access of HIV-2 to CD169-dependent Trans Infection 
Pathway is Attenuated Compared to HIV-1 
 
Introduction 
There are two viruses that cause Acquired Immune Deficiency Syndrome (AIDS) 
in humans, HIV-1 and HIV-2. Zoonotic transmissions of both viruses to the 
human populations have occurred presumably due to repeated human exposure 
to infected non-human primates (238). HIV-2, is believed to have made a 
zoonotic jump from SIVsmm-infected sooty mangabeys (Cercocebus atys) in 1940 
± sixteen years while the major pandemic strain of HIV-1 (Group M), has been 
hypothesized to have made the jump from SIVcpz-infected chimpanzees (Pan 
troglodytes) in 1930 ± fifteen years (154). Less is known about HIV-2 than HIV-1, 
although it appears to have the same mode of transmission and is associated 
with similar immune deficiency in end stage disease as HIV-1. In contrast to the 
rapid disease course of HIV-1 in the absence of highly active antiretroviral 
therapy, progression to end-stage disease in HIV-2-infected individuals is 
characterized as heterogeneous, with a minority of infected individuals 
progressing to AIDS, while a majority of HIV-2 infected individuals display a 
longer asymptomatic stage with relative viral control and high CD4+ T cell counts 
(63, 162). Interestingly, the survival rate of HIV-2+ individuals is 100% five years 
post-seroconversion compared to 67% in HIV-1+ individuals (63). The 
mechanistic explanation behind these differences is not fully understood. These 
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observed differences in the course of disease in HIV-1 and HIV-2 infections has 
lead to the hypothesis that HIV-2 is an attenuated form of HIV-1.  
 
CD4+ T cells are the primary targets of both HIV-1 and HIV-2, while dendritic 
cells (DCs), the front line of defense for the immune system, also play a role in 
HIV pathogenesis (273). In contrast to the reported disparities on establishment 
of productive infection in DCs by HIV-1 and HIV-2, most studies are in agreement 
that HIV-2 is capable of infecting CD4+ T cells at an equivalent level as HIV-1 
(49, 70). As the main target cell for HIV pathogenesis, dissemination to and 
establishment of virus replication in CD4+ T cells is critical for viral spread In 
addition to CD4 and chemokine co-receptors, DCs express a number of virus 
attachment factors, such as DC-SIGN and CD169 that can bind HIV-1 particles 
and mediate trans infection of CD4+ T cells (90, 125, 130, 211). Unlike all 
previously identified HIV-1 attachment factors that recognize the virus 
glycoprotein, gp120, CD169, also called sialoadhesin or Siglec1 (sialic acid 
binding Ig-like lectin 1), a member of the immunologlobin-like lectin superfamily 
(106), binds α2,3-sialylated GSLs, GM1 and GM3, incorporated in the virus 
particle membrane (124, 213). GM3-dependent capture of HIV-1 particles by 
CD169 results in virus particle localization and preservation of virus particle 
infectivity within CD81+ CD169+ plasma membrane invaginations in mature DCs 
(7), and upon establishment of mature DC – CD4+ T cell conjugates, transfer of 
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captured particles to CD4+ T cells across virological synapses (125, 211).  
 
The ability of HIV-1 to establish productive infection in DCs is attenuated 
primarily due to the existence of numerous post-entry restrictions to virus 
replication, such as SAMHD1 (118, 147), that block virus replication at the 
reverse transcription step. In contrast, HIV-2 encoded Vpx has been shown to be 
necessary and sufficient to counteract SAMHD1 and facilitate productive 
infection of DCs (118, 147). However, other studies have reported that infections 
with primary or lab-adapted HIV-2 isolates do not result in robust replication in 
DCs (49, 70).  
 
In our study, we have investigated whether HIV-2 is capable of utilizing the 
CD169/GM3 dependent mature DC-mediated trans infection pathway for efficient 
dissemination to CD4+ T cells. We observe significantly less capture of HIV-2 by 
mature DCs and hence, subsequently less mature DC-mediated transfer of HIV-2 
to autologous CD4+ T cells. We demonstrate that incorporation of GM3 is 
reduced in HIV-2 virions, presumably due to HIV-2 assembly and exit from GSL-
deficient membrane sites in virus-producer cells. These findings suggest that 
attenuated access of HIV-2 to the CD169-dependent trans infection pathway 
contributes to the diminished spread and reduced pathogenicity.  
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Results 
1.1 Attenuated Capture of HIV-2 VLPs by CD169  
CD169 or Siglec 1, a myeloid cell-specific protein, captures HIV-1 and facilitates 
mature DC-mediated HIV-1 trans infection of CD4+ T cells (125, 211). We 
hypothesized that lower HIV-2 viral loads in vivo (12, 32, 162) might be attributed 
to inefficient access to the CD169-dependent mature DC-mediated trans 
infection pathway. We have previously described a Gag-eGFP VLP based virus 
capture assay (108, 127) to determine that CD169 recognizes sialylated-GSLs, 
such as GM1 and GM3, in the virus particle membrane (124, 125, 211, 213). To 
determine if HIV-2 particles are also captured by CD169, and if HIV-2 capture by 
CD169 is also dependent on sialylated GSLs, mature DCs were challenged with 
fluorescent unmodified or GSL-depleted HIV-2 Gag-eGFP VLPs.  Virus particle 
inputs for the different VLP preparations were normalized using a quantitative 
western blot analysis for GFP content (Figure 4A). We observed a significant 
decrease in the capture of HIV-2 VLPs by mature DCs compared to capture of 
HIV-1 Gag-eGFP VLPs (Figure 4B). Depletion of GSLs, the ligand for CD169, 
from both HIV-1 and HIV-2 Gag-eGFP VLPs (PDMP treatment of virus producer 
cells) resulted in a further decrease in VLP capture suggesting that capture of 
both HIV-1 and HIV-2 VLPs by mature DCs is dependent on GSLs (Figure 4B). 
Furthermore, capture of HIV-2 Gag-eGFP VLPs by THP/CD169 cells was 
significantly lower than that observed with HIV-1 Gag-eGFP VLPs (Figure 4C), 
suggesting a diminished ability of CD169 to recognize HIV-2 Gag-eGFP VLPs.  
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Figure 4. Attenuated Capture of HIV-2 VLPs by CD169. (A) Representative 
quantitative western blot analysis of VLP lysates for measuring GFP content of 
virions. Standard curve of recombinant GFP (included in each western blot) was 
used to quantify the GFP content in HIV-2 Gag-eGFP and HIV-1 Gag-eGFP 
VLPs. PDMP treatment of HEK293T cells was used to deplete GSLs in VLPs. 
NT=non-treated (B) Quantitative FACS analysis of VLP capture by mature DCs. 
Mature DCs were challenged with 10ng GFP containing HIV-1 or HIV-2 VLPs 
(NT = non-treated or PDMP = GSL depleted) at 37°C for 2 hr. The data from six 
independent experiments with cells derived from six independent donors (each 
symbol) is shown as means ± SEM (horizontal lines). *p=0.04 (C) Attenuated 
capture of HIV-2 VLPs by THP-1/CD169. THP-1 monocytic cell line constitutively 
expressing CD169 were challenged with 10ng GFP containing HIV-1 or HIV-2 
VLPs at 37°C for 2 hr, washed, fixed and quantified via flow cytometry. The data 
from 5 independent experiments (each symbol) is shown as means ±SEM 
(horizontal lines). ****p<0.0001. 
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1.2 Decreased Incorporation of GM3 in HIV-2 Gag-eGFP VLPs 
To determine if the significantly reduced capture of HIV-2 VLPs by mature DCs 
and THP1/CD169 cells is attributed to reduced levels of GSL incorporation by 
HIV-2 virions, we quantified the lipidomic contents of HIV-1 and HIV-2 Gag-eGFP 
VLPs. We employed both a multi-spectral plasmonic nanocoupling analysis to 
measure phosphatidylserine (PS) and GM1 levels (77) and ELISA to measure 
GM3 incorporation in VLP membranes. While both HIV-1 and HIV-2 Gag-eGFP 
VLPs contained similar levels of PS (Figure 5A) and GM1 (Figure 5B), there was 
a 2-3-fold decrease in GM3 content in HIV-2 Gag-eGFP VLPs (Figure 5C).  
 
HIV-1 Gag defines the virus particle assembly site and hence determines 
specificity of incorporation of host-determinants such as GSLs (6). To determine 
if HIV-1 and HIV-2 assemble at divergent membrane locations, HEK293T cells 
were co-transfected with HIV-1 Gag-mCherry and HIV-1 or HIV-2 Gag-eGFP 
expression plasmids and processed for confocal microscopy. As expected, there 
was extensive co-localization between HIV-1 Gag-eGFP and HIV-1 Gag-
mCherry fusion proteins at the plasma membrane (Figure 5D and E). 
Interestingly, HIV-2 Gag-eGFP was localized at both the plasma membrane and 
intracellular sites (Figure 5D, middle and bottom rows), and co-localization 
between HIV-2 Gag-eGFP and HIV-1 Gag-mCherry at both these sites was 
infrequently observed (Figure 5D and E), suggesting that altered choice of HIV-2 
Gag-directed virus assembly site might account for the reduced GM3 
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Figure 5. Decreased Incorporation of GM3 in HIV-2 Gag-eGFP VLPs. 
Phosphatidylserine (PS) (A) and GM1 (B) content of HIV-1 and HIV-2 Gag-eGFP 
VLPs was determined by multi-spectral plasmonic nanocoupling analysis; n.s. = 
not significant (C) GM3 content in HIV-1 and HIV-2 Gag-eGFP VLPs was 
determined by an ELISA. Values for HIV-2 Gag-eGFP VLPs were normalized to 
those observed with HIV-1 Gag-eGFP VLPs (set as 1) and is the mean of 3 (for 
PS and GM1) and 4 (GM3) independent measurements ± SEM. *p=0.01. (D) 
HEK293T cells were co-transfected on glass cover slips with HIV-1 Gag-eGFP or 
HIV-2 Gag-eGFP expression plasmids with HIV-1 Gag-mCherry expression 
plasmid. Cells were counterstained with DAPI to visualize nuclei. The left panel 
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shows expression of the HIV-1 or HIV-2 Gag-eGFP, middle panel shows the HIV-
1 Gag-mCherry expression and the right panel is the overlay. (E) Co-localization 
between green (Gag-eGFP) and red (Gag-mCherry) is reported as mean 
Pearson’s coefficient of co-localization ± SEM. **p=0.005.
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incorporation in HIV-2 VLPs  
 
1.3 Interactions of HIV-2iGFP Virions with Mature DCs and THP1/CD169 
Cells are Attenuated 
 To determine if infectious HIV-2 particles are also deficient for capture by 
CD169, we constructed a proviral plasmid that encodes GFP between MA and 
CA and flanked by protease cleavage sites (HIV-2-iGFP), such that upon virus 
maturation GFP is cleaved out and remains associated as a fluid phase 
fluorescent marker of virions, similar to the previously described HIV-1-iGFP 
virus (120) (Figure 6A). GFP was incorporated in both HIV-1 and HIV-2 virions 
and was cleaved by the viral protease (Figure 6B). While HIV-2-iGFP virions 
incorporated Env to similar levels as HIV-2/ROD (Figure 6B), infectivity of HIV-2-
iGFP was attenuated compared to HIV-2/ROD (Figure 6C), similar to what has 
been previously reported with HIV-iGFP (120) (Figure 6C). To determine the site 
of Gag localization, HIV-1iGFP or HIV-2iGFP transfected HEK293T cells were 
stained with WGA-AF594 and processed for laser scanning confocal microscopy. 
Interestingly, while GFP expression in HIV-1iGFP transfected cells was primarily 
co-localized at the plasma membrane with WGA (Figure 6D and E), 
intracytoplasmic GFP puncta were clearly visible in HIV-2iGFP transfected cells 
and co-localized poorly with WGA at the plasma membrane (Figure 6D and E). 
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Figure 6. Characterization of HIV-2iGFP. (A) Genome organization of the HIV-
1 and HIV-2 proviral plasmids used in this study, which encode GFP between MA 
and CA, flanked by protease cleavage sites (indicated by the scissors symbol), 
such that infectious virus particles contain GFP. (B) Representative western blot 
analysis for Env, GFP, and p24gag or p27gag in virus particle lysates. (C) TZM-bl 
cells were infected with virus particles (HIV-1/Lai-Bal, HIV-1iGFP, HIV-2/ROD9 or 
HIV-2iGFP), washed, and cultured for 2 days. Cells were lysed 2 days post 
infection and the luciferase activity (RLU =relative light units) per p24gag or p27gag 
measured via TZM-bl infections and AG3.0 ELISA were determined and the 
values for the iGFP proviruses normalized to that observed with isogenic viruses 
lacking GFP. The data shown is from a representative experiment (out of 2 
independent experiments) performed in triplicate  (D) HEK293T cells were 
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transfected with either HIV-1iGFP or HIV-2iGFP plasmid and stained with 
AlexaFluor 594-conjugated Wheat Germ Agluttinin (WGA-AF594) and 
counterstained with DAPI, one day post-transfection. The yellow arrowhead 
indicates an area of co-localization while a white arrowhead indicates lack of co-
localization between GFP and WGA staining (E) Co-localization between green 
(GFP) and red (WGA) is reported as mean (±SEM) Pearson’s coefficient of co-
localization. **p=0.001.
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GFP content of HIV-1iGFP and HIV-2iGFP virions derived from transient 
transfections of HEK293T cells was determined using a quantitative western blot 
analysis. Virus particles containing equal amounts of GFP were used in virus 
capture experiments with mature DCs. These viruses allowed us to employ a 
FACS-dependent measure of capture of fluorescent virus particles by cells. 
Although capture of both HIV-1iGFP and HIV-2iGFP by mature DCs increased in 
a dose-dependent manner (Figure 7A), capture of HIV-2iGFP by mature DCs 
was consistently lower than that observed with HIV-1iGFP especially, at lower 
viral inputs (Figure 7A). We performed virus capture studies with both mature 
DCs and THP1/CD169 cells with a single virus input (25 ng or 8.3 ng of GFP 
equivalent, respectively) at 4°C to prevent non-specific phagocytosis of virus 
particles. Though the extent of virus capture varied amongst mature DCs derived 
from multiple independent donors, the differences in virus capture (2-fold) 
between HIV-1iGFP and HIV-2iGFP were statistically significant (p=0.009; Figure 
4B). Additionally, there was a 2.5-fold decrease (p=0.026) in capture of HIV-
2iGFP (relative to HIV-1iGFP) by THP1/CD169 cells (Figure 7C). These findings 
suggest that CD169-dependent capture of HIV-2 by mature DCs is attenuated.  
 
 
 
 
 
	  84 
	  
Figure 7. Capture of HIV-2iGFP Virions by Mature DCs is Attenuated. (A) 
Mature DCs were challenged with increasing amounts (ng of GFP) of HIV-1iGFP 
(blue) or HIV-2iGFP (red) virions at 37°C for 2 hours, washed, fixed and the 
percentage of GFP+ cells quantified using flow cytometry. The data shown is the 
mean ± SEM from 3 independent donors. Nonlinear regression was used to 
estimate a fitted curve in GraphPad Prism 5 (B) Mature DCs were challenged 
with 25ng of GFP containing HIV-1iGFP or HIV-2iGFP virus particles at 4°C for 2 
hours, washed, fixed and the percentage of GFP+ cells quantified using flow 
cytometry. The data shown is relative decrease of HIV-2iGFP capture (HIV-
1iGFP capture set as 1) and is the mean of 8 independent experiments with cells 
from 8 independent donors (± SEM); p=0.009. (C) THP1/CD169 cells were 
challenged with 8.3 ng of GFP containing HIV-1iGFP or HIV-2iGFP virions at 4°C 
for 2 hours, washed, fixed and the percentage of GFP+ cells quantified using flow 
cytometry. The data shown is relative decrease of HIV-2iGFP capture (HIV-
1iGFP capture set as 1) and is the mean (± SEM) of 3 independent experiment; 
p=0.026. 
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1.4 HIV-1 and HIV-2 Traffic to a CD169+CD81+ Compartment in Mature DCs 
Our lab and others have shown that upon capture by CD169, virus traffics to a 
CD81+ compartment (7, 125, 211, 277, 278). To determine localization of HIV-2 
following capture by mature DCs, cells were challenged with either HIV-1iGFP or 
HIV-2iGFP and stained for cellular markers CD81, CD63 or LAMP1. Similar to 
HIV-1iGFP, captured HIV-2iGFP particles were also co-localized with CD169 in a 
CD81+ compartment (Figure 8A and B).  Furthermore, neither HIV-1 nor HIV-2 
were located in compartments that are CD63+ or LAMP1+ (Figure 8C and D), 
similar to previously published findings with HIV-1 localization in mDCs. These 
results suggest that while efficiency of HIV-2 interaction with CD169 is lower, 
HIV-2 particles that are captured by CD169 are trafficked to similar non-
lysosomal CD81+ compartments in mature DCs as HIV-1. 
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Figure 8. Both HIV-1iGFP and HIV-2iGFP Traffic to a CD169+CD81+ 
Compartment. Immunofluorescent microscopy shown with DAPI staining the nuclei 
of mature DCs, either HIV-1iGFP or HIV-2iGFP in green, cell markers (A) CD169, 
(B) CD81, (C) CD63, (D) LAMP1 (AF594) in red, Brightfield and the merged image. 
Mature DCs were pulsed with 25ng GFP virus input of either HIV-1iGFP or HIV-
2iGFP for 2 hours at 37°C, washed, fixed, permeabilized and stained for cell 
markers. 
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1.5 Reduced Access of HIV-2 to the Mature-DC Mediated Trans Infection 
Pathway. 
We next asked whether reduced capture of HIV-2 by CD169 results in decreased 
access to the mature DC-mediated trans infection pathway of CD4+ T cells. 
Mature DCs were challenged with replication competent HIV-1 (Lai-YU2) or HIV-
2 (CDC77618) virus particles, washed and cultured alone or co-cultured with 
autologous CD4+ T cells.  Cell-free supernatants on day six post-infection were 
added to TZM-bl cells to measure the amount of virus produced by the co-
cultures compared to virus produced by mature DCs or CD4+ T cells alone. Note 
that CD4+ T cells were infected to a similar extent by HIV-1 and HIV-2 (Figure 
5B). While infecting mature DCs with either HIV-1/Lai-YU2 or HIV-2/CDC77618 
and culturing alone in the absence of CD4+ T cells did not result in production of 
infectious virus (data not shown), infections of mature DC – T cell co-cultures 
resulted in robust production of infectious HIV-1 virions (Figure 9A). Surprisingly, 
production of infectious HIV-2 virions was dramatically attenuated in mature DC-
T cell co-cultures (~100-fold reduction compared to HIV-1) (Figure 9A). These 
findings suggest that HIV-2 is less efficiently transferred by mature DCs to 
autologous CD4+ T cells.   
 
Next we used GFP expressing single-cycle viruses to determine if the differences 
in HIV-1 and HIV-2 virus replication in mature DC – CD4+ T cell co-cultures can 
be attributed to the inability of HIV-2 to access the mature DC-mediated trans 
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Figure 9. Access of HIV-2 to Mature DC-Mediated Trans Infection Pathway 
is Diminished. Mature DCs (A) or activated CD4+ T cells (B) were pulsed with 
either HIV-1 (Lai-YU2) or HIV-2 (CDC77618) at an MOI=0.1. Virus-exposed 
mature DCs were washed to remove unbound virus and co-cultured with 
autologous CD4+ T cells. Mature DC-T cell co-culture supernatants or CD4+ T 
cell supernatants were harvested on day 6 post-infection and added to TZM-bl 
cells. The data shown is luciferase activity (RLU) in TZM-Bl cell lysates harvested 
48 hr post initiation of infection and is the mean ±SEM from 4 experiments 
derived from cells from 4 independent donors. (C) Mature DCs were infected with 
GFP expressing single cycle replication competent viruses (pseudotyped with 
HIV-1/BaL Env or HIV-2 ST Env) at MOI=5.  Virus-exposed mDCs were washed 
and cultured with autologous CD4+ T cells. Additionally, CD4+ T cells were 
infected directly (cell-free infection) in parallel. The percentage of GFP positive 
CD4+ T cells was quantified via flow cytometry. The data from 6 independent 
infections with cells from 6 donors is shown (mean ±SEM). *p=0.01  
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infection pathway. Mature DCs were challenged with GFP-expressing (upon 
establishment of infection) single-cycle of replication competent HIV-1 or HIV-2, 
pseudotyped with either HIV-1 Bal Env or HIV-2 ST Env. There was no difference 
in the level of cell-free infection of CD4+ T cells by Bal-Env pseudotyped HIV-
1/GFP or ST-Env pseudotyped HIV-2/GFP (Figure 9C). However, transfer of ST-
Env pseudotyped HIV-2/GFP by mature DCs was 4.5-fold less efficient than 
transfer of Bal-Env pseudotyped HIV-1/GFP (Figure 9C). These findings suggest 
that inefficient access of HIV-2 to the CD169-dependent mature DC mediated 
trans infection pathway results in reduced virus transmission to autologous CD4+ 
T cells and consequently less virus spread.  
 
Discussion 
In this study, we investigated the efficiency of mature DCs to transmit captured 
HIV-1 and HIV-2 particles to autologous CD4+ T cells. Previous studies by others 
and us have demonstrated that virion incorporation of host-derived ganglioside 
GM3 is crucial for Env-independent capture and dissemination of HIV-1 by 
mature DCs (124, 213). However, very little is known about HIV-2 capture and 
transfer by mature DCs. We constructed a HIV-2 Gag-eGFP expression plasmid 
and an HIV-2 proviral plasmid that encodes GFP between MA and CA and 
flanked by protease cleavage sites (HIV-2-iGFP), such that VLPs and infectious 
virions contain GFP. We were thus able to compare HIV-1 and HIV-2 Gag-eGFP 
VLP and HIV-iGFP virus capture by a quantitative FACS based assay, and 
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demonstrated that HIV-2 capture by CD169-expressing mature DCs and THP1 
cells was decreased compared to HIV-1 (Figures 4 and 7). Furthermore, 
decreased HIV-2 capture by mature DCs resulted in attenuated HIV-2 transfer to 
autologous CD4+ T cells (Figure 8). Interestingly, decreased HIV-2 capture by 
CD169 could primarily be attributed to reduced incorporation of GM3, but not 
GM1, in HIV-2 virions (Figure 5). These findings provide additional confirmation 
that GM3 is the critical virus particle determinant necessary for optimal 
interactions of HIV with CD169.  
 
In the lentiviral replication cycle, newly synthesized Gag proteins are targeted to 
the plasma membrane for assembly and budding of new virions.  Our previous 
studies have suggested that GM3 incorporation in HIV-1 virions is dependent on 
HIV-1 MA-defined virus assembly sites (6). MA proteins of HIV-1 and HIV-2 Gag 
are both co-translationally myristoylated at the N-terminal end, which plays a 
critical role in virus assembly at the plasma membrane. HIV-1 MA binding to 
phosphatidylinositol 4,5-biphosphate (PI(4,5)P2), which is enriched at the inner 
leaflet of plasma membrane microdomains, induces exposure of the myristyl 
group. This myristyl group confirmation change from hidden to exposed is critical 
for stable plasma membrane association of HIV-1 Gag (227). In contrast, the 
myristyl group in HIV-2 MA is more tightly sequestered and less sensitive to 
PI(4,5)P2 binding  resulting in a lower rate of association of HIV-2 Gag with the 
plasma membrane (227). Additionally, affinity of HIV-2 Gag to model yeast 
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spheroplasts (membranes) is lower than that of HIV-1 Gag that results in HIV-2 
assembly and budding defects from these model membranes (181). Our confocal 
microscopy studies of transfected HEK293T cells revealed HIV-2 Gag 
association with both WGA-enriched plasma membrane microdomains as well as 
at intracellular membranes that did not co-localize with HIV-1 Gag (Figures 5 and 
6). Since GSLs, such as GM1 and GM3 are enriched at the plasma membrane in 
distinct microdomains (82), and intracellular membrane composition of lipids is 
distinct from that of plasma membranes (140), reduced incorporation of GM3, but 
not GM1, in HIV-2 virions might reflect the heterogeneity in HIV-2 assembly site 
as observed with HIV-1 MA mutants (6). Studies are in progress to determine if 
mutations in HIV-2 MA that alter virus assembly site result in enhanced virion 
incorporation of GM3 and rescue capture of HIV-2 virions by CD169. 
 
In contrast to reduced capture by CD169, HIV-1 and HIV-2 are equally captured 
by the DC attachment factors, galactosylceramide (102) and DC-SIGN (208). As 
opposed to CD169 whose expression is induced upon maturation of DCs (125, 
211), expression of DC-SIGN is decreased in DCs upon maturation, and 
neutralization of DC-SIGN function has negligible impact on mature DC-mediated 
HIV-1 trans infection (211). Thus, we hypothesize that selective deficiency in the 
ability of HIV-2 to interact with CD169 compromises its ability to access the 
mature DC trans infection pathway. As opposed to trans infection, HIV-2 virus 
particle fusion (cis infection) is significantly more promiscuous than HIV-1 (184). 
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HIV-2 can utilize multiple co-receptors, such as CCR1, CCR2b, CCR3, orphan 
receptor BONZO or BOB in addition to CD4, CCR5 and CXCR4, for fusing with 
target cells (184, 198). Though HIV-2 Vpx can overcome restriction by SAMHD1 
(118, 147), LPS-matured DCs remain a hostile environment for HIV-2 replication 
(200) that places additional roadblocks to establishment of productive infection. 
Whether engagement of CD169-independent attachment factors and chemokine 
co-receptors by HIV-2 results in fusion and entry within mature DCs remains to 
be determined, though recent studies have questioned the ability of HIV-2 to 
successfully fuse and replicate in immature DCs (49).  
 
We have previously postulated that mature DCs in an inflammatory 
microenvironment are critical cellular vectors for mediating HIV-1 dissemination 
by capturing virus, trafficking to lymph nodes and efficiently transferring captured 
virus to CD4+ T cells (138). CD169 is a myeloid cell specific antigen (57) whose 
expression is positively correlated with viral loads in HIV-1 infected individuals 
(218, 265).  For instance, increased expression of CD169 on circulating 
monocytes has been observed in acutely infected and untreated HIV-1 patients 
(205, 218, 265) and in pathogenic lentiviral infections of non-human primates (37, 
131, 139). Additionally, CD169 is also constitutively expressed on tissue resident 
myeloid cells, particularly macrophages in the subcapsular sinus and the 
marginal zone of secondary lymph nodes (106, 139). Since CD169 is an 
interferon stimulated gene (211), early type I interferon responses to acute 
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lentivirus infection that induce expression of CD169 on peripheral blood 
monocytes and tissue-resident macrophages, can paradoxically result in 
enhanced dissemination of HIV-1 (218). Additionally, CD169 expression on DCs 
can also be induced by TGFβ, the most abundant cytokine found in semen, and 
hence CD169 may also play a role in in sexual transmission of HIV-1 (62). Thus, 
the relative inability of HIV-2 to exploit the CD169-dependent trans infection 
pathway might contribute to the decreased transmission rates and reduced viral 
loads in HIV-2 infected individuals. These studies highlight the need for the 
development of therapeutics, which specifically inhibit CD169-dependent HIV-1 
dissemination, as additional approaches to curtail the virus pandemic. 
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CHAPTER TWO: Consequences of Establishment of Productive Infection of 
Immature Dendritic Cells by HIV-2 
Introduction 
The level of infection of myeloid cells by HIV and how that contributes to the viral 
reservoir in vivo is a topic of controversy. Although DCs are susceptible to 
infection by HIV-1, productive infection of DCs in vitro and in vivo is 10–100 fold 
lower than CD4+ T cells (273). Some studies argue that existence of multiple 
restriction factors in myeloid cells presents a hostile cellular environment for HIV-
1 replication, and question the importance of myeloid cells towards HIV-1 viremia 
(35). However, other studies have demonstrated de novo HIV-1 production from 
productively infected myeloid cells and efficient dissemination of myeloid cell-
derived virus to CD4+ T cells (263). Despite the limited spread of HIV-2 in human 
populations, studies on HIV-2 pathogenesis have became more prominent once 
it was discovered that SAMHD1 is a critical restriction factor that blocks 
retroviruses at the reverse transcription step in myeloid cells and that HIV-2 viral 
protein Vpx counteracts SAMHD1 restriction by targeting SAMHD1 for 
proteasomal degradation (118, 147). These findings, therefore, suggest that HIV-
2, unlike HIV-1, can establish robust productive infection of myeloid cells. 
However, more recent findings in the literature have called this hypothesis into 
question.  
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Studies have reported that infections with some primary or lab-adapted HIV-2 
isolates do not result in robust replication in DCs, primarily due to a block to HIV-
2 entry and fusion in DCs (49, 70). Robust establishment of HIV-2 infection in 
DCs was observed, if the entry and fusion block of HIV-2 in DCs was overcome 
by pseudotyping with VSV-G (49).  
 
While, induction of SAMHD1 degradation by Vpx can facilitate enhanced reverse 
transcription, increased levels of viral reverse transcripts can be sensed by 
nucleic acid sensors, such as cyclic-GMP-AMP synthase or cGAS (87, 253) 
resulting in induction of robust type I IFN responses (148, 215). In contrast to 
detection of HIV-2 reverse transcripts by cGAS, HIV-1 reverse transcripts are 
hypothesized to be protected from sensing by cytoplasmic nucleic acid sensors 
because of incorporation of host proteins, cyclophillin A (CypA) and CPSF6 by 
the incoming HIV-1 capsids that shield the viral reverse transcripts from detection 
(148, 215).  In contrast, HIV-2 CA has a lower affinity for CypA (148), and the 
incoming HIV-2 capsid uncoats at a faster rate (252) that might result in 
increased detection of HIV-2 RT intermediates by cGAS. These findings suggest 
that despite encoding Vpx, HIV-2 either does not establish productive infection in 
DCs, or Vpx-dependent SAMHD1 degradation and establishment of productive 
infection triggers a robust myeloid cell-intrinsic innate immune response that 
blocks HIV-2 replication and spread.  
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These findings leave open the question as to whether there are replication 
differences between HIV-1 or HIV-2 infections of myeloid cells, such as DCs, and 
whether establishment of productive infection in DCs by HIV-2 confers a 
replicative fitness disadvantage to HIV-2. Specifically, we tested the hypothesis 
that HIV-2 infection of DCs triggers innate immune sensing and induction of type 
I IFN responses that inhibit virus replication. Therefore, in this chapter, I asked 
whether the differences seen in pathogenesis between HIV-1 and HIV-2 in vivo 
are due to the differences in interactions of these viruses with DCs.  
 
2.1 HIV-2 is More Efficient at Infecting Immature Dendritic Cells 
In studies described below, I used DCs differentiated from peripheral blood 
CD14+ monocytes in the presence of GM-CSF and IL-4 (213) for six days.  DCs 
were infected with either HIV-1, BruYU2 (CCR5-tropic) molecular clone, or HIV-2 
primary isolate CDC77618 at an MOI of 0.1, washed and cultured for eight days. 
The HIV-2 primary isolate, CDC77618, was provided by the NIH AIDS reagent 
program and was originally isolated from a diagnostic culture from an Ivorian 
AIDS patient (198). We determined the amount of virus produced from infected 
cells by collecting cell-free supernatants every two days from infected DCs, and 
adding them to a HIV reporter cell line, TZM-bl, which expresses Tat-inducible 
luciferase protein. Thus, detection of luciferase activity in TZM-bl cell lysates 
provides a quantitative measure of infectious virus production in immature DC 
cultures. Across many donors we consistently observed that the HIV-2 primary 
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isolate, CDC77618, productively infected immature DCs more robustly that HIV-1 
BruYU2 (Figure 10A and B). Depending on donor, HIV-2 infection peaked four to 
six days post infection, with 15-fold and 8-fold more HIV-2 infectious virus 
production, respectively, compared to HIV-1 (Figure 10B). We saw similar trends 
with another HIV-2 primary isolate, 310319, and HIV-2 molecular clones ROD10 
and GH1 (data not shown).  Therefore, our results suggest that HIV-2 can 
productively infect immature DCs and produce infectious progeny virions from 
these cells.  
 
2.2 HIV-2 Induces a Spreading Infection of Immature Dendritic Cells 
Next we wanted to investigate whether HIV-2 is able to cause a spreading 
infection in dendritic cell cultures. In order to measure virus spread in infected DC 
cultures, cells were infected in the presence or absence of a viral protease 
inhibitor, Indinavir, which inhibits production of infectious (mature) virus particles. 
We used a FACS-based readout for these studies. Infected cells in the culture 
were detected by staining with an anti-Gag monoclonal antibody (Clone KC-57 
that detects intracellular expression of both HIV-1 and HIV-2 Gag) and the 
percentage of Gag positive cells determined by flow cytometry (Figure 11). To 
test the ability of virus to spread in immature DC cultures, we infected cells with 
replication competent HIV-1 (Bru-YU2) and HIV-2 (ROD10) that were also 
pseudotyped with VSV-G, so as to overcome any entry or fusion differences in 
the initial round of virus infection. Additionally, immature DCs were infected at a 
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high MOI=1, so as to enable detection of intracellular viral Gag protein 
expression by FACS as a measure of productive virus infection. We observed 
approximately 2-3% Gag positive cells in all of the infection conditions at day 3 
post infection (Figure 11A). While the number of Gag positive cells increases 
from day 3 to day 6 in HIV-2 infected cultures, only a minimal increase is 
observed in the number of HIV-1 Gag+ cells (Figure 11A). Furthermore, Indinavir 
treatment (dashed lines) blocked the increase in number of HIV-2 and HIV-1 
Gag+ cells suggesting that HIV-2 can establish a spreading infection in immature 
DCs. These experiments were performed with immature DCs derived from two 
additional donors with similar results (Figure 11B).  
 
Dendritic cells are known to traffic to secondary lymph nodes upon maturation 
from peripheral mucosal sites and are hypothesized to ferry virus captured in the 
periphery to the to T cell rich regions within secondary lymph nodes (273). Since 
CD4+ T cells are the predominant source of viremia in vivo, virus access to the 
CD4+ T cell compartment is critical for establishment of infections in vivo. Since 
previous studies have suggested that productively infected macrophages and 
DCs can transmit HIV-1 to CD4+ T cells (170, 263), we sought to determine if 
establishment of robust  
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Figure 10. HIV-2 Productively Infects Immature DCs. Immature DCs were 
infected at an MOI=0.1 with either HIV-1 BruYU2 or HIV-2 primary isolate 
CDC77618 for 2 hours at 37°C, washed and cultured for 8 days. (A) Representative 
Infection kinetics of HIV-1 and HIV-2 in immature DCs. (B) Virus production from 
nine different donors across day 2, 4, 6 and 8 post infection. RLU= relative light units 
of infection supernatants on TZM-bl cells as a readout. *p=0.01 for day 6 and 
**p=0.003 for day 8 post infection  
n.s. p=0.06 
n.s. p=0.11 
* p=0.01 ** p=0.003 
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Figure 11. HIV-2 Causes a Spreading Infection in DC Cultures. The left panel 
displays data from a representative infection. The numbers of % p24/p27 (Gag) 
positive cells on days 3 and 6 post infection was determined via flow cytometry. 
Cells were either non-treated (NT) (solid lines) or treated with 1 µM Indinavir 
(IDV) (dotted lines). (B) Infection kinetics of HIV-1 and HIV-2 in immature myeloid 
dendritic cells from three different donors in the presence or absence of Indinavir 
(1 µM). Data is shown as fold difference in % p24/p27 (Gag) positive cells in non-
treated (NT) cultures over that observed with Indinavir (IDV) treated cultures on 
day 6 post infection. 
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levels of productive HIV-2 infection in immature DCs results in enhanced virus 
spread to CD4+ T cells. Thus we determined if HIV- 2 is able to spread within 
DC-T co-cultures. Immature DCs were challenged with either HIV-1 Bru-YU2 or 
HIV-2 primary isolate, CDC77618, for two hours at an MOI=0.1, washed and 
cultured alone, or co-cultured with autologous CD4+ T cells. Additionally, CD4+ T 
cells were also infected in parallel and cultured alone (in the absence of DCs). 
The amount of virus produced from the infected cultures was measured using 
TZM-bl reporter cells, as described above. Interestingly, we observed less virus 
production in HIV-2 infected DC-T co-cultures than either DCs or T cells infected 
with HIV-2 in isolation (Figure 12A). There was a 7-fold and 2-fold reduction in 
HIV-2 (CDC77618) production from virus-exposed DC-T cell co-cultures 
compared to that observed with HIV-2 infections of DCs or T cells alone, 
respectively (Figure 12A). In contrast, there was a low level of HIV-1 infection in 
immature DCs, which was enhanced upon co-culture with T cells (Figure 12A). 
We have repeated this experiment multiple times and have represented this data 
as fold-enhancement of infectious virus production observed in DC – T cell co-
cultures over that observed with DC infections in isolation. We find that in 
contrast to the dramatic enhancement of HIV-1 replication in DC-T cell co-
cultures, there was a reduction or no enhancement of infectious HIV-2 virus 
production at days 2 and 4 of DC – T cell co-cultures (Figure 12B).  Therefore, 
addition of CD4+ T cells to DC cultures inhibited HIV-2 replication and spread 
while enhancing HIV-1 replication. 
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2.3 Differential Immune Sensing of HIV-1 and HIV-2 in Dendritic Cells  
To investigate the mechanism of HIV-2 restriction in DC-T cell co-culture, we 
sought to determine if co-culture of HIV-2 exposed DCs with CD4+ T cells 
induces antiviral innate immune responses. Previous studies have demonstrated 
that HIV-2 reverse transcripts are detected by the nucleic acid sensor cGAS, in 
DCs (87, 253). Hence, we started by determining if innate immune activation is 
induced upon infections of DCs alone with HIV-1 or HIV-2 (Figure 13). DCs were 
infected with HIV-1 (Bru-YU2) or HIV-2 (ROD10) pseudotyped with VSV-G (to 
overcome entry restrictions) at an MOI of 2 and lysed for isolation of cellular RNA 
forty-eight hours post infection. Using Affymetrix Human Gene 1.0 ST arrays, we 
profiled DCs that were derived from three independent donors. The arrays were 
normalized together using the Robust Multiarray Average (RMA) algorithm and a 
CDF (Chip Definition File) that maps the probes on the array to unique Entrez 
Gene identifiers. The result is a matrix in which each row corresponds to an 
Entrez Gene ID and each column corresponds to a sample. The expression 
values are log2-transformed by default. By sorting for gene families, we observed 
that a large group of interferon-stimulated genes (ISGs) are induced in DCs 
infected with HIV-2 compared to DCs infected with HIV-1 (Figure 13). These 
results suggest that HIV-2 infection of DCs triggers innate immune sensing and 
induction of ISGs, in agreement with recently published findings (87, 148).  
 
	  103 
To begin confirming the results of the microarray results, we measured by 
luminex assays and qRT-PCR, for IP-10, interferon gamma induced protein 10, 
also known as CXCL10, expression in infected DCs. IP-10 is associated with 
many TH1-type inflammatory diseases and is thought to be critical in recruiting 
activated T cells to sites of inflammation (69).  We tested infection supernatants 
from DCs infected with HIV-1 (BruYU2), HIV-2 lab isolate (ROD10) or HIV-2 
primary isolate (CDC77618) via a multiplex luminex assay and observed 
induction of IP-10 only in the HIV-2 infected cultures (Figure 14A). Additionally, 
measurement of IP-10 mRNA by qRT-PCR demonstrated that infection of DCs 
with HIV-2 (CDC77618) induced robust levels of IP-10 expression in comparison 
to that observed with HIV-1 or mock infected DCs (Figure 14B). Collectively, 
these findings suggest that HIV-2 infection of DCs triggers a type I interferon-
induced gene signature.  
 
We next tested the amount of type I interferon produced in HIV-2 infected 
cultures by a bioassay. Briefly, interferon alpha (IFN-α) production in infected DC 
cultures was measured in HEK293 cells stably expressing luciferase under the 
control of a ISRE (Interferon Sensitive Response Element) promoter that produce 
luciferase upon exposure to type I interferon (151). The level of IFN-α in culture 
supernatants was determined by comparing luciferase activity to 
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Figure 12. DC-T Co-Cultures Infected with HIV-2 Produce Less Virus Than 
DCs or T Cells Alone. (A) Cells were infected with either HIV-1 Bru-YU2 or HIV-
2 CDC77618 at an MOI=0.1 for 2 hours, washed and cultured for two days. Cell-
free supernatants were harvested on day 2 post infection and added to TZM-Bl 
reporter cells to measure level of infectious virus production in DC, T cell or DC-T 
cell co-cultures. TZM-bl cells were lysed 2 days post infection with DC, T, or DC-
T supernatants, and the cell lysates used for measuring luciferase activity. Data 
shown is relative light units (RLU) from three donors. Bars indicate the mean and 
SEM. *p=0.01 via One Way ANOVA (B) Fold enhancement of DC-T co-
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cultures/DCs alone corresponding to infections in (A) from day 2 post infection 
(left) and day 4 post infection (right)
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that observed upon addition of known amounts of recombinant IFN-α to HEK293-
ISRE-luc cells. In contrast to induction of ISGs, negligible amounts of IFNα were 
produced by HIV-2 infection of DCs alone (Figure 15B), Furthermore, infections 
of CD4+ T cells alone also failed to induce type I IFNs (Figure 15C). Interestingly, 
DC-T cell co-cultures infected with two HIV-2 primary isolates, CDC77618 and 
310319, but not HIV-1, produced type I interferon (Figure 15A). To determine if 
establishment of productive HIV-2 infection in DC-T cell co-cultures was 
necessary for induction of IFN-α, cultures were treated with AZT (10µM) to block 
reverse transcription (early step in the virus life cycle) or Sequinvir (1µM) to block 
maturation of de novo produced virus particles (late step in the virus life cycle). 
One donor’s corresponding infection supernatants (HIV-1 BruYU2 and HIV-2 
CDC77618 ± AZT or SQV) are shown. Infection supernatants were added to 
TZM-bl cells to measure virus production (Figure 15D-F). As described 
previously, despite a low level of infection in DCs alone by HIV-1, virus 
replication is enhanced in DC-T co-cultures (Figure 15E and D, respectively). In 
contrast, there is a decrease in infectious HIV-2 production in infected DC – T 
cell co-cultures compared to the infections of DC cultures alone (Figure 15E). As 
seen previously, both HIV-1 and HIV-2 are able to equivalently infect CD4+ T 
cells (Figure 15F). Interestingly, induction of type I IFN production was 
dependent on establishment of virus infection and de novo production of HIV-2 in 
the DC-T co-cultures since infections in presence of either AZT or Sequinavir 
blocked induction of type I IFN (Figure 15A).  
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To determine if the amount of type I IFN produced in HIV-2 infected DC – T cell 
co-cultures could block virus replication, immature DCs (Figure 16A and B) or 
CD4+ T cells (Figure 16C and D) were infected with luciferase expressing VSV-G 
pseudotyped HIV-1 or HIV-2 viruses in the presence or absence of 50U/ml IFN-α. 
Cells were infected at an MOI=0.5 for 2 hours, washed, and cultured for three 
days before lysing. The luciferase activity in these cultures was determined and 
used as a measure of the extent of virus replication. Data shown is duplicate 
infections from one donor and is reported as relative infection (non-treated is set 
at 1). Our preliminary data shows that 50U/ml IFN-α (similar to the amount of 
type I IFN produced in HIV-2 infected DC-T cell co-cultures; Figure 15A) can 
substantially restrict both HIV-1 and HIV-2 infection of both DCs and T cells 
(Figure 16A-D).  
 
We next tested if infection of replication-competent HIV-2 viruses is also blocked 
by the presence of IFN-α. DCs or CD4+ T cells (untreated or treated with 50 U/ml 
IFN-α) were infected with replication competent HIV-1 (Bru-YU2) or HIV-2 
(CDC77618) at an MOI=0.1. Both DCs (Figure 16E and F) and T cells (Figure 
16G 
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Figure 13. HIV-2 Infection of Myeloid DCs Trigger and Interferon Signature. 
Microarray results from 3 donors (indicated by i, ii, or iii) infected with double 
pseudotyped (VSV-G) HIV-1 (Bru-YU2) or HIV-2 (ROD10) at an MOI=5). The 
experiment is comprised of 12 Affymetrix Human Gene 1.0 ST arrays, profiling 
primary human monocyte-derived dendritic cells 48 hours post infection. The 
arrays were normalized together using the Robust Multiarray Average (RMA) 
algorithm and a CDF (Chip Definition File) that maps the probes on the array to 
Expression scaled to fold change over mock  
(blue/white/red: fold change = −2/1/+2) 
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unique Entrez Gene identifiers. The result is a matrix in which each row 
corresponds to an Entrez Gene ID and each column corresponds to a sample. 
The expression values are log2-transformed by default. Shown is the family of 
Interferon stimulated genes and mock infected cells expression is subtracted out.  
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Figure 14. Induction of IP-10 (CXCL10) Production in HIV-2 Infected DCs. 
(A) DCs were infected at an MOI=0.1 and supernatants from day 2, 4 and 6 post 
infection were tested for IP-10 production by luminex. (B) DCs were infected at 
an MOI=2, total RNA was isolated from mock infected and infected DCs 48 hours 
post infection and mRNA was measured by qRTPCR. Data are normalized to 
GAPDH and are expressed as the relative fold increase over normalized RNA 
from mock infected DCs. 
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and H) were infected for 2 hours, washed, and cultured for three days before 
harvesting and adding infection supernatants to TZM-bl reporter cells. Again, we 
observed restriction of infection of DCs and T cells with HIV-1 and HIV-2 in the  
presence of IFNα. Thus, we propose immune sensing of HIV-2 in DC-T co-
cultures triggers type I interferon production that restricts HIV-2 spread. In 
contrast, HIV-1 infection in DC – T cell co-culture is not sensed and results in 
virus spread to CD4+ T cells and enhancement of virus replication. 
 
Conclusions and Future Directions 
Mechanisms accounting for the drastic differences between the HIV-1 and HIV-2 
epidemics have remained unclear. Since HIV-2 encodes Vpx and can degrade 
the myeloid restriction factor, SAMHD1, research has focused on the potential 
consequences of productive infection of the myeloid compartment on viral 
pathogenesis. Unlike HIV-1, HIV-2 is able to productively infect myeloid dendritic 
cells. We have demonstrated that both primary isolates and molecular clones of 
HIV-2 can productively infect DCs and spread within these cultures. This is in 
contrast to other recently reported findings, but may depend on the diversity of 
the primary isolates used in these studies (49, 70). Interestingly, HIV-2 infected 
DC-T co-cultures produce less infectious virus particles than infections of DCs or 
T cells alone. We have observed that productive infection of DCs by HIV-2 can 
induce expression of type I IFN responses (Figures 13 & 14) which fail to restrict 
HIV-2 spread in DCs. Interestingly, addition of CD4+ T cells to HIV-2 exposed 
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DCs resulted in production of IFNα at levels that restrict virus spread (Figures 15 
and 16).  
 
In agreement with our findings, a previous study has reported that macrophages 
can be productively infected by HIV-2, but after initial burst of infection, 
macrophage-derived progeny virus infectivity on a per particle basis was 
significantly reduced by unclear mechanisms (170).  Others have found that 
degradation of SAMHD1 by exogenous Vpx allows HIV-1 to induce increased 
antigen presentation and CTL killing (17). These results suggest that HIV-2 has 
restricted viral spread due to induction of effective CTL responses in vivo (17). 
Therefore, we propose infection of DCs and resulting reverse transcription and 
accumulation of viral DNA in the cytoplasm triggers ISG production. For example, 
we observe IP-10 (CXCL10), which is a chemokine known for T cell recruitment. 
This ISG may have a limited effect in DCs alone, but could enhance DC-T 
conjugates in co-culture and result in clustering of cells allowing virus to fuse and 
enter more DCs meeting a threshold to trigger interferon. The interferon induction 
may mature the DCs, restricting subsequent rounds of infection in the co-culture. 
This may partially explain the lower viral loads observed in HIV-2 infected 
individuals. Studies investigating the mechanisms how HIV-1 infected elite 
controllers control virus without treatment have found potent cell-intrinsic immune 
responses in DCs (173). Interestingly, this cohort of untreated HIV-1 infected 
individuals are able to control virus and demonstrate the ability to sense cytosolic 
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HIV-1 viral products, produce type I interferon and prime a specific T cell 
response via the cGAS-STING pathway (173). Therefore, future studies are 
needed to test if induction of type I IFN responses by cGAS and STING 
dependent pathways are observed in myeloid cells from HIV-2 infected patients 
and if these enhanced innate immune responses account for the reduced viremia 
and decreased pathogenesis of HIV-2 infections. 
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Figure 15. Type I Interferon Production by HIV-2 infected DC-T Co-Cultures. 
Immature DCs or T cells were infected with HIV-1 (Bru-YU2), HIV-2 (CDC77618) 
or HIV-2 (310319) at an MOI=0.1 in the presence or absence (NT) of AZT (10 
µM), Sequinavir (SQV; 1µM). Cells were washed and cultured alone or DCs were 
cultured with autologous CD4+ T cells. The amount of type I IFN in cell-free 
supernatants from DC-T cell co-cultures (A), DCs alone (B) or T cells alone (C) 
was determined by IFN bioassay. The data shown is from day 4 post infection 
from 4 donors (E-F) The corresponding cell-free supernatants were also added to 
TZM-bl cells for measurement of infectious virus production. Relative Light Units 
(RLU) correspond to amounts of virus produced from DC-T co-cultures (D) DCs 
(E) and T cells (F) infected with either HIV-1 Bru-YU2 or HIV-2 CDC77618 at an 
MOI=0.1. Data is from one donor 4 days post infection.   
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Figure 16. Interferon Restriction of HIV-2 Infection of T cells and DCs. (A-D) 
Either immature DCs (A and B) or CD4+ T cells (C and D) were infected with 
VSV-G pseudotyped luciferase expressing HIV-1 (BruΔenv-luc) or HIV-2 
(ROD9Δenv-luc) viruses. Cells were infected at an MOI=0.5 for 2 hours, washed, 
and cultured for three days before lysing and measuring luciferase activity in the 
cell lysates. Data is shown is duplicate infections from one donor and is reported 
as relative infection (non-treated is set at 1). (E-H) Either immature DCs (E and 
F) or CD4+ T cells (G and H) were infected with replication competent HIV-1 
(Bru-YU2) or HIV-2 (CDC77618) at an MOI=0.1 for 2 hours, washed, and 
cultured for three days. Cell-free supernatants were harvested and added to 
TZM-bl reporter cells for two days. Data is shown is duplicate infections from one 
donor and is reported as relative infection (non-treated is set at 1)  
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CHAPTER THREE: Design and Validation of GM3-incorporating Membrane 
Encapsulated Nanoparticles to Target CD169+ Myeloid Cells In Vivo 
 
Introduction 
Recent advancements in nanotechnology suggest that nanoparticles (NPs) will 
be critical for the next generation of drug delivery. Nanoparticle technology fulfills 
the increasing requirement to target specific cells or distinct cellular organelles in 
specific cell types leading to a decrease in off-target effects of toxic therapeutics. 
Typically smaller than 100 nm, NPs can be modulated to emulate viruses or virus 
like particles (VLPs). Other drug delivery systems have been modeled after 
viruses: VLPs (257, 271), liposomes (51, 194, 258), and systems that combine 
biomolecules with nanoparticles (10, 175, 237, 266). However, none of the 
systems tested thus far have been able to mimic the size, composition or 
mechanism of target cell interactions of HIV-1 such as those mediated by GM3 in 
the HIV-1 virion. Incorporation of GM3 in HIV-1 particles is critical for capture by 
myeloid cells and transfer to T cells (125, 211). We hypothesize that inclusion of 
GM3 in NPs will allow efficient and specific targeting of NPs to CD169+ myeloid 
cells. 
 
We have observed immune activation and limited viral spread in HIV-2 infected 
dendritic cells when co-cultured with CD4+ T cells (Chapter 2). We hypothesize 
that this myeloid cell-intrinsic innate immune sensing is one aspect of viral control 
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seen in the majority of HIV-2 infected population. We propose targeting CD169+ 
cells in secondary lymph nodes using GM3 coated nanoparticles to trigger a 
innate immune activation in CD169+ myeloid cells as a novel strategy to 
suppress HIV-1 replication. The relevance of CD169 capture and trans infection 
has been supported by multiple studies that investigated the level of CD169 on 
circulating monocytes in HIV-1 infected patients (218, 265). Individuals with high 
viral loads and those that had progressed to AIDS had increased expression of 
CD169 on their circulating monocytes compared to patients with undetectable 
viral load (218, 265). The authors point to up-regulation of CD169 on monocytes 
due to early induction of type I IFN responses and suggest the possibility that 
CD169+ monocytes are enhancing systemic dissemination of virus (218). 
Additionally, a recent study demonstrated that TGFβ, the most abundant cytokine 
found in semen, increased expression of CD169 on DCs resulting in increased 
virus capture suggesting an in vivo role in sexual transmission (62). Furthermore, 
CD169 expression in lymphatic tissues is conserved across species, and has 
been shown to be prevalent in secondary lymphoid organs, tissue sites that are 
integral to HIV-1 dissemination (107). Therefore, it will be important to investigate 
the consequences of blocking CD169 in HIV-1 dissemination.	  Our collaborators 
have shown that they can mimic HIV-1/cell interactions by constructing 
membrane-encapsulated NPs containing GM3 as the targeting ligand 
incorporated within the membrane layer (which are termed, artificial virus 
nanoparticles, or AVNs) to mimic the HIV-1 virion but with a metal (Gold, Au) NP 
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core (277). Thus, delivering a specific signal to critical sentinel cells, we 
hypothesize will trigger an antiviral state without inducing widespread non-
specific immune activation.   
 
The first step to rationally designing this therapeutic is to construct nanoparticles 
that mimic virus interactions with CD169+ cells. Figure 17 diagrams the 
composition of a virus compared to the engineered AVN produced by our 
collaborators. The obvious internal differences are the protein capsid (CA) core 
containing viral RNA in the virus particle versus the Au NP core. The AVNs 
contain a self-assembled lipid membrane that contain 51% 
dipalmitoylphosphatidylcholine (DPPC), 45% Cholesterol, 0.1% TopFluor 
cholesterol (lipid dye), 1% Phosphatidylserine (PS), and 3% GM3, while the virus 
membrane typically contains 8.8% phosphatidylcholine (PC), 18.4% 
sphingomyelin (SM) and dihydrosphingomyelin (DHSM), 19.2% 
phosphatidylethanolamine (PE) and plamaenylethanolamine (pI-PE), 45.1% 
Cholesterol, 8.4% PS, and approximately 1.6% GM3 (277). In contrast to 
liposomes containing GM3, the engineered AVNs have similar spatial and 
temporal interactions with cells as HIV-1 due to the gold (au) core supplying a 
mechanical stiffness to the AVNs (142, 191). Importantly, the gold core provides 
a high contrast for many types of imaging: optical, electron and x-ray (185, 274). 
Gold particles have a large scattering efficiency, which enables single particle 
detection via dark field microscopy (235, 274). Therefore, Au NPs are the ideal 
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core for AVNs due to their stability, distinct surface properties, and ease of 
imaging.  
 
Our lab and others have highlighted the importance of the trans infection 
pathway via GM3/CD169 (125, 211). The receptor/ligand interaction between 
CD169 and GM3 has been exploited by HIV-1 to spread efficiently to CD4+ T 
cells from DCs via virological synapses.  However, if AVNs can exploit this same 
pathway and traffic to the synapse formed between DCs and T cells, then 
therapeutics can be delivered to T cells or T cells can be primed or activated by 
the components of the NP. In addition to conventional DCs, subcapsular and 
medullary zone macrophages express CD169. These two subsets of 
macrophages are found in lymph nodes and directly interact with flowing lymph 
(Figure 18) (143). Although they express overlapping receptors the two subsets 
differ phenotypically. Subcapsular macrophages (SCS) are less endocytic than 
medullary macrophages and have the ability to retain captured virus on the 
surface for hours (135, 202, 220, 260). Meanwhile, medullary macrophages are 
known to phagocytose antigens and rapidly clear them. Importantly, antigens 
larger than 4nm exiting the lymph are caught in the subcapsular macrophages. 
Studies have shown that subcapsular macrophages and medullary macrophages 
capture virus just minutes after peripheral inoculation (143). Both macrophage 
subsets have been shown to be critical in cell recruitment to the lymph nodes and 
modulating the immune systems.  For instance, in response to apoptotic cells 
	  122 
marginal zone or medullary macrophages induce chemokine CCL2, resulting in 
recruitment of Foxp3+ Tregs and CD11c+ DCs and a tolerogenic immune 
response (216). Thus, this CD169+ population of macrophages is essential in 
modulating the early innate immune response. We hypothesize particles 
expressing GM3 (AVNs) can be targeted to all of these myeloid cell populations.  
 
Adjuvants are critical components for vaccine design. The purpose of vaccination 
is to elicit a specific immune response mounted against the presented antigen to  
impart long term protection against infection (201). Adjuvants enable non-
immunogenic substances to become immunogenic, can enhance immunogenicity 
of poorly immunogenic antigens, and ultimately can boost the quantity and 
potentially the quality of the response.  The majority of vaccines currently used or 
in development contains an adjuvant. For example, attenuated viruses or 
bacterial antigens are used as adjuvants to enhance the immune response to 
other components of the vaccine. Currently there are many different adjuvants 
such as MF59, AS03, and AF03, which are oil in water emulsions, aluminum 
salts, virosomes and AS04 (monophosphoryl lipid A preparation (MPL) with 
aluminum salt (217).  
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Figure 17. Design of AVNs. (a) Scheme of HIV-1 structure. HIV-1 is composed 
of a host-derived lipid bilayer membrane wrapped around a protein MA core that 
contains the viral RNA. The viral membrane contains additional lipids, including 
GM3, albeit with significantly lower concentration. Another membrane component 
is the virus-encoded glycoprotein gp120. (b) Scheme of minimalistic artificial 
model systems, AVN1 (left) and AVN2 (right). Both AVNs are assembled from 80 
nm Au NP cores and comprise a self-assembled lipid membrane. AVN1 contains 
a lipid bilayer, whereas AVN2 contains a lipid monolayer anchored in a self-
assembled octadecanethiol layer. The thiol covalently attaches to the NP 
surface. (277) *Credit Dr. Xinwei Yu 
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Figure 18. Schematic Diagram Showing Lymph Node Sinus-Resident 
Macrophage Populations Along with the Surface Markers they Express. 
Subcapsular sinus (SCS) macrophages are either completely contained within 
the SCS or they reside in B cell follicles but extend cellular protrusions into the 
SCS lumen. Medullary macrophages lie within medullary sinuses (143). 
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Table 2 summarizes the current adjuvants in development, their class, 
mechanism of action, receptor targeted and the immune response they trigger 
(217). Adjuvants must align to certain criteria including stability, with a long shelf 
life, and most importantly not induce an immune response against themselves 
(201). Many new vaccine strategies are including toll like receptor (TLR) agonists 
in an attempt to trigger specific T cell responses. TLRs are a family of pattern 
recognition receptors (PRRs) that are triggered by pathogen associated 
molecular patterns (PAMPs). These ligands occur naturally in pathogens, and in 
addition to synthetic compounds, are being used experimentally as adjuvants. 
For instance, single stranded viral RNA is recognized by TLR7 or TLR8, double 
stranded viral RNA is recognized by TLR3, and CpG rich DNA found both in 
bacteria and viruses triggers TLR9, triacyl lipopeptides and bacterial soluble 
factors are recognized by TLR1 and TLR2, TLR4 recognizes lipopolysaccharide 
(LPS), and TLR5 is triggered by bacterial flagellin. (5). In addition to TLRs, nod 
like receptors (NLRs) recognize core structures of bacterial peptidoglycan (5). 
Importantly, downstream signaling after TLR activation leads to distinct gene 
expression and activation of innate immunity, which can lead to antigen-specific 
adaptive immunity (5). Determining the ideal blend of adjuvant and vaccine 
component depends on many factors including target vaccine demographic, 
route of administration, and especially the type of immune response sought after. 
Many issues with vaccines involve specificity and being universally effective for a 
broad population. One main benefit of adjuvants is they may allow for a lower 
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dose of the vaccine to be administered to create the same level of immune 
response (217). The supply of vaccines for a global response to an epidemic 
such as influenza and adding adjuvants to an effective dose may allow for a 
vaccine supply to be available to more people. Figure 19 is a summary of the 
benefits of adjuvants in vaccine delivery.  
 
By combining the GM3/CD169 targeting mechanism and inclusion of immuno-
modulatory agents in the nanoparticle design, we seek to establish an immune 
activated state similar to the myeloid cell-dependent innate immune activation 
seen in HIV-2 infected DCs. We hypothesize that NP therapeutics such as AVNs 
can exploit the evolutionarily optimized design of HIV-1 particles by avoiding 
degradation and targeting cells expressing CD169 to prime the immune system 
to limit virus pathogenesis. 
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Table 3. Classes of Clinically Used and Tested Adjuvants. This table lists the 
adjuvant name, class, mechanism, resulting immune response and the current stage 
of development.(217) 
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Figure 19. Diagram of Possible Advantages to New Adjuvants.  By 
innovating the different combinations of vaccine components and adjuvants 
many issues with vaccines could be solved. (217) 
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Results 
3.1 CD169 Specifically Binds α-2,3 sialylated GSLs and is Highly Conserved 
Across Species 
Siglec1 or CD169 is highly conserved in mammalian species, particularly in the N 
terminal extracellular domain (57). Interestingly, the sequence of the region 
necessary for sialic acid recognition, the N-terminal V-set Ig-like domain, is highly 
conserved between human and mouse CD169 proteins (106). GM3, which is 
highly enriched in lipid rafts of he plasma membrane, is also incorporated into 
another retrovirus, murine leukemia virus (MLV) (47). Additionally, studies have 
shown that ecotropic-MLV particles can compete with HIV-1 particles for capture 
by mature DCs (126). We investigated whether GM3-dependent binding of HIV-1 
particles is also observed with murine CD169, especially since future in vivo 
animal studies would determine if GM3-encapsulated NPs could target murine 
CD169+ myeloid cells in vivo.  
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Figure 20. Retroviral Capture and Transfer Function is Conserved Between 
Human and Murine CD169. A. Expression of murine CD169 on HEK293T cells 
determined by FACS. Capture of untreated (NT) or GSL-depleted HIV Gag-eGFP 
VLPs (B) or MLV Gag-YFP VLPs (C) by mock transfected or murine CD169 
expressing HEK293T cells was determined by FACS. D. Capture of untreated 
(NT), or GSL-depleted (PDMP) MLV Gag-YFP VLPs, or capture of MLV Gag-
YFP VLPs, in the presence of a-CD169 nAb by mDCs was determined by FACS. 
E. HEK293T/murine CD169 mediated trans infection of Lai-Balenv/luc+ to CD4+ T 
cells (E), or transfer of MLV-E/luc to Rat-2 cells (F) was determined by 
measuring luciferase activity in HEK293T/CD4+ T cell and HEK293T/Rat-2 co-
cultures, respectively, 2 days post-infection. G. Transfer of MLV-E/luc by mDCs 
in the presence or absence of a-CD169 nAb was determined by measuring 
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luciferase activity in mDC/Rat-2 cell co-cultures 2 days post-infection. The data 
shown is from one experiment, performed in triplicate (mean ± SD), and is 
representative of 2 independent experiments. 
doi:10.1371/journal.ppat.1003291.g008 
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We transiently expressed murine CD169 in HEK293T cells and demonstrated 
high cell surface expression of murine CD169 (Figure 20A) and capture of both 
HIV Gag-eGFP (Figure 20B) and MLV Gag-YFP VLP capture (Figure 20C) by 
murine CD169-expressing HEK293T cells. To investigate if GSLs are also 
required for MLV capture by murine CD169 we produced GSL-depleted MLV 
Gag-YFP VLPs from PDMP-treated HEK293T cells. Depletion of GSLs from both 
HIV and MLV VLPs decreased capture by murine CD169 suggesting that GSLs 
are also critical for capture of retroviral VLPs by murine CD169 (Figure 20B and 
C). Therefore, both human and murine CD169 capture retroviral VLPs in a GSL 
dependent manner (Figure 20D).  
 
Next we tested the subsequent transfer of HIV-1 by both human and murine 
CD169 to CD4+ T cells and MLV particles to murine cells. HEK293T cells 
transiently expressing either human or murine CD169 were challenged with 
single cycle of replication competent luciferase expressing HIV-1/Lai-Bal or 
ecotropic-MLV (MLV-E) particles, washed and then co-cultured with human CD4+ 
T cells or MLV-E susceptible Rat-2 cells. We found robust transfer of HIV-1 
particles to CD4+ T cells (Figure 20E) and transfer of ecotropic MLV particles to 
Rat-2 cells (Figure 20F) by murine CD169. Finally, mDCs also transferred MLV-E 
particles to Rat-2 cells and this transfer mechanism was dramatically decreased 
if capture of MLV-E particles by mDCs was carried out in the presence of anti 
CD169 blocking antibody prior to initiation of co-cultures (Figure 20G).  
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Figure 21. Murine DCs Transfer HIV-1 More Efficiently than HIV-2 to Human 
CD4+ T Cells. A. Representative FACS histogram of CD169 expression on 
immature and mature (stimulated with 1000U/ml IFNα for 48hr) murine bone-
marrow derived DCs (BMDCs). B. Capture of HIV-1 by murine BMDCs is 
enhanced upon maturation. Quantification of HIV-1 capture by BMDCs by p24gag 
ELISA. Immature or mature (105) BMDCs were challenged with 20ng p24gag 
equivalent of HIV-1 isolate (BruΔenv/Bal-single cycle of replication competent 
virus pseudotyped with CCR5-tropic Bal Env) in triplicate for 2 hrs at 37°C, 
washed and lysed for ELISA The data reported is the mean  ± SEM of cell-
associated p24gag (ng/ml) C. Murine BMDCs efficiently transfer virus to human 
CD4+ T cells. Mature (105) murine BMDCs were challenged at an MOI=0.1 with 
replication competent HIV-1 (BruYU2) or HIV-2 (CDC77618) virus isolates for 2 
hs at 37°C, washed and co-cultured with human CD4+ T cells. Supernatants 
were collected 2 days post infection and added to TZM-bl cells for luciferase 
readout (RLU) as a quantitative measure of infectious virus production from 
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murine BMDC-CD4+ T cell co-cultures. The data reported is from one donor in 
triplicate. 
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We next sought to confirm if CD169 on primary murine myeloid cells (as opposed 
to exogenous over-expression in human cell lines) can capture HIV-1 particles 
and mediate HIV-1 trans infection.  We used murine bone marrow-derived DCs 
(BMDCs) from C57BL/6 mice. We tested if CD169 was upregulated upon 
maturation by stimulating cells with 1000u/ml IFNα for 48hr (Figure 21A).  
Maturation of murine BMDCs with IFNα induced increased expression of CD169 
and increased the capture of HIV-1 (Figure 21B). Interestingly, mature murine 
BMDCs were able to efficiently transfer HIV-1 to co-cultured human CD4+ T cells 
in agreement with previous results (41). However, consistent with our findings 
with mature human DCs, trans infection of GM3-deficient HIV-2 (CDC77618) 
particles by murine BMDCs to human CD4+ T cells was significantly lower than 
that observed with HIV-1 (Bru-YU2) (Figure 21C). These results suggest that 
capture of HIV-1 particles by murine CD169 was also dependent on presence of 
GM3 in the virus particle membrane. Importantly, this conservation of function 
across species of CD169 function will be useful for testing feasibility of GM3-NPs 
to specifically target CD169+ myeloid cells in mice.  
 
3.2 Nanoparticle Designed to Imitate Virus Composition and Trafficking 
As mentioned earlier, virological synapses are critical in trafficking virions from 
DCs to target CD4+ T cells (133, 134, 203). In order to reduce the likelihood of 
non-specific phagocytosis or macropinocytosis by DCs or macrophages, NPs 
need the critical ligand, GM3, to interact with CD169 on the cell surface. Once 
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the NP is captured by CD169 expressing cell, we hypothesize that it should traffic 
to a non-lysosomal compartment similar to captured HIV-1 particles (Figure 22).  
 
First we wanted to test whether the GM3 containing NPs (AVNs) mimic virus 
interaction with CD169 on the surface of mature DCs. We challenged mature 
DCs with GM3-NPs (structure described in Figure 17). Mature DCs were 
challenged with GM3-NPs, GalCer-NPs or blank controls at three different 
NP/mDC ratios (1x107/3x105; 1x108/3x105; 1x109/3x105) for 5min at 37°C before 
the number of gold (Au) NPs (mean ± S.D.) bound per mDC was determined by 
ICP-MS (Figure 22A). The nanoparticles also contain a fluorescent dye 
associated with the cholesterol in the lipid layer and therefore we can measure 
capture of NPs by cells via flow cytometry. Mature DCs were challenged with 
fluorescently labeled GM3-NPs, GalCer-NPs or blank controls at three different 
NP/mDC ratios (1x107/3x105; 3x107/3x105; 1x108/3x105) for 15 or 30 min at 37°C 
before the relative mean fluorescence intensities (MFI) of cells were determined 
by flow cytometry (Figure 22B). Mature DCs captured nanoparticles expressing 
GM3 preferentially over those containing GalCer or blank control particles (Figure 
22A and B). Furthermore, we observed a dose-dependent increase in the 
capture of GM3 NPs (Figure 22A and B).  
 
Next we wanted to know whether the AVNs mimic the trafficking of captured 
virus. Using fluorescent microscopy we observed captured AVNs co-localize with 
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CD169 and CD81 but not lysotracker suggesting that AVNs were localized within 
non-lysosomal compartments, a finding that duplicates the localization of 
captured HIV-1 particles in mature DCs (211, 277) (Figure 22C). Additionally, our 
collaborators were able to image a cluster of AVNs near the surface of a mature 
DC using SEM (Figure 22D). The composition of the enlarged field via Energy 
Dispersive X-ray analysis (EDAX) (inset, left right corner) confirms that the 
imaged NPs are gold NPs. Therefore, GM3 containing AVNs are specifically 
captured by mature DCs and trafficked to peripheral non-lysosomal 
compartments similar to captured HIV-1 particles.   
 
Ultimately, we sought to determine whether captured GM3 NPs migrate to the 
synapse between mature DCs and autologous T cells. Mature DCs were 
pretreated with GM3-NPs for 1.5 hours to ensure AVN cluster formation before 
autologous pre-stained (cell tracker orange) CD4+ T cells were added (1:1 
mDC/T cell ratio). We used dark field microscopy and confocal microscopy to 
determine if GM3 NPs are present at the synapse between mature DCs and T 
cells.  T cells were loaded with cell tracker orange dye (pseudo-colored as cyan 
in Figure 23) and co-cultures were additionally stained with CD81, CD169, and 
phalloidin (colored green) and found to co-localize with the red GM3 NPs 
resulting in yellow (Figure 23A, B, and C). The ability of the GM3 AVNs to traffic 
to  
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Figure 22. GM3-AVNs Recapitulate GM3-CD169 Mediated HIV-1 
Sequestration into Peripheral Non-Lysosomal Compartments in mDCs. a. 
Mature DCs were challenged with GM3-AVNs, GalCer-AVNs or blank controls at 
three different AVN/mDC ratios (1x107/3x105; 1x108/3x105; 1x109/3x105) for 5min 
at 37°C before the number of gold (Au) NPs (mean ± S.D.) bound per mDC was 
determined by ICP-MS. Data were collected in two independent experiments 
(two donors) for each dosage. The design of the AVNs is included in the inset. b. 
Mature DCs were challenged with fluorescently labeled GM3-AVNs, GalCer-
AVNs or blank controls at three different AVN/mDC ratios (1x107/3x105; 
3x107/3x105; 1x108/3x105) for 15 or 30 min at 37°C before the relative 
fluorescence intensities were determined by flow cytometry. Data for each 
dosage represent means of duplicate measurements from one donor. c. Staining 
of lysosomes (lysotracker; top panel), CD81 (middle panel), and CD169 (bottom 
panel) in GM3-AVNs containing mDCs. The AVN/mDC ratio was 1x108/3x105 
and the incubation time was 1h. Scale bars = 1µm. d. SEM of an mDC section 
shows a peripheral AVN cluster located close to the cell surface. The Energy 
Dispersive X-ray analysis (EDAX) (inset, left right corner) shows the elementary 
composition of the enlarged field, which confirms that the imaged NPs are gold 
NPs. (278) 
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Figure 23. Characterization of Oriented mDC-T cell Conjugates Through 
Correlated Darkfield / Fluorescence Imaging. The cells were stained for 
CD169 (a), CD81 (b) and F-actin (c). The left row shows the darkfield color 
image, the middle row the monochromatic fluorescence image, and the right row 
shows a false-color overlay. Colocalization is indicated in yellow (AVN = green, 
fluorescence marker = red). T cells were stained with CellTracker Orange and 
are plotted in cyan pseudo color. Nuclei were stained with DAPI fluorescence 
stain and are marked blue. Scale bars = 1µm. *credit Xinwei 
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the synapse between DCs and T cells points to their potential use in targeted 
therapeutics. 
 
3.3 Nanoparticles Carrying Adjuvant Specifically Stimulate Dendritic Cells 
Having shown that we can target GM3 coated nanoparticles to CD169+ cells 
(Figure 22); the next question we asked was whether the nanoparticles can 
specifically stimulate myeloid cells. Our first proof of concept test was challenging 
immature human monocyte derived DCs with nanoparticles containing an 
adjuvant. Our overall goal is to develop nanoparticles incorporating an adjuvant 
that would specifically target CD169+ cells in lymph nodes. Alternatively, 
CD169+cells present in the periphery would capture AVNs and then migrate to 
lymph nodes to activate a specific immune response. We are testing this 
hypothesis in collaboration with the Reinhard and Wetzler laboratories. The 
composition of particles and process of making them is described in Figure 24.  
The AVNs have an outer single layer of membrane with a gold particle core. 
Neutravidin was added in excess, washed, and biotinylated Pam3CSK4, a 
synthetic TLR2 ligand, was added. Negative controls included plain NPs that 
contain just the lipid layer surrounding a gold core.   
 
We challenged immature human DCs with varying concentrations of soluble 
Pam3CSK4, plain particles (lipid layer + gold core), NPs loaded with biotinylated 
Pam3CSK4, or plain NPs co-administered with soluble Pam3CSK4 (Figure 25). 
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DCs were incubated with increasing concentrations of NPs (106, 107, 108, and 
109) for twenty-four hours at 37°C, washed thoroughly, stained for activation 
marker CD86 surface expression and fixed. Using flow cytometry we measured 
MFI of activation marker CD86 and demonstrated that NPs + Pam3CSK4 induce 
expression of CD86 in immature DCs above that observed upon challenge with 
plain particles. More importantly, the level of activation observed with 109 NPs + 
Pam3CSK4 which contain less than 1ng/ml of adjuvant (Pam3CSK4) is similar to 
that observed in DCs incubated with 100ng/ml soluble Pam3CSK4. Therefore 
delivery of adjuvant using NPs might allow use of a lower dose of adjuvant with 
similar activation profile, which we speculate will assist in limiting off-target 
effects of adjuvants. 
 
3.4 NPs with PAM3csk4 Specifically Trigger Cytokine Stimulation in CD169+ 
Cells 
In addition to DCs, multiple macrophage subsets are known to express CD169. 
To begin to understand the in vivo viability of the NPs and their ability to traffic to 
target cells in secondary lymphoid tissues, murine myeloid cells were also 
incubated with nanoparticles. In collaboration with the Wetzler lab, nanoparticles 
were incubated with murine bone marrow derived macrophages (BMDMs) and 
tested for activation and pro-inflammatory cytokine release at 24 hours post 
challenge (Figure 26). BMDMs are a model for tissue resident macrophages and 
are one step closer to looking at the potential for AVN use in vivo. As previously 
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described, CD169+ macrophages are present in the marginal zone and 
subcapsular region of lymph nodes, and may play an important role, in the 
initiation of adaptive immune response in the secondary lymphoid tissues 
because of the many contacts established with T and B cells in the parafollicular 
region and the germinal center (143).  
 
In collaboration with Dr. Michael Reiser of the Wetzler lab we measured a myriad 
of activation markers on murine BMDMs.  Murine BMDMs stimulated with 
nanoparticles loaded with Pam3CSK4 triggered up-regulation of macrophage 
activation markers: CD40, CD54 and CD69 (data not shown). Additionally, we 
observed that nanoparticles loaded with Pam3CSK4 triggered significant TNF-α 
cytokine release similar to other known soluble TLR ligands: LPS, soluble 
Pam3CSK4 (Pam 3) and Por B (Figure 26).  
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Figure 24. Formulation of Nanoparticles with Pam3CSK4. Liposomes are 
loaded with a 40nm gold core and then neutravidin is added to the surface in 
excess (Molar Ratio to the particles: 105NTV/particle). Preparation was washed 
thoroughly followed by addition of biotinylated Pam3CSK4 in excess and a final 
wash resulting in 5:1 stoichiometric amount of (5 molecules of Pam3CSK4 per 
NP) Pam3CSK4 on the surface of NPs.   
*credit Fangda Wu 
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Figure 25. Immature Human DCs are Activated by Nanoparticles Containing 
Pam3CSK4. Peripheral blood monocyte derived DCs, non-treated (NT), 
stimulated with increasing concentrations of soluble Pam3CSK4  (1ng/ml, 10ng/ml 
and 100ng/ml; black bars with increasing concentrations), stimulated with 
increasing amounts (106, 107, 108, 109) of plain nanoparticles (blue bars), 
Pam3CSK4-bearing nanoparticles (red bars) or plain particles with soluble 
Pam3CSK4 added to the culture media (purple bars) were harvested 24 h post 
challenge. Expression of activation antigen, CD86, was assayed via flow 
cytometry. The data reported is the mean fluorescence intensity (MFI) of CD86 
expression on DCs and is from one representative experiment (out of two 
separate experiments), with cells from two independent donors. 
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Conclusion 
GM3 coated nanoparticles are a promising direction for rational design of drug 
delivery. We have demonstrated that critical elements for capture of HIV-1 via 
CD169 is conserved across species and that nanoparticles can be constructed to 
mimic the interaction of HIV-1 virions with human and murine CD169+ cells.  
Additionally, we have observed GM3-NPs traffic to non-lysosomal CD81+ 
CD169+ compartments and eventually the synapse between DCs and autologous 
CD4+ T cells. These results indicate that drug delivery systems can hijack the 
trans infection pathway to tune an immune response. 
 
Preliminary results demonstrate that GM3 coated AVNs have the ability to 
stimulate both human monocyte derived DCs and murine bone marrow derived 
macrophages. Therefore, use of these nanoparticles in targeted therapeutics has 
the potential to specifically target CD169+ cells in vivo and trigger a desired 
immune response. There will be many benefits of this type of therapeutic. Not 
only will it be specific to the CD169+ cells, but also it can be combined with 
adjuvants in priming the immune response. This combination might require a 
much lower dose than a broadly administered therapeutic.  Therefore, we 
speculate that this strategy should have much fewer off-target effects and lower 
toxicity. 
 
	  147 
Future Directions 
The next steps of this project will be to test the trafficking of nanoparticles in 
small animal models. Specifically, it will be important to determine how 
nanoparticles function when injected into the footpad of wild-type mice versus 
CD169 KO mice. The goal will be to observe migration and retention of the 
nanoparticles to secondary lymph nodes and specific association with CD169+ 
myeloid cells in the tissues. Subsequently, the dose of the nanoparticles will have 
to be thoroughly tested with pharmacokinetic studies to measure the threshold 
necessary for a robust response without inducing toxicity. Additionally, to test the 
efficacy of this model for inducing an antiviral response, adjuvant loaded GM3-
nanoparticles should be tested in the rhesus macaque model of HIV. Preliminary 
studies with collaborators have already shown that SIV co-localizes with CD169+ 
cells in rhesus lymph nodes. Therefore, utilizing this virus host interaction for 
directed therapeutics has promise. 
 
	  148 
  
Figure 26. Nanoparticles Activate Murine BMDMs and Trigger TNFα 
Release. Murine bone marrow derived macrophages (BMDMs) were incubated 
with increasing doses of blank particles (NP), nanoparticles with Pam3CSK4 in 
the media (NP+P3), nanoparticles containing Pam3CSK4 (P3-NP), or soluble 
TLR ligands (LPS, Pam3CSK4 or PorB). Supernatants were taken at 24 hours 
and measured for cytokine release using a TNFα ELISA pg/ml. *credit Dr. 
Michael Reiser 
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Concluding Remarks 
Summary of Results 
We have investigated the differences in how HIV-1 and HIV-2 interact with 
dendritic cells to further understand the differences in pathogenesis seen in 
infected individuals. The field’s current understanding of the closely related virus, 
HIV-2, is limited. It was first believed that HIV-2 was an attenuated version of 
HIV-1 due to the large percentage of HIV-2 infected individuals AIDS free five 
years post seroconversion (100% compared to 67% for HIV-1) (128). However, 
cohort studies have demonstrated that when HIV-1 and HIV-2 infected 
individuals are matched based on baseline viral loads, there is similar rates in 
CD4 decline between HIV-1 and HIV-2 (128).  However, in contrast to HIV-1 
long-term non-progressors (LTNP), a classification of individuals that have 
controlled viral loads and maintained high CD4 counts 10 years post 
seroconversion without treatment, which have detectable viremia (24) 
asymptomatic HIV-2 individuals maintain undetectable plasma viremia (13, 25). 
Interestingly baseline viremia has been shown to be a good predictor of disease 
progression (13, 26, 104). Since the initial interaction between virus and the 
immune system may determine the disease course, we investigated whether 
differential interactions of HIV-1 and HIV-2 with sentinel dendritic cells may play a 
role in the divergent disease courses of HIV-1 and HIV-2. 
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If there is a race between the virus and immune system, I propose that HIV-2 is 
at a disadvantage compared to HIV-1 due to many factors. There are a few 
explanations for the immune system having an advantage against HIV-2 
compared to HIV-1. One is a difference in virus dissemination efficiency. We 
investigated an aspect of this by testing if HIV-2 can access the CD169-mediated 
trans infection pathway, which we postulate is critical for HIV-1 dissemination 
(138). As demonstrated in Chapter 1, HIV-2 is captured inefficiently by the 
mature DC attachment factor, CD169, and subsequently has attenuated access 
to trans infection of CD4+ T cells (Figure 27A and B right panels). HIV buds from 
lipid rafts of producer cells incorporating host lipids in its membrane. Previous 
studies in our lab and others have demonstrated GM3 is the critical ligand for 
capture and trans infection by CD169 (124, 213). Studies have demonstrated 
conserved differences in MA between HIV-1 and HIV-2, which affect Gag stability 
at the plasma membrane during assembly and budding (227). The authors 
proposed the instability of Gag interaction with the plasma membrane affects the 
kinetics of virus particle budding though it still remains unclear why HIV-1 would 
have evolved a more stable interaction (227). Additionally, I propose that the 
differential interaction of HIV-2 Gag with the plasma membrane in the virus 
producer cell affects the site of virus particle assembly and the level of GM3 
incorporation.  
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The N-terminus side chain in helix 1 of HIV-2 MA contains a conserved Lysine at 
position 12, meanwhile in HIV-1 it is substituted for a conserved Glutamate, 
which creates a stable salt bridge structure (227). One possibility is that HIV-1 
may have evolved a more stable interaction with the plasma membrane to exploit 
cell-to-cell adhesion (CD169-GM3) pathway to disseminate. Future studies are 
needed to test whether mutating this conserved amino acid in HIV-2 MA (Glu ! 
Lys) will enhance the kinetics of virus assembly and alter the location of HIV-2 
assembly such that HIV-2 particles incorporate similar levels of GM3 to that 
observed with HIV-1.  Therefore, my studies suggest that access to CD169-
mediated virus dissemination is deficient in HIV-2 and this might account for the 
observed differences in viral pathogenesis.  
 
Another explanation for the equilibrium between virus and immune system to 
favor the immune system is that there is both earlier and a stronger innate 
immune sensing and/or a more effective adaptive immune response against HIV-
2. One way that HIV-1 may evade immune detection in mature DCs by trafficking 
to a CD169 induced pocket (7) whereas HIV-2 has attenuated interaction with 
CD169 and may be present for antigen presentation to effector cells. Additionally, 
many studies have demonstrated a more robust HIV-2 specific cytotoxic T cell 
responses (reviewed in (225), while others have shown that when matched for 
disease stage there are no differences in CTL response between HIV-1 and HIV-
2 infected individuals (92, 132, 281). Additionally, when comparing matched HIV-
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1 and HIV-2 infected individuals demonstrating CD4+ T cell responses, the HIV-2 
specific responses are not only more polyfunctional releasing MIP-1β and TNFα 
in addition to IFNγ, but also are more robust producing 15-20 times more 
cytokines on a per cell basis (71). Studies have shown that a greater percentage 
of HIV-2 infected individuals generate neutralizing antibodies that can neutralize 
the predominant virus found in the patient’s serum (31) and the authors propose 
this contributes to viral control. Our recently published studies suggest that 
CD169 is not a phagocytic receptor, and HIV-1 particles captured by CD169 are 
retained at the cell surface in plasma membrane invaginations (7).  Whether lack 
of interaction with CD169 results in enhanced phagocytosis and exposure of HIV-
2 antigens to antigen presentation pathways remains to be determined. We 
hypothesize that diminished interactions of HIV-2 with CD169 on dendritic cells 
might provide a mechanistic explanation for the robust polyfunctional adaptive 
immune responses observed in HIV-2 infected individuals.   
 
Interestingly, the immune activation observed in HIV-1 infected individuals during 
chronic infection is also seen in chronic infection with HIV-2 when stratified by 
viral load (153). This immune activation is also seen in LTNPs, however not in 
HIV-2 infected non-progressors who tend to maintain their viral load below 
detection (153). The ability to control virus replication at a low enough level 
without triggering pro-inflammatory responses suggests that immune control 
might be more effective against HIV-2.  
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We investigated differences in cis infection of immature DCs and potential 
differences in subsequent innate immune sensing in Chapter 2. This may be a 
critical difference affecting the disease course between HIV-1 and HIV-2. 
Infection of DCs by HIV-1 is limited by restriction factor SAMHD1 (Model A left 
panel) resulting in low levels of virus production. In the model in Figure 27A (left 
panel), HIV-1 cis infection is postulated to be attenuated due to SAMHD1 
restriction and therefore any viral nucleic acid sensors will be exposed to limited 
amounts of viral RNA or DNA. In contrast, we observed more productive infection 
of DCs by HIV-2 (depicted in Figure 27B left panel). Interestingly, at a high MOI 
of HIV-2 infection of immature DCs we detected increased ISG expression 
(Figure 13 and 14). Layahe et al. observed similar induction of ISGs ant type I 
IFN production in VSV-G pseudotyped HIV-2 infections of immature DCs and 
proposed that this viral sensing may be due to a cytosolic sensor (148). In 
contrast, we observed spread of HIV-2 infection in immature DC cultures but did 
not observe type I interferon production in productively infected immature DC 
cultures (Figure 27B left panel). Thus, even if there was any innate immune 
sensing of HIV-2 infection in DCs, it was insufficient to restrict virus replication. 
Others have demonstrated type I interferon production in immature DCs infected 
with HIV-1 in the presence of SIV Vpx (169, 250). However, I propose that there 
is an infection threshold necessary for the induction of type I interferon that is 
dependent on MOI and the amount of Vpx delivered upon infection. By infecting 
at high MOIs and delivering high levels of Vpx this innate immune sensing is 
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heightened compared to the low MOI I have used in DC infections with 
replication competent HIV-2. Future studies are necessary to assess if HIV-2 
infection of immature DCs at a high MOI results in robust sensing and type I 
interferon production. Importantly, some studies have proposed that similar to 
some SIV isolates such as SIVmac239, HIV-2 is more sensitive and less adapted to 
IFNα than HIV-1 (30). Therefore, this reinforces that the timing and effect of the 
immune response and control of virus is critical in the attenuated disease course 
observed in HIV-2 infected individuals.  
 
We have used immature DC-T cell co-cultures as a model of cell-cell interactions 
that may occur in the mucosa or secondary lymph nodes during HIV infection. It 
is compelling that we observe type I interferon production from HIV-2 infected 
DCs co-cultured with autologous T cells. We have demonstrated that this level of 
type I interferon can restrict infection of both DCs and T cells (Figure 16). Figure 
27D displays what may be occurring in DC-T co-cultures infected with HIV-2.  It 
is possible that the infection threshold is reached and DC-T conjugates allow for 
viral reverse transcripts to accumulate in the cytoplasm of DCs, triggering the 
cGAS/STING/interferon pathway resulting in type I interferon production and 
maturation of the DCs in the culture as well as restriction of viral spread.   
 
In contrast, studies have demonstrated that in HIV-1 infected DC-T co-cultures 
the presence of T cells at the immunological synapse with DCs alleviates the 
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SAMHD1 restriction allowing for infection of DCs (248). We observed a similar 
expansion of HIV-1 infection in DC – T cell co-cultures (Figure 27C). However, 
since HIV-2 Vpx can further induce degradation of SAMHD1, the presence of T 
cells at the immunological synapse and the resulting DC – T cell crosstalk may 
boost the level of HIV-2 infection in DCs. Signaling initiated from the DC - T cell 
immunological synapse may also alleviate additional reverse transcription 
restrictions such as p21, which has been shown to limit dNTP synthesis (8). 
Presence of enhanced levels of HIV-2 RT intermediates might lead to increased 
sensing by cGAS and production of type I IFNs. Another possibility is that the 
HIV-2 infected DC-T co-cultures trigger other cytokines such as MIP-1β, seen in 
the cohort studies that would block co-receptor CCR5 and restrict viral spread. 
Although HIV-2 is more promiscuous in co-receptor usage, the level of 
expression on DCs and the in vivo relevance is still unknown. Therefore, I have 
demonstrated that productive infection of DCs by HIV-2 and the subsequent 
sensing in cultures alone or in co-cultures may have a role in restricting viral 
spread in vivo. 
 
Finally, knowing that a lower baseline viral set point is associated with better 
disease prognosis (104) combined with our results described above, it is critical 
to design a therapeutic to target CD169+ cells and trigger a cell-intrinsic antiviral 
immune response. This therapeutic may have a broad role against other 
enveloped viruses or bacterial pathogens that express host lipid, GM3, such as 
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henipavirus or Campylobacter jejuni (6, 140). Through recapitulating attenuated 
trans infection by blocking CD169 and inducing immune sensing via adjuvant 
delivery, we can design an anti-HIV-1 therapeutic using the characteristics we 
have observed between DCs and HIV-2. In Chapter 3, we demonstrated that 
virus-like GM3-NPs (AVNs) can target CD169+ cells and that NPs loaded with 
adjuvant can trigger activation in CD169+ cells. Thus, I have established GM3-
NPs as a possible therapeutic to restrict HIV-1 initial dissemination. Future 
studies using animal models will be necessary to assess the in vivo combined 
effect of blocking CD169 and triggering immune activation in CD169+ cells.   
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Figure 27. Model of How HIV-1 and HIV-2 Interact with Dendritic Cells (A) 
HIV-1 Interaction with Immature DCs (Left panel) and Mature DCs (Right Panel). 
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HIV-1 has restricted infection of immature DCs due to restriction factors such as 
SAMHD1.  It also can be targeted to the lysosome via interaction with DC-SIGN. 
HIV-1 efficiently interacts with CD169 on Mature DCs, traffics to a CD81+ CD169+ 
pocket and is transferred to CD4+ T cells. (B) HIV-2 Interaction with Immature 
DCs (Left Panel) and Mature DCs (Right Panel). HIV-2 productively infects 
Immature DCS with viral protein Vpx targeting SAMHD1 for proteasomal 
degradation. I propose there is a level of immune sensing of viral transcripts that 
trigger ISGs. HIV-2 is less efficient in accessing the trans infection pathway via 
CD169 shown in Chapter 1. (C) HIV-1 interaction with DC-T Co-Cultures, the low 
level of infection of immature DCs spreads efficiently and robustly expands in 
DC-T co-cultures. (D) HIV-2 Interaction with DC-T Co-Cultures. There is a 
contact dependent interaction between DCs and T cells that enhances the 
immune sensing of HIV-2 in multiple rounds of infection triggering type I IFN and 
restriction of viral spread.  Legend depicts symbols used throughout model. 
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APPENDIX: Different Assays to Compare HIV-1 and HIV-2 
 
Effective ways to compare HIV-1 and HIV-2 Infection of Target Cells 
Throughout my project I explored many different assays to measure HIV-1 and 
HIV-2. These assays included, flow cytometry, viral DNA via qRTPCR, 
exogenous RT detection, capsid ELISA, and western blot. The goal was to detect 
both viruses with equal affinity in order to compare viral input and viral infection 
level in target cells.  
 
AG3.0 ELISA 
Assay Description: This is a modification of the p24 capsid ELISA described in 
the methods section.  Instead of using the p24 hybridoma as a primary antibody, 
cross-reactive capsid antibody AG3.0 (generous gift from Dr. Brigitte Sanders-
beer)  
Results: Detects both HIV-1 and HIV-2 (primary isolate CDC77618 and ROD10). 
However, it appears to have a lower affinity to HIV-2. I also observed this via 
western blot. 
Advantages and Disadvantages: If comparing within HIV-2, it is a fine 
assessment of capsid amount. However, not a good assay to measure the 
amount of virus to use for infections due to its lower detection of HIV-2 (would 
lead to using too much HIV-2). 
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AG3.0 FACS 
Assay Description: Using the above antibody for intracellular staining for infected 
cells. 
Results: There are definitive differences in MFI in using this antibody (less of a 
population shift of HIV-2 infected cells).  
Advantages and Disadvantages: If comparing within HIV-2, it is a fine 
assessment of capsid amount. However, not a good assay to measure the 
amount of infection due to its lower detection of HIV-2 (would lead to an 
underestimate of HIV-2 infection). 
 
KC57FITC FACS 
Assay Description: Using KC57FITC for intracellular staining of infected cells. 
Results: The MFI differences seen using AG3.0 are not as clear using KC57. 
However, it takes till day 6 to see a clear shift of HIV-2 in a positive population, 
but that may be due to HIV-2 infection kinetics. 
Advantages and Disadvantages: This is useful for estimating the number of cells 
infected, but may not correspond to the amount of virus produced in the culture. 
 
Exogenous RT Assay 
Assay Description: Measuring RT activity in viral stocks or infected cells using 
radioactively labeled template. 
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Results: I trouble shot this assay with many different membranes (DEAE), with a 
different buffer recipe, and buying new template in case the problem was that it 
was old. I was able to see signal with sucrose concentrated viral stocks, but was 
not able to see a linear dilution of viral stocks.  I either got a strong signal or no 
signal even with a RT standard input. 
Advantages and Disadvantages: I was unable to observe a consistent read out 
with a standard input 
 
qRTPCR for Viral RNA 
Assay Description: Measuring viral RNA in infected DCs. Infections were lysed, 
followed by RNA isolation using a kit  
Results: I used a BRU-YU2, ROD10, and GH1 as plasmid DNA to make a 
standard curve. I was able to optimize the standard curve for Bru-YU2 and GH1. 
However, the primary isolate HIV-2CDC77618 was not picked up as well by the 
primer and probes that were designed for ROD.  
Advantages and Disadvantages: Optimizing allowed me to observe HIV-1 and 
HIV-2 viral RNA levels, but further optimization is needed before it is a trusted 
assay for input and output. 
 
iGFP comparison 
Assay Description: Development of a proviral clone encoding GFP between 
matrix and capsid, which is cleaved by protease (described in methods) 
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Results: Using iGFP for capture worked very well 
Advantages and Disadvantages: It was necessary to concentrate ~13 plates of 
transfected cells to get a highly concentrated stock that I could use for multiple 
experiments/donors. However, I usually observed approximately equivalent yield 
of both HIV-1 and HIV-2. Both iGFP constructs have significant reduction in 
infectivity. Therefore, it is not useful for quantifying trans infection. 
 
nef-GFP comparison 
Assay Description: I used delta envelope virus with GFP in the place of nef to 
quantify trans infection. I pseudotyped RODenv- nef- GFP with ST envelope 
compared to Bru3gfpenv-nef- with Bal envelope and infected cells at an MOI=5 
and measured GFP expression at day 6 post infection. 
Results: It was necessary to use a high MOI and to look at day 6 due to very low 
levels of GFP expression. Additionally, it was necessary to spinoculate T cells in 
parallel to get a robust infection.  
Advantages and Disadvantages: Advantage is GFP expression is induced upon 
infection and can easily be measured in T cells by gating on the small population 
and staining with CD3 PE in co-cultures. Disadvantage is the low level of 
infection. Also, it was difficult to get a high titer of the virus.  
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